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were identified; the graph displays the median RFU-values, and the error bars represents the 
MAD on the citrullinated microarray. Abbreviations include: CRC = colorectal cancer; HC = 
healthy control; RFU = relative fluorescence units; nm = nanometre; MAD = median absolute 
deviation           85 
Figure 3.12. Non-citrullinated microarray: top 5 citrullinated antigens. CRC patient and HC 
samples were processed on the citrullinated microarray. The top 5 citrullinated antigens were 
identified; the graph displays the median RFU-values, and the error bars represents the MAD 
on the non-citrullinated microarray. Abbreviations include: CRC = colorectal cancer; HC = 
healthy control; RFU = relative fluorescence units, nm = nanometre; MAD = median absolute 
deviation           86 
Figure 3.13. PCA between CRC patients and HCs. CRC patient and HC plasma were processed 
on the citrullinated CT100plus microarray, and the top 5 citrullinated antigens in CRC patients 
were log2-transformed and selected for 1D and 2D PCA multivariate testing using the Perseus 
(version 1.5.4.1). The 1D and 2D PCA plots display distinct CRC patient (green) and HC (orange) 
clusters. Abbreviations include: PCA = principle component analysis; CRC = colorectal cancer; 
HC = healthy control; 1D = one-dimensional; 2D = two-dimensional   88 
Figure 3.14. ROC-derived cut-off-values for CRC patients. ROC analyses between CRC patients 
and HCs produced cut-off-values for each antigen; each bar represents the cut-off-value per 
antigen. These values were used for baseline-correction for each antigen prior to 
clinicopathological statistical analysis. Abbreviations include: ROC = receiver operator 
characteristic; CRC = colorectal cancer; HCs = healthy controls    90 
Figure 3.15. Crystal structure of CDK7 with arginine residues highlighted in red. CDK7 was 
detected at medium and high signal intensities on the citrullinated microarray, but low signal 
intensities on the non-citrullinated microarray, indicating that the citrullinated version CDK7 
induces an autoantibody response in CRC patients. The image represents the crystal structure 
of CDK7 (PDB: 1UA2). The arginine-residues available for PAD-induced citrullination are 
indicated in red. Abbreviations include: CRC = colorectal cancer; PAD4 = protein arginine 
deiminase isoform 4; PDB = protein data bank      95 
Figure 3.16. Crystal structure of SYCP1 with arginine residues highlighted in red. SYCP1 was 
detected at medium and high signal intensities on the citrullinated microarray, but low signal 
intensities on the non-citrullinated microarray, indicating that the citrullinated version SYCP1 
induces an autoantibody response in CRC patients. The image represents the crystal structure 
of SYCP1 (PDB: 4YTO). The arginine-residues available for PAD4-induced citrullination is 
indicated in red. Abbreviations include: CRC = colorectal cancer; PAD 4 = protein arginine 
deiminase isoform 4; PDB = protein data bank      97 
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Figure 4.1. Antigen intensities for a Blank SENGENICS IMMUNOME™ microarray. The 
SENGENICS IMMUNOME™ microarray was incubated with serum albumin buffer (PBS, BSA and 
Triton™ X-100) and Cy3-conjugated anti-human IgG detection antibody. Fluorescence images 
were obtained at 532 nm, and numerical data extrapolated. The net intensity for each antigen 
was obtained, and the data was subsequently filtered using stringent criteria (control CV = 20%; 
antigen CV = 10%; noise threshold = 2 SD above background). The scatter plot displays the 
median intensity-values for each antigen. The image represents only a quarter of the 
microarray, which contains one of the 4 quadruplicate antigens spots. Abbreviations include: 
PBS = phosphate buffer saline; BSA = bovine serum albumin; Cy3 = cyanine 3; IgG = 
immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD = standard deviation
            103 
Figure 4.2. Antigen intensities for the SENGENICS IMMUNOME™ microarray treated with 
pooled HC plasma. The SENGENICS IMMUNOME™ microarray was incubated with pooled HC 
plasma and Cy3-conjugated anti-human IgG detection AB to determine baseline signal 
intensities for various antigens. Fluorescence images were obtained at 532 nm, and numerical 
data extrapolated. The net intensity for each antigen was obtained, and the data was 
subsequently filtered using stringent criteria (control CV = 20%; antigen CV = 10%; noise 
threshold = 2 SD above background). The scatter plot displays the median intensity-values for 
each antigen. The image represents only a quarter of the microarray, which contains one of the 
4 quadruplicate antigens spots. Abbreviations include: HC = healthy control; Cy3 = cyanine 3; 
IgG = immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD= standard 
deviation           103 
Figure 4.3. Scatterplot representing the autoantibody intensities for CRC038 on CT100plus 
microarray. The CT100plus microarray was incubated with the blood plasma of CRC038, and 
subsequently incubated with fluorescently-labelled anti-human IgG. Fluorescence images were 
obtained at 635 nm, and numerical data extrapolated using the CT100plus.jar software: 
Antigen net intensities were obtained, and the data was processed and filtered: whole array CV 
= 25%; replicate probe CV = 20%; noise threshold = 2 SD above background). The scatter plot 
displays the median intensity-values for each antigen. Abbreviations include: IgG = 
immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD = standard deviation
            105 
Figure 4.4. Scatterplot representing the autoantibody intensities for CRC050 on CT100plus 
microarray. The CT100plus microarray was incubated with the blood plasma of CRC050, and 
subsequently incubated with fluorescently-labelled anti-human IgG. Fluorescence images were 
obtained at 635 nm, and numerical data extrapolated using the CT100plus.jar software: 
Antigen net intensity were obtained, and the data was processed and filtered: whole array CV 
= 25%; replicate probe CV = 20%; noise threshold = 2 SD above background). The scatter plot 
displays the median intensity-values for each antigen. Abbreviations include: IgG = 
immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD = standard deviation
            105 
Figure 4.5. Microarray image and scatter plot for CRC038 plasma on the SENGENICS 
IMMUNOME™ microarray. The SENGENICS IMMUNOME™ microarray was incubated with the 
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blood plasma of CRC038, and subsequently incubated with Cy3-conjugated anti-human IgG 
detection antibody. Fluorescence images were obtained at 532 nm, and numerical data 
extrapolated. The net intensity for each antigen was obtained, and the data was subsequently 
filtered using stringent criteria (control CV = 20%; antigen CV = 10%; noise threshold = 2 SD 
above background). The scatter plot displays the median intensity-values for each antigen. The 
image represents only a quarter of the microarray, which contains one of the 4 quadruplicate 
antigens spots. Cy3 = cyanine 3; IgG = immunoglobulin G; nm = nanometres; CV = coefficient of 
variation; SD = standard deviation        107 
Figure 4.6. Microarray image and scatter plot for CRC050 plasma on the SENGENICS 
IMMUNOME™ microarray. The SENGENICS IMMUNOME™ microarray was incubated with the 
blood plasma of CRC050, and subsequently incubated with Cy3-conjugated anti-human IgG 
detection antibody. Fluorescence images were obtained at 532 nm, and numerical data 
extrapolated. The net intensity for each antigen was obtained, and the data was subsequently 
filtered using stringent criteria (control CV = 20%; antigen CV = 10%; noise threshold = 2 SD 
above background). The scatter plot displays the median intensity-values for each antigen. The 
image represents only a quarter of the microarray, which contains one of the 4 quadruplicate 
antigens spots. Cy3 = cyanine 3; IgG = immunoglobulin G; nm = nanometres; CV = coefficient of 
variation; SD = standard deviation        108 
Figure 4.7. CRC patient plasma volume as a function of IgG eluted from Protein G beads. 
CRC010 patient plasma, at 0 µl, 2.5 µl, 5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated 
with 50 µl MagReSyn® Protein G magnetic beads to capture IgG. Bound proteins, including IgG 
and any non-specific proteins, were eluted and the resulting protein mass (µg) is displayed as 
a function of plasma volume (µl)        110 
Figure 4.8. Relative quantitation of CRC plasma-derived IgG eluted from MagReSyn® Protein 
G magnetic beads. CRC010 patient plasma, at 0 µl, 2.5 µl, 5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 
µl, was incubated with 50 µl MagReSyn® Protein G magnetic beads to capture IgG. Bound 
proteins were eluted, and separated by SDS-PAGE, and stained with AQUASTAIN. Distinct 
protein bands formed at 25 kDa and 55 kDa from 2.5 µl plasma, corresponding to the light and 
heavy chains, respectively, of IgG. Densitometric analysis was performed for the 25 kDa band, 
and the resulting stain intensity is displayed as a function of plasma volume (µl). Abbreviations 
include: CRC = colorectal cancer; IgG = immunoglobulin G; SDS-PAGE = sodium dodecyl sulphate 
polyacrylamide gel electrophoresis        111 
Figure 4.9. Western blot analysis of IP eluents for CRC038. CRC patient plasma, at 0 µl, 2.5 µl, 
5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated with 50 µl MagReSyn® Protein G magnetic 
beads to capture IgG from CRC038 plasma. Unbound proteins and bound proteins were eluted, 
and IgG light and heavy chains were detected by Western blot. Densitometric analysis was 
performed for the 25 kDa band, and the resulting stain intensity is displayed. Abbreviations 
include: IgG = immunoglobulin G, FP = free protein, FPW = free protein wash, AB = antibody
            113 
Figure 4.10. Western blot analysis of IP eluents for CRC050. CRC patient plasma, at 0 µl, 2.5 µl, 
5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated with 50 µl MagReSyn® Protein G magnetic 
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beads to capture IgG from CRC050 plasma. Unbound proteins and bound proteins were eluted, 
and IgG light and heavy chains were detected by Western blot. Densitometric analysis was 
performed for the 25 kDa band, and the resulting stain intensity is displayed. Abbreviations 
include: IgG = immunoglobulin G, FP = free protein, FPW = free protein wash, AB = antibody
            114 
Figure 4.11. Protein quantitation of eluents after crosslinking IgG to MagReSyn® Protein G 
magnetic beads with DMP. IgG was crosslinked to Protein G beads with DMP to prevent, or 
decrease, IgG contamination when eluting potential cancer antigens. Here, 7.5 µl or 15 µl 
plasma was incubated with 50 µl Protein G magnetic beads, and cross-linked using DMP. Beads 
incubated with 15 µl plasma, with no crosslinking were used as a negative control. All proteins 
that were not crosslinked were eluted and quantified using the BCA protein quantification kit. 
Abbreviations include: IgG = immunoglobulin G; DMP = dimethyl pimelimidate dihydrochloride; 
BCA = bicinchoninic acid         115 
Figure 4.12. SDS-PAGE and AQUASTAIN of eluents after crosslinking IgG to MagReSyn® 
Protein G magnetic beads with DMP. IgG and Protein G were crosslinked with DMP to prevent, 
or reduce, IgG contamination when eluting potential cancer antigens. Here, 7.5 µl or 15 µl 
plasma was incubated with 50 µl Protein G magnetic beads, and cross-linked using DMP. Beads 
incubated with 15 µl plasma, with no crosslinking was used as a negative control. All proteins 
that was not cross-linked was eluted and separated on an SDS-PAGE gel and stain with 
AQUASTAIN. Abbreviations include: IgG = immunoglobulin G; DMP = dimethyl pimelimidate 
dihydrochloride          116 
Figure 4.13. Protein quantitation of SHSY5Y cell-line lysates. SH-SY5Y human neuroblastoma 
cells were lysed with non-denaturing lysis buffers containing different detergents, including 1% 
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 1% IGEPAL® CA-630, 
1% Triton™ X-100, a mixture of detergents (0.25% CHAPS, 0.5% IGEPAL® CA 630, and 0.5% 
Triton™ X-100), and a negative control with no detergent (No det). Various lysis conditions were 
also assessed for protein yield: lysis only refers to lysates generated by incubating with lysis 
buffers and incubated on ice with intermittent vortexing only; lysis + homogenization refers to 
lysates generated by incubating with lysis buffers and homogenizing using a Potter-Elvehjem 
homogenizer, and then incubated on ice with intermittent vortexing; lysis + shaking refers to 
lysates generated by incubating with lysis buffers and homogenizing with a Potter-Elvehjem 
homogenizer, and then continuous vortexing at 4 °C     118 
Figure 4.14. AP-MS data analysis pipeline. Cancer (AP-MS with plasma and CRC tissue), Normal 
(AP-MS with plasma and normal mucosa) and Plasma (AP-MS with plasma only) samples of 
CRC004 were processed using Protein A or Protein G beads, and analysed using the Q Exactive 
mass spectrometer. The raw files were processed through MaxQuant (version 1.5.3.12) using 
intensity-based absolute quantitation (iBAQ) and match between runs. Subsequent data 
filtering included the removal of reverse hits, contaminants and protein groups with < 2 
peptides, and the data was normalised using median iBAQ values. Plasma proteins were 
removed from Cancer and Normal for Protein A and Protein G samples. Cancer-enriched, 
defined as proteins detected at ≥ 2-fold iBAQ in Cancer than Normal, and Cancer-unique, 
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defined as cancer-derived proteins that were present in Cancer only, were subsequently 
identified. Abbreviations include: MQ = MaxQuant      120 
Figure 4.15. Box plot of median-based iBAQ normalisation. Cancer (AP-MS with plasma and 
CRC tissue), Normal (AP-MS with plasma and normal mucosa) and Plasma (AP-MS with plasma 
only) samples of CRC004 were processed using Protein A or Protein G beads, and analysed using 
the Q Exactive mass spectrometer. The raw files were processed through MaxQuant (version 
1.5.3.12) using iBAQ and match between runs. Subsequent data filtering included the removal 
of reverse hits, contaminants and protein groups with < 2 peptides, and the data was 
normalised using median iBAQ values. Abbreviations include: AP-MS = affinity purification-
mass spectrometry; iBAQ = intensity-based absolute quantitation    121 
Figure 4.16. Number of proteins identified for AP-MS with MagReSyn® Protein A magnetic 
beads for CRC004. For the AP-MS assay, Igs from CRC004 were captured using Protein A 
magnetic beads, and proteins were subsequently captured from CRC004 cancer and paired 
normal native lysate. The captured proteins were eluted, analysed by mass spectrometry. The 
negative controls included Plasma, which refers to proteins from Protein A magnetic beads 
incubated with CRC004 plasma; and Normal, which refers to proteins from Protein A magnetic 
beads incubated with CRC004 plasma and paired normal tissue. Abbreviations include: AP-MS 
= affinity purification-mass spectrometry; Igs = immunoglobulins    121 
Figure 4.17. Number of proteins identified for AP-MS with MagReSyn® Protein G magnetic 
beads for CRC004. For the AP-MS assay, Igs from CRC004 were captured using Protein G 
magnetic beads, proteins were subsequently captured from CRC004 cancer and paired normal 
native lysate. The captured proteins were eluted, analysed by mass spectrometry. The negative 
controls included Plasma, which refers to proteins from Protein G magnetic beads incubated 
with CRC004 plasma; and Normal, which refers to proteins from Protein G magnetic beads 
incubated with CRC004 plasma and paired normal tissue. Abbreviations include: AP-MS = 
affinity purification-mass spectrometry; Igs = immunoglobulins    122 
Figure 4.18. Cancer-enriched proteins shared proteins between Protein A and G. For the AP-
MS assay, Igs from CRC004 were captured using Protein A or G magnetic beads, and proteins 
were subsequently captured from CRC004 cancer and paired normal native lysate. Proteins 
were identified using MaxQuant software (version 1.5.3.12). Proteins identified in the Plasma 
data were removed from Cancer and Normal data, and proteins with higher signal in Cancer 
versus Normal (i.e. Cancer-enriched) were identified, displayed in the Venn diagram. 
Abbreviations include: AP-MS = affinity purification-mass spectrometry; Igs = immunoglobulins
            122 
Figure 4.19. Cancer-unique shared proteins between Protein A and G. For the AP-MS assay, 
Igs from CRC004 were captured using Protein A or G magnetic beads, and proteins were 
subsequently captured from CRC004 cancer and paired normal native lysate. Proteins were 
identified using MaxQuant software (version 1.5.3.12). Proteins identified in the Plasma and 
Normal data were removed from Cancer data, and proteins specific to Cancer (i.e. Cancer-
unique) were identified, and displayed in the Venn diagram. Abbreviations include: AP-MS = 
affinity purification-mass spectrometry; Igs = immunoglobulins    123 
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Figure 4.20. String analysis of Cancer proteins common for Protein A and Protein G. Cancer-
enriched and Cancer-unique proteins were identified for AP-MS samples with Protein A and 
Protein G and analysed using STRING (https://string-db.org)    124 
Figure 4.21. Box plot of median-based iBAQ normalisation. Cancer (AP-MS with plasma and 
CRC tissue), Normal (AP-MS with plasma and normal mucosa) and Plasma (AP-MS with plasma 
only) samples of CRC002 and CRC004 were processed AP-MS. The raw files were processed 
through MaxQuant (version 1.5.3.12) using intensity-based absolute quantitation (iBAQ) and 
match between runs. Subsequent data filtering included the removal of reverse hits, 
contaminants and protein groups with < 2 peptides, and the data was normalised using median 
iBAQ values. Abbreviations include: iBAQ = intensity-based absolute quantitation; AP-MS = 
affinity purification-mass spectrometry       129 
Figure 4.22. Cancer-unique proteins matched to the AAgAtlas autoantigen database. Cancer-
unique proteins, defined as proteins characterised with at least 2 unique peptide specific to the 
Cancer sample, for CRC002 and CRC004 were matched it to the AAgAtlas human autoantigen 
database (version 1.0). The Venn diagram represents the number of proteins that are unique 
to, or overlap between, Cancer-unique and the AAgAtlas proteins    130 
Figure 4.23. Cancer-enriched proteins matched to the AAgAtlas autoantigen database. 
Cancer-enriched proteins, defined as proteins with higher expression in Cancer versus Normal 
(and Plasma-specific proteins removed), for CRC002 and CRC004 were matched to the AAgAtlas 
human autoantigen database (version 1.0). The Venn diagram represents the number of 
proteins that are unique to, or overlap between, Cancer-enriched and the AAgAtlas proteins
            130 
Figure 5.1. CT100plus microarray c-Myc control. Each of the 123 recombinant proteins on the 
CT100plus microarray contains a c-Myc tag. The microarray was treated with Cy3-labelled anti-
c-Myc antibody, which was used to confirm the successfully immobilisation of recombinant 
proteins on the slide surface with an anti-c-Myc antibody, as depicted in the microarray image. 
Abbreviations include: Cy3 = cyanine 3       143 
Figure 5.2. CT100plus microarray negative control pooled plasma sample. As a negative 
control, the CT100plus microarray was incubated with pooled plasma of HCs. Low or no signal 
is detected for the buffer, ICL, and BCCP negative control spots, indicating low levels of non-
specific binding. High signal was detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive 
control spots, anti-human IgG was detected (boxed in red), and human IgG was detected 
(boxed in blue). Low or no signal is detected for recombinant proteins. Abbreviations include: 
HCs = healthy controls; ICL = insect cell lysate; BCCP = biotin carboxyl carrier protein; IgG = 
immunoglobulin G; Cy5 = cyanine 5; BSA = bovine serum albumin    144 
Figure 5.3 CT100plus microarray positive control pooled plasma sample. For the positive 
control sample, the CT100plus microarray was incubated with pooled plasma of HCs. Low or no 
signal is detected for the buffer, ICL, and BCCP negative control spots, indicating low levels of 
non-specific binding. High signal was detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive 
control spots, anti-human IgG was detected (boxed in red), and human IgG was detected 
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(boxed in blue). Distinct and varying autoantibody signal intensity was detected for 
recombinant proteins. Abbreviations include: HC = healthy controls; ICL = insect cell lysate; 
BCCP = biotin carboxyl carrier protein; IgG = immunoglobulin G; Cy5 = cyanine 5; BSA = bovine 
serum albumin          145 
Figure 5.4. Temporal assessment of cytochrome P450 3A4 for patient 14 pre-normalisation. 
The samples of patient 14 were assayed in the same and separate batches, and here use to 
assess batch-to-batch effects with cytochrome p450 3A4 as an example. It is evident that 
assaying samples in separate batches (orange line) results in a greater variation in signal 
intensity compared to processing the samples within the same batch (blue line). Abbreviations 
include: RFU = relative fluorescence units       147 
Figure 5.5. Volcano plot for the CT100 antigens pre-normalisation. A volcano plot was 
constructed in RStudio (version 1.0.136) to determine significant fold-changes in signal 
intensities between sample batches. Blue dots indicate a significant difference (adjusted p-
value ≤ 0.05, fold-Δ ≥ 0.25) in signal intensity between batches, whereas the red dots indicate 
a non-significant (adjusted p-value > 0.05, fold-Δ < 0.25) difference in signal intensities. Here, it 
is evident that all antigen signals are dysregulated between batches, and furthermore, 
significant differences were detected between B1 and B2, B3 as well as B4, despite similar 
intensities viewed on the CT100plus images       148 
Figure 5.6. Temporal assessment of cytochrome P450 3A4 for patient 14 post-normalisation. 
The samples of patient 14 were assayed in the same and separate batches, although assays 
performed in separate batches result highly variable signal intensity that does not correlate 
with visual intensity. To account for batch-to-batch effects seen pre-normalisation (orange 
line), sample batches were normalised using Equation 5.2. The results indicate that signal 
intensities post-normalisation (grey line) are now likened to signal intensities of samples 
processed together (blue line). Abbreviations include: RFU = relative fluorescence units 150 
Figure 5.7. Volcano plot for the CT100 antigens for batches post-normalisation. A volcano plot 
was constructed in RStudio (version 1.0.136) to determine significant fold-changes in signal 
intensities between sample batches. Blue dots indicate a significant difference (adjusted p-
value ≤ 0.05, fold-Δ ≥ 0.25) in signal intensity between batches, whereas the red dots indicate 
a non-significant (adjusted p-value > 0.05, fold-Δ < 0.25) difference in signal intensities. Now, 
antigen signals are no longer dysregulated between batches    151 
Figure 5.8. ROC curve for melanoma patients and HCs. The ROC curve was constructed using 
CombiROC. A combination of the CEACAM1 and FRGR2 produce the highest AUC is displayed, 
with the resulting sensitivity-, specificity- and AUC-values of 0.93, 0.96 and 0.94, respectively. 
Abbreviations include: ROC = receiver operating characteristic; AUC = area under the ROC curve
            154 
Figure 5.9. Pre-immunotherapy-treated melanoma patient and HC raw data files were batch 
processed using the CT100plus software, and a ROC test performed to identify the top 10 
upregulated antigens in cancer patients. The graph displays the median RFU-values for the top 
10 potential antigen biomarkers on the CT100plus microarray, and the error bars represents 
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the MAD. Abbreviations include: HC = healthy control; ROC = receiver operator characteristic; 
RFU = relative fluorescence units; MAD = median absolute deviation   155 
Figure 5.10. Unsupervised clustering of pre-immunotherapy melanoma patients and HCs. 
Pre-immunotherapy melanoma patient (N = 52) and HC (N = 14) plasma and/or sera were 
processed on the CT100plus microarray, and the 10 most significantly upregulated antigens in 
melanoma patients were log2-transformed and selected for unsupervised hierarchical 
clustering using the Perseus software (version 1.5.4.1). Here, the HC and melanoma patients 
form two major clusters. Most of the HCs clustered together, except for HCs HC10 and HC12 
who cluster separate from the major HC cluster. Furthermore, HC1 and HC9 are separate from 
other HCs, clustering with patients 17A and 19A. Abbreviations include: HCs = healthy controls; 
N = number of patients         157 
Figure 5.11. PCA between pre-immunotherapy treated melanoma patients and HCs. Pre-
immunotherapy treated melanoma patient (N = 52) and HC (N = 14) plasma and/or sera 
samples were processed on the CT100plus microarray, and the 10 proteins with the highest 
AUC-values were log2-transformed and selected for 1D and 2D PCA multivariate testing using 
the Perseus (version 1.5.4.1). The 1D and 2D PCA plots display melanoma patient (red) and HC 
(blue) clusters, with overlap between melanoma patient 42A and HC10. Abbreviations include: 
PCA = principle component analysis; HC = healthy control; N = number of patients; AUC =area 
under the receiver operator characteristic curve; 1D = one-dimensional; 2D two-dimensional
            158 
Figure 5.12. ROC curves for ROPN1, AKT1 and DPPA2. Melanoma patient serum/plasma before 
(TP0) and after (TP0) immunotherapy were assayed on the CT100plus microarray to determine 
changes of autoantibody levels against CT100plus antigens. A non-significant change (adjusted 
p-value > 0.05, Benjamini-Hochberg) in autoantibody levels were detected. This result was 
supported by ROC analysis for the 3 proteins with the lowest p-values, to include ROPN1, AKT1 
and DPPA2, which produced AUC-values of 0.38, 0.38 and 0.39, respectively. ROC = receiver 
operator characteristic curve; AUC = area under the ROC curve    168 
Figure 5.13. ROC curves for GRWD1. The serum/plasma of ipilimumab-treated melanoma 
patients before (TP0) and after (TP0) immunotherapy were assayed on the CT100plus 
microarray to determine changes of autoantibody levels against CT100plus antigens. A non-
significant change (adjusted p-value > 0.05, Benjamini-Hochberg) in autoantibody levels were 
detected. This result was supported by ROC analysis for the proteins with the lowest p-value, 
i.e. GRWD1, which produced an AUC-value of 0.38      171 
Figure 7.1. 384-well Genetix microplate 1. The figure depicts the layout and contents of a 384-
well Genetix microplate 1 compatible with the Qarrayer microarray printer. The microplate was 
prepared by adding cancer antigens labelled 1-60 (Table 7.1), as well as the controls: Cy5-biotin-
BSA, human IgG, anti-human IgG AB and control buffer to the wells indicated. Grey-shaded 
wells were empty          188 
Figure 7.2. 384-well Genetix microplate 2. The figure depicts the layout and contents of a 384-
well Genetix microplate compatible with the Qarrayer microarray printer. The microplate was 
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prepared by adding cancer antigens labelled 61-123 (Table 7.2), as well as the controls: BCCP-
c-Myc and control buffer (Buffer) to the wells indicated. Grey-shaded wells were empty 190 
Figure 7.3. Pin positioning for CT100plus printing. The Qarray2 robotic arrayer printer head 
and pin positioning use to print CT100plus microarrays in a four-plex format. Pin set 1 prints 
microarray set 1; pin set 2 prints microarray set 2 on a streptavidin-coated NEXTERION® H slide. 
The 5, 10 and 15 ng/µl Cy5-biotin-BSA controls were used for downstream pin-to-pin and array-
to-array normalisation         193 
Figure 7.4 Layout of the CT100plus microarray. CT100plus microarrays were printed in a 4-plex 
format on streptavidin-coated NEXTERION H slides. Each microarray is subdivided into 8 
subarrays, each containing 123 cancer antigens, as well as positive (Cy5-biotin-BSA, human IgG, 
anti-human IgG) and/or negative controls (buffer, BCCP-c-Myc, insect cell lysate) printed in 
triplicate. Abbreviations include: Cy5 = cyanine 5; BSA = bovine serum albumin; IgG = 
immunoglobulin G; BCCP = biotin carboxyl carrier protein ICL = insect cell lysate  194 
Figure 7.5. SHSY-5Y lysate generation. SHSY-5Y neuroblastoma cells were used to optimise lysis 
buffer detergent composition for CRC tissues in the AP-MS assay. The non-denaturing lysis 
buffer was supplemented with either CHAPS, Triton™ X-100, IGEPAL® CA-630, “mix”, or no 
detergent. The supernatants were collected, and protein quantification was performed using 
the BCA protein quantitation kit (Pierce™). Here the lysis conditions are described for lysis 
buffer only (generated with 350 µl lysis buffer on ice for 2 hours, with intermittent vortexing), 
although the same procedure was used for lysis buffer & PE (generated with 350 µl lysis buffer 
and homogenizing using a Potter-Elvehjem homogenizer, and incubation on ice for 2 hours, 
with intermittent vortexing) and lysis buffer & shaking (generated with 350 µl lysis buffer and 
homogenizing with a Potter-Elvehjem homogenizer, and continuous vortexing 4°C). 
Abbreviations include: CRC = colorectal cancer; AP-MS = affinity purification-mass 
spectrometry; BCA = bicinchoninic acid; PE = Potter-Elvehjem; min. = minute  202 
Figure B1. Signal intensity for antigens on anti-c-Myc-treated CT100plus microarray. The 
CT100plus microarray antigens each have a c-Myc tag which is used as a quality control 
measure to confirm the presence of the CT100plus antigens. For the assay, the CT100plus 
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Table 1.1. List of cancer antigen-types, definitions and examples. Tumour antigens can be 
defined as TAAs, which are antigens similar to proteins found in normal cells, but are modified 
or overexpressed; or TSA, which are antigens found only in or on tumour cells, and not in 
normal cells. The table below lists cancer antigen-types, definitions and examples. 
Abbreviations: TAAs = tumour-associated antigen; TSAs = tumour associated antigen 20 
Table 1.2. Substrates and locations of PAD isozymes in humans. Abbreviations include: PAD = 
protein arginine deiminase. [Adapted from (Witalison et al., 2015)]   35 
Table 2.1. Sensitivity-, specificity-, AUC-, and cut-off-values for top 10 antigens for CRC 
patients on the CT100plus microarray. Abbreviations include: AUC = area under the receiver 
operator characteristic curve.        53 
Table 2.2. Shapiro-Wilk, Kruskal-Wallis and Benjamini-Hochberg tests values for the top 10 
antigens for CRC on the CT100plus microarray      55 
Table 2.3. Clinicopathological features of CRC patients. The clinicopathological data of CRC 
patients tested on the CT100plus microarray are summarised. Abbreviation include: N = 
number of patients; SD = standard deviation; N/A = not available; TNM = tumour, node, 
metastasis; MSI = microsatellite instability; MSI-H = high microsatellite instability; MSI-L = low 
microsatellite instability; HNPCC = hereditary non-polyposis colorectal cancer; BMI = body mass 
index            59 
Table 2.4. Clinicopathological features and autoantibody signal with p-values ≤ 0.01. Mann-
Whitney U and Kruskal-Wallis test indicate a significant difference in antigenic signal for gender, 
hypertensive state, MS status, recurrence and cancer stage, although it is not statistically 
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Cancer is a heterogenous disease capable of forming and spreading in most tissues of the human 
body. Cancer screening and diagnosis can be performed through medical procedures, which are 
highly invasive, requiring an intensive infrastructure. It is therefore important to create cost-
effective, non-invasive cancer diagnostic tools that also gives an indication of disease prognosis. 
With this in mind, the Blackburn lab previously created a cancer-testis antigen microarray 
(CT100plus) functionalised with tumour-associated and tumour-specific antigens, capable of 
detecting plasma- or serum-derived autoantibodies in the picogram per millilitre (pg/ml) range.  
In this thesis, a newly established statistical pipeline was used to analyse colorectal cancer (CRC) 
patient-derived CT100plus data. Using the pipeline, the 10 antigens with the highest receiver 
operator characteristic (ROC)-derived area under the ROC curve (AUC)-values were identified as 
potential autoantibody-based biomarkers. The top 10 antigen biomarker candidates include 
CEACAM 1, COL6A1, GRWD1, MAGEA1, MAGEA5, MAGEA10, NY-CO-1, SGY-1, SPANXB1 and 
THEG. Using these biomarker candidates, distinct clusters of healthy controls (HCs) and CRC 
patients were observed using both unsupervised hierarchical clustering and principle component 
analysis (PCA) analysis. Combinatorial ROC analysis indicates that CEACAM1 and GRWD1 as the 
top autoantigen combination for CRC diagnosis, together producing sensitivity-, and specificity-, 
and AUC-values of 1.00, 0.77 and 0.94, respectively. Furthermore, other top autoantigens, 
including COL6A1, THEG and CEACAM7, a homologue of CEACAM1, were also identified in this 
thesis by affinity purification-mass spectrometry (AP-MS) for patients from the same cohort, 
providing supporting evidence that these antigens are associated with CRC. 
The CT100plus microarray content was enzymatically modified to include citrullinated proteins, 
with the subsequent assessment of CRC patient autoantibody response. Significantly (p-value ≤ 
0.05; adjusted p-value ≤ 0.05) higher signal intensities were detected in CRC patients versus HCs 
for citrullinated CDK7, MAGEB1, MAGEB5, MAGEB6 and SYCP1, whereas no significant (adjusted 
p-value > 0.05) difference in autoantibody signal was detected for these autoantigens on the non-
citrullinated microarray for the same patient cohort. ROC analyses of these antigens resulted in 
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an AUC-, sensitivity- and specificity-values of 0.91, 0.87 and 0.89, respectively. Together, this 
thesis shows for the first time that cancer patients elicit an autoantibody response to citrullinated 
proteins, resulting in potential novel CRC biomarkers. 
A novel AP-MS assay was developed to detect autoantibody responses to autologous native CRC 
tissue proteins. Using the optimised methodology, proteins or homologues of proteins that were 
significantly (> cut-off value) detected on the CT100plus microarray for the same 5 patients were 
re-identified by the orthogonal AP-MS method. Using the methodology, PAD2, an enzyme that 
catalyses the conversion of arginine to citrulline was also identified. In addition, citrullinated 
antigens associated with cancer were identified, including homologues of CDK7 and MAGEB 
supporting the conclusion that citrullinated homologues of these proteins induce an 
autoantibody response in CRC patients. 
Finally, serum and/or plasma samples of a cohort melanoma patients were analysed using the 
CT100plus microarray, and autoantibody signals were compared to those of healthy control (HC) 
samples. Using the established statistical pipeline, the 10 antigens with the highest ROC-derived 
AUC-values were identified as potential biomarkers. The top 10 biomarker autoantigen 
candidates for melanoma included CEACAM 1, DPPA2, FGFR2, ITGB1, MAGEA10, NANOG, PIM1, 
SPANXB1, THEG and XAGE1B. Using these biomarker candidates, distinct clusters of HCs and 
melanoma patients were identified in both unsupervised hierarchical clustering and PCA analysis. 
Combinatorial ROC analysis indicates that CEACAM1 and FGFR2 were identified as the top 
antigens for melanoma diagnosis, together producing sensitivity-, and specificity-, and AUC-
values of 0.96, 0.94 and 0.93, respectively.  
In conclusion, a statistical pipeline was established for microarray data, enabling the 
identification of potential antigens associated with cancer diagnosis, and the potential to 
determine disease prognosis. Using the established pipeline, cancer antigens associated with CRC 
and melanoma were identified. In addition, an AP-MS assay was developed for the identification 









1.1. Hallmarks of cancer 
Cancer is a heterogenous disease capable of forming and spreading almost anywhere in the body. 
The disease is complex, where healthy cells encounter multiple insults before progression to a 
state of malignancy. Several characteristics mark a cell as cancerous; these characteristics have 
been termed the six hallmarks of cancer by Hanahan & Weinberg (Hanahan and Weinberg, 2000) 
(Figure 1.1).  
 
 
Figure 1.1. The six hallmarks of cancer. The six hallmarks of cancer provide a logical framework for the 
altered biological properties acquired by cells during tumour development. The six hallmarks include: 
resistance to cell death, sustained proliferative signalling, evasion of growth suppressors, evasion of 
metastasis, enabled replicative immortality, and the induction of angiogenesis [Adapted from (Hanahan 
and Weinberg, 2000)]. 
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The hallmarks, which provide a logical outline for understanding the disruption of tissue 
homeostasis leading to cancer development, can be summarized as follows: 
1. Sustained proliferative signalling: Healthy cells control the production and release of growth-
promoting signals that instruct cells to undergo cell division. In cancer, these mitogenic signals 
are disrupted to sustain proliferative signalling either through autocrine proliferative signalling; 
growth factor-supply from normal cells (Bhowmick et al., 2004; Cheng et al., 2008); disrupting 
negative-feedback mechanisms that attenuate proliferative signalling (O’Reilly et al., 2006; Yuan 
and Cantley, 2008; Jiang and Liu, 2009; Sudarsanam and Johnson, 2010); upregulating receptor 
expression or augmenting protein structure to enhance growth factor binding; and/or growth 
factor-independent proliferation through pathways downstream to the receptor (Yuan and 
Cantley, 2008; Jiang and Liu, 2009; Davies and Samuels, 2010).  
2. Evasion of growth suppressors: Complementary to sustained proliferative signalling, cancer 
cells additionally acquire the ability to evade growth suppressors. Tumour suppressors are 
inactivated in many cancers, including the prototypical tumour suppressors, retinoblastoma-
associated (RB) protein and p53, which act as central nodes with complementary cellular 
mechanisms that govern cellular proliferation. 
3. Activation of invasion and metastasis: Once the cancer has metastasised, it is almost 
impossible to treat. Cancer invasion and metastasis is a multistep process termed the invasion-
metastasis cascade, depicted as local invasion, cancer cell intravasation into nearby blood and 
lymphatic vessels, transit of cancer cells through lymphatic and hematogenous systems, cancer 
cell escape from the lumina, followed by the formation of small cancer cell nodules, and finally 
growth of metastatic lesions (Fidler, 2003; Talmadge and Fidler, 2010). The invasion-metastasis 
cascade results from changes in cancer cell morphology and their attachment to other cells, 
caused by the loss of E-cadherin, a key cell-to-cell adhesion molecule (Cavallaro and Christofori, 
2004; Berx and van Roy, 2009).  
4. Resistance to cell death: In healthy cells, apoptosis serves as a natural barrier to cancer 
development by balancing pro- and anti-apoptotic proteins (Evan, 1998; Lowe et al., 2004; Adams 
and Cory, 2007). Tumour cells develop strategies that circumvent apoptosis through the loss of 
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the p53 tumour suppressor gene; increased expression of anti-apoptotic proteins, Bcl-2 and Bcl-
XL; and the downregulation of pro-apoptotic proteins, Bax, Bim and Puma.  
5. Enabled replicative immortality: Healthy cells pass through a limited number of successive cell 
growth and division cycles before ending in senescence or cell death. Cancer cells circumvent 
senescence and cell death, enabling unlimited proliferation, and a great wealth of evidence 
suggests it is due to telomere protection of chromosome ends (Shay and Wright, 2000; Blasco, 
2005). The length of telomeric DNA at the ends of DNA dictates the number of successive cell 
generations its progeny can pass through. Telomerase, the specialised DNA polymerase that adds 
telomeric repeats at DNA ends, is almost absent in non-immortal cells, but present at significantly 
higher levels in the majority (~90%) of immortalised cells, including cancer.  
6. Angiogenesis: Like normal tissues, tumours require nutrients and oxygen, and the removal of 
metabolic waste and carbon dioxide. Angiogenesis normally only occurs during embryogenesis, 
wound healing and the female reproductive cycling. However, for the acquisition of nutrients and 
the removal of waste, angiogenesis is constitutively activated during tumourigenesis and 
sustained after neoplastic growth (Hanahan and Folkman, 1996). Evidence indicates that this 
angiogenic switch is controlled by countervailing factors that are inhibitory, e.g. 
thrombospondin-1 (TSP-1), or stimulatory, e.g. vascular endothelial growth factor-A (VEGF-A) 
(Bergers and Benjamin, 2003; Baeriswyl and Christofori, 2009). 
Following on from their first paper on the Hallmarks of Cancer, Hanahan & Weinberg published 
additional enabling characteristics and emerging hallmarks of cancer (Figure 1.2) (Hanahan and 
Weinberg, 2011). These emerging hallmarks of cancer can be summarized as follows:  
7. Reprogramming cellular energy: Under aerobic conditions, healthy cells undergo aerobic 
respiration for energy production, although cancer cells undergo anaerobic respiration, resulting 
in an ~18-fold decrease in adenosine triphosphate (ATP) production. Although opting for 
anaerobic metabolism appears to be counterintuitive, it is hypothesized that cancers use the 
glycolytic intermediates in the production of nucleosides and amino acids that are required to 
assemble new cancer cells.  
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8. Evading immune destruction: It is thought that cells and tissues are under constant immune 
surveillance that recognizes and eliminates nascent tumours. Thus, it appears that developed 
cancers evade detection and destruction by the immune system. These findings are supported 
by in vivo studies where tumours developed more frequently in immunodeficient mice (Kim et 
al., 2007; Teng et al., 2008). Clinical epidemiology also shows evidence of anti-tumour immune 
responses in some forms of human cancer (Nelson, 2008; Bindea et al., 2010; Ferrone and 
Dranoff, 2010) 
These enabling characteristics constitute the development of genomic instability in cancer cells 
and the inflammatory state of premalignant and malignant tissues, both promoting tumour 
progression. Taken together, it is clear that numerous complementary insults that affect DNA 
and protein expression leads to cancer development. Understandable, these molecules make for 
excellent targets in principle for improved cancer chemo- and immuno-therapy, and cancer 
diagnostics and screening. 
 
 
Figure 1.2. Emerging hallmarks and enabling characteristics. Besides the 6 core hallmarks of cancer 
previously described, two additional hallmarks emerged, including the deregulation of cellular energetics 
and cancer evasion of immunological destruction. Additionally, two consequential enabling characteristics 
of neoplasia facilitate the acquisition of core and emerging hallmarks, including genomic instability and 
inflammation by innate immune cells.[Adapted from (Hanahan and Weinberg, 2011)] 
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1.2. Global cancer epidemiology  
In 2015, the World Health Organisation (WHO) reported that of the 56.4 million deaths 
worldwide, more than half were due to the top 10 diseases: ischaemic heart disease (8.8 million), 
stroke (6.2 million deaths), chronic obstructive pulmonary disease (3 million deaths), lung cancer 
(including trachea and bronchus cancers) (1.7 million deaths), diabetes mellitus (1.6 million), 
dementia (1.5 million), diarrhoeal disease (1.4 million), tuberculosis (1.4 million), and road kill 
injury (1.3 million) (http://www.who.int) (Figure 1.3). Lung, trachea and bronchus cancers 
increased from 1.26 million to 1.69 million deaths from 2000 to 2015. The world population size 
increased from ~6.1 billion in 2000 to ~7.2 billion in 2015, indicating that the rate of lung, trachea 
and bronchus cancers increased.  
 
Figure 1.3. Top 10 causes of death worldwide in 2015. The worldwide leading causes of death are 
summarized as deaths per million. Cancers of the trachea, bronchus and lung increased from 1.26 million 
deaths in 2000 to 1.69 million deaths in 2015, as the fifth leading cause of death worldwide (adapted 
from: http://www.who.int).  
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Although trachea, bronchus and lung cancers are the fifth leading cause of death worldwide, all 
cancer-types are cumulatively responsible for most deaths worldwide: Based on GLOBOCAN 
2008, ~12.7 million cancer cases and ~7.6 million cancer deaths occurred in 2008; of these, 56% 
of the cases and 64% of the deaths occurred in developing countries (Jemal et al., 2011). 
According to the GLOBOCAN (2012), these numbers increased to ~14.1 million new cancers, and 
~8.2 million deaths in 2012 worldwide (http://globocan.iarc.fr).  
The GLOBOCAN summarized the global cancer incidence and mortality rates, depicted in global 
incidence (Figure 1.4) and mortality (Figure 1.5) maps, based on age-specific rates (ASR) across 
all cancer types, excluding non-melanoma skin cancers. Here, it is evident that areas presenting 
the highest incidence numbers and highest mortality numbers do not overlap. These disparities 
are probably due to differential risk factors, screening practices, and/or the availability of cancer 
treatment in developing countries (Jemal et al., 2011). 
 
 
Figure 1.4. Global cancer incidence rates. The map represents the age-specific rates (ASR) of global 
incidence for all cancer-types, except for non-melanoma skin cancers. The blue gradient scale correlates 





Figure 1.5. Global cancer mortality rates. The map represents the age-specific rates (ASR) of global 
mortality for all cancer-types, except for non-melanoma skin cancers. The blue gradient scale correlates 
with cancer incidence, while grey indicates that no data is available. [Adapted from: 
http://globocan.iarc.fr]. 
 
Although the cancer incidence rates in developing countries are half of those reported in 
developed countries, the overall mortality rates are similar, regardless of patient gender. The 
most prevalent cancers worldwide include breast, prostate and colorectal cancer (CRC). The 
mortality and incidence rates for the top 20 cancers, including both genders, are summarised in 
Figure 1.6. 
For females, breast cancer is the most frequently diagnosed (23% of total cases) cancer, and the 
leading cause of cancer death (14% of total deaths) in developed and developing countries; 
whereas lung cancer is most frequently diagnosed (17%) cancer in men, accounting for 23% of 
total cancer deaths (Jemal et al., 2011). Furthermore, cancer incidence rates are almost 25% 





Figure 1.6. Global cancer prevalence in developed and developing regions. The 5-year cancer prevalence 
(blue bars) and cancer incidence (red bars) is summarised, with estimations numbers (×100), for 
developed and developing countries for both males and females. [Adapted from: http://globocan.iarc.fr]. 
 
Together, the incidence and mortality rates highlight the need to reduce cancer burden 
worldwide. Prevention modalities include cancer screening and increased awareness of risk 
factors, such as smoking, alcohol consumption, diet, obesity, poor exercise. Treatment modalities 




1.3. Cancer immunology 
The innate and adaptive immune responses are raised against cancer. The innate immune 
response is rapid, and the first line of defence. It consists of soluble factors (e.g. complement 
proteins) and cellular components, including granulocytes (including basophils, eosinophils and 
neutrophils), mast cells (MC), macrophages, dendritic cells (DCs) and natural killer cells (NK). The 
adaptive immune response is slower, although it is antigen-specific and provides immunological 
memory. The components of the adaptive immune system consist of T-lymphocytes, which 
include T-helper cells (CD4+), cytotoxic T-cells (CD8+), regulatory T-cells (Tregs). Other immune cells 
of the adaptive immune system are B-lymphocytes (B-cells), which are responsible for antibody 
(Ab) secretion, natural killer T-cells and γδ T-cells which are both cytotoxic lymphocytes at the 
interface of innate and adaptive immunity (Figure 1.7) (Dranoff, 2004).  
 
 
Figure 1.7. Components of the innate and adaptive immune system. The innate immune response is 
rapid, and includes soluble components (e.g. complement proteins), granulocytes (e.g. basophils, 
eosinophils and neutrophils), mast cells (MC), dendritic cells (DCs), macrophages, natural killer cells (NK). 
The adaptive immune, which is slower, but more specific and provides immune memory retention. It 
includes T lymphocytes (e.g. CD4+ T-cell, CD8+ T-cells, regulatory T-cells) and B lymphocytes. Natural killer 
T-cells and γδ T-cells are cytotoxic lymphocytes at the interface of innate and adaptive immunity [Adapted 
from (Dranoff 2004)]. 
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In the anti-cancer immune response, antigen presenting cells (APCs) lyse and present tumour-
associated antigens (TAAs) on major histocompatibility complex (MHC) molecules at the surface 
of T-cells. MHC I molecules occur on all nucleated cells and platelets, but not on red blood cells. 
The MHC I complex is composed only of β2 subunits, and are recognised by CD8+ T-cell receptors 
trigging a cascade of events that lead to CD8+ T-cell proliferation, cytokine production and target 
cell lysis (Johnsen et al., 1999; Seliger et al., 2000). For MHC I production, a large mutlicatalytic 
protease complex called the proteasome degrades endogenous proteins, e.g. TAAs. The peptides 
are transported to the lumen of the endoplasmic reticulum (ER) by transporter-associated with 
antigen processing (TAP) proteins. Accessory proteins facilitate the folding and assembly of 
complete MHC I molecules which interacts with the immunogenic peptide in the ER, which is 
subsequently transported from the ER through the Golgi apparatus for antigen presentation on 
the cell surface.  MHC II molecules have β1 and β2 subunits, and are crucial for the activation of 
CD4+ T-cells. MHC II molecules can be expressed on all cell-types, although they are usually 
expressed on professional APCs including macrophages, B-cells and DCs. MHC II molecules are 
also expressed on tumour cells, including colorectal and breast carcinomas. TAAs are degraded 
to form peptides by degradative processes in multivesicular bodies (MVBs) in tumour cells. In the 
ER, three MHC II αβ heterodimers bind to trimeric proteins called invariant chains, forming a 
nonameric complex. The complex is transported through the Golgi apparatus or cell surface to 
MVBs, where proteases degrade the invariant chain. Concurrently, non-classical MHC II HLA-DM 
and -DO dimerize in the ER and re-locate to the MVBs. Free HLA-DM interacts with HLA-DR and 
mediate peptide exchange following the inward budding of the limiting membrane. Peptide-
loaded MHC II molecules then egress to the cell surface for antigen presentation (Thibodeau et 
al., 2012) to interact with CD4+ T-cells. 
Multiple mechanisms have been proposed for the immune evasion of tumours; one such 
mechanism is through downregulated expression of MHC molecules in and on cancer cells as a 
result of somatic mutations. MHC I is almost replete in multiple cancers, reportedly as low as 13% 
in CRC (Cabrera et al., 1998), 4% in breast cancer (Cabrera et al., 1996), 4% in cervical carcinomas 
(Koopman et al., 2000), and 30% in laryngeal cancers (Cabrera et al., 2000). Multiple studies 
propose that the major force contributing to the appearance of MHC negative tumour clones is 
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due to T-cell immunoselection, whereby T-cells recognise tumour antigens displayed on MHC 
positive tumour cells.  The remaining MHC-defective tumour cells evade immune surveillance, 
and acquire a growth advantage that allow the tumour to expand (Kaklamanis and Hill, 1992; 
Lehmann et al., 1995; Jäger et al., 1997). The loss of MHC can occur during HLA synthesis, 
assembly, transport, or expression on the cell surface (Garrido et al., 1997; Ruiz-Cabello and 
Garrido, 1998). A molecular mechanism analysis provided evidence that MHC I-deficient 
metastatic nodes in immunocompetent mice showed co-ordinated suppression of multiple 
components of the MHC I antigen presenting machinery. Interestingly, treatment with 
interferon-γ (IFN-γ) transcriptionally induces the re-expression of downregulated antigen 
processing machinery, and consequently enhances MHC I surface expression (Garcia-Lora et al., 
2003); thus the inclusion of IFN-γ with immunotherapy treatment may improve patient 
outcomes.  
The antigen-specific B-cells encounter, recognize and bind activated CD4+ T-cell cells (Goodnow 
et al., 2005); this process is maximized by lymphocyte circulation into secondary lymphoid organs 
and peripheral tissues. The interaction between T-cells and B-cells activates cytokine and 
chemokine production, leading to B-cell proliferation. A portion of the B-cells serve as memory 
cells, whereas the remainder act as effector cells that differentiate into antibody-producing 
plasma cells responsible for the production and release of antigen-specific antibodies 
(Wardemann and Nussenzweig, 2007). The B-cell response to a specific antigen is thus dependent 
on T-cells and occurs in three phases: extrafollicular, follicular and germinal centre (GC) reaction 
(Qi, 2016). During the first phase, B cell growth is driven by T- helper cells and early waves of 
plasma cells are produced from the T-cell – B-cell border of the follicle. In the second phase, T-
cells and B-cells interact inside the follicle, culminating in GC formation followed by cycles of B-
cell somatic mutation, clonal proliferation and selection that result in affinity maturation in the 
third phase (Qi, 2016). 
Peripheral tolerance mechanisms usually ensure that self-reactive T- and B-cells (i.e. displaying 
T- or B-cell receptors for self-antigens) are suppressed. However, in certain circumstances, 
peripheral tolerance can be broken, resulting in proliferation of autoantigen-specific T- and B-
cells. Simplistically, peripheral tolerance can be broken for a number of reasons, for example if 
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the self-antigen is significantly over-expressed in a tissue or if neoantigens are somehow 
presented to the host immune system. Such neoantigens can include mutated peptide epitopes, 
aberrantly spliced or aberrantly post-translationally-modified epitopes, or new discontinuous 
epitopes resulting from misfolding of the antigen. One consequence of this loss of peripheral 
tolerance can be the production of self-antigen-specific autoantibodies. 
The interaction between autoantibodies and TAAs leads to the destruction of transformed cancer 
cells containing the B-cell primed antigen by labelling them for faster macrophage recognition 
and phagocytosis. Autoantibody-induced tumour killing subsequently occurs as a result of direct 
interaction between autoantibodies and TAAs, which blocks tumour cell surface receptors 
associated with tumour cell proliferation and survival. The autoantibodies can also induce 
tumour-associated antigen (TAA) uptake via DC Fc gamma receptors, leading to antigen cross-
presentation and strong CD4+ and CD8+ T-cell responses, complement-dependent cytotoxicity 
and NK cell-mediated antibody-dependent cellular cytotoxicity (Carter, 2001). 
Antibodies are secreted heterodimeric proteins comprising of light and heavy chains produced 
through recombination of V(D)J segments in developing B-lymphocytes. At any given time, there 
are thought to be of the order of 107-108 different Ab sequences present in human serum. In 
response to the presence of foreign antigens or pathogens, somatic hypermutation processes 
drive the affinity maturation of specific Ab sequences, resulting in the production of high affinity, 
antigen-specific antibodies. Also, known as immunoglobulins (Igs), affinity matured antibodies 
are produced by plasma cells and secreted into the blood stream where they scavenge their 
cognate antigen for destruction. Antibodies thus play a crucial adaptive role in mammalian 
defence mechanisms against harmful components that can cause disease. There are 5 classes of 
antibodies; IgG, IgM, IgE, IgD and IgA, which differ in their structures and immune functions. IgG 
is the major Ab in the blood and has the longest serum half-life of all Ig isotypes (Schroeder and 
Cavacini, 2010). It contributes directly to an immune response including neutralisation of toxins 
and viruses. IgA is also involved in the direct neutralization of toxins, viruses and bacteria; 
however, it concentrates particularly in mucosal surfaces. IgM, a pentameric Ig, is the largest Ab 
and it is associated with a primary immune response and is frequently used to diagnose acute 
exposure to an immunogen or pathogen (Schroeder and Cavacini, 2010). IgD and IgE are found 
15 
 
in trace amounts in the blood with short half-lives. IgD remains membrane-bound and is involved 
in regulation of cell activation while IgE is associated with hypersensitivity and allergic reactions 
(Schroeder and Cavacini, 2010). Autoantibodies are antibodies produced by the immune system 
that target one or more of the host proteins, resulting in autoimmune diseases. Classical 
autoantibodies are typically IgMs and include: anti-nuclear antibodies (ANA), which bind to 
nuclear membrane, nucleoplasm, nucleoli and nuclear organelles of cells. Rheumatoid Factor 
(RF), which binds with relatively low affinity to the Fc region of IgGs and which is found in the 
serum of Rheumatoid Arthritis (RA) patients (Ma et al., 2017); Anti-double-stranded DNA 
antibodies, anti-Sm antibodies, antiphospholipid antibodies, anti-Ro, anti-ribonucleoprotein and 
anti-La Antibodies which are all frequently found in Systemic Lupus Erythematosus (SLE) patients 
(Ma et al., 2017); & Anti-Sjogren’s syndrome A (SSA) and -B (SSB) antibodies, which are found in 
many patients with Sjogren’s Syndrome (Ma et al., 2017). 
In cancer, multiple aberrations result in autoantibody production against TAAs, including 
tolerance defects and inflammation, changes in TAA expression levels, altered protein structure, 





Figure 1.8. The proposed causes of antibody production in cancer [Adapted from (Zaenker et al., 2016)]. 
Abbreviations include: TAA = tumour-associated antigen. 
 
1. Tolerance defects and inflammation:  Roughly half of the lymphocytes in lymphocytic organs 
are directed against autoantigens. Upon circulation, these self-reactive lymphocytes enter a 
series of checkpoints that control central tolerance. Thus, only lymphocytes that are non-self-
reactive will mature. However, self-tolerance is complex and subject to error. For example, 
maintaining clonal anergy requires constant receptor interaction and signalling, which can be 
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reversed by antigen dissociation, leading to autoantibody production. Tolerance defects also 
stem from the downregulation of Tregs. Studies indicate delayed tumour growth due to decreased 
Tregs levels, which correlate with increased levels of effector T helper cells, germinal centre B-
cells, and high titres of autoantibodies (Kim et al., 2010). Lastly, lasting chronic inflammatory 
responses are associated with cancer. Inflammation assists with increased vasculature 
permeability allowing immune cell accumulation at the tumour site (Alvarez Arias et al., 2014). 
The inflammatory response is suggested to facilitate the release and exposure of intracellular 
antigens to the immune system, resulting in autoantibody production in cancer patients (Carl et 
al., 2005). 
2. Changes in protein expression levels: Autoimmune responses to TAAs are largely due to 
antigen overexpression during tumourigenesis. Studies with hepatocellular carcinoma showed 
an association with increased CENPF levels with anti-CENPF autoantibody production (Ménard et 
al., 2004). Breast cancer patients with increased Her2/Neu and MUC1 produced anti-HER2/Neu 
and anti-MUC1 autoantibodies, whereas autoantibodies were not detected in patients with low 
Her2/Neu and MUC1 expression levels, respectively. Autoantibody production may result from 
protein expression in an aberrant location. Cancer-testis antigen (CTA) expression is normally 
confined to immunoprivileged sites, e.g. testis, ovaries, or trophoblast of the placenta (Scanlan 
et al., 2002), and expression in many cancer types results in autoantibody production (Simpson 
et al., 2005). Similarly, 21% of hepatocellular carcinoma patients produce autoantibodies against 
oncofoetal antigen IMP2, a protein normally expressed only during prenatal development and 
shortly after birth (Zhang et al., 1999). 
3. Altered protein structure: Neoepitopes may be created by somatic mutations that alter protein 
structure, or due to the exposure of epitopes normally located within enclosed protein regions 
(Liu et al., 2012). Genetic instability, a hallmark of cancer (See section 1.1), also results in the 
expression of neoantigens that induce an autoimmune response (Joseph et al., 2014). 
Autoantibody responses have also been raised against mutated cancer proteins. For example, 
p53 is frequently mutated in various cancers, resulting in autoantibody production. However, 
only 20-40% of patients produce autoantibodies against mutated p53, indicating that not all 
protein aberrations induce autoantibody responses (Soussi, 2000) or that not all cancers have 
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mutated p53. Although protein products of missense mutations result in autoantibody 
production, protein products of stop, splice and frameshift mutations have been reported to not 
cause autoantibody production in lung cancer (Reuschenbach et al., 2009). In contrast, frame 
shift mutations do induce immunological responses in CRC patients (Schwitalle et al., 2008). The 
mRNA translation from alternative open reading frames can also generate proteins capable of 
triggering an autoimmune response. Examples of such proteins are CTAG1B (Wang et al., 1998) 
and opioid growth factor receptor (OGFr) (Mollick et al., 2003). Lastly, aberrant post-translational 
modifications (PTMs) on cancer proteins, e.g. glycosylation, methylation, phosphorylation, 
sumoylation, adenosine diphosphate-ribosylation, ubiquitination, acetylation and citrullination, 
are also capable of inducing an autoantibody response.  
4. Cellular death mechanisms:  
The exact mechanism leading to an autoimmune response against cancer is still to be elucidated. 
Several studies provide evidence that post-apoptosis, insufficient clearance of accumulated 
nuclear and cytoplasmic proteins plays an important role. Also, cell lysis following tumour cell 
necrosis and autophagy results in the spillage of autologous proteins into blood, triggering an 
immune response that leads to autoantibody production. 
Tumour cell lysis may also occur through cytokine secretion, including tumour necrosis factor 
(TNF) and IFN-γ by T-cells.  Also, TAAs present on the surface of tumours cells may induce an 
immune response that promotes autoantibody production. Furthermore, apoptotic cancer cells 
present altered cleavage products and post-translationally modified self-antigens on the surface 
of blebs, which also promotes autoimmunity (Joseph et al., 2014). 
1.4. Tumour antigens and cancer-testis antigens 
Tumour antigens are antigenic substances produced in tumour cells that trigger an autoimmune 
response in the host. Tumour antigens can be defined as TAAs, which are antigens similar to 
proteins found in normal cells, but are modified or overexpressed; or TSA, which are antigens 
found only in or on tumour cells, and not on normal cells.   
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Tumours were first observed to be immunogenic during the 1940s and 1950s, when rodents 
showed immune-mediated rejection of syngeneic transplanted tumours (Gross, 1943). 
Subsequently, the identities of many tumour antigens, in mice and humans revealed that they 
can be oncovirus proteins such as E6 and E7 (Stauss et al., 1992); mutated proteins such as RAS 
and p53 (Peace et al., 1991; Skipper and Stauss, 1993); fusion proteins such as BCR-Able (Chen et 
al., 1992); over-expressed proteins such as HER2/neu (Schechter et al., 1984); differentiation 
proteins such as CD20 (Anderson et al., 1984); or contain aberrant PTMs. A list defining cancer 


















Table 1.1. List of cancer antigens-types, definitions and examples. Tumour antigens can be defined as TAAs, which are antigens similar to proteins 
found in normal cells, but are modified or overexpressed; or TSA, which are antigens found only in or on tumour cells, and not on normal cells.  
The table below lists cancer-antigen-types, definitions and examples. Abbreviations: TAAs = tumour-associated antigens; TSAs = tumour-specific 
antigens. 
Cancer antigen-type Definition Examples Reference 
Cancer-testis antigens 
Cancer proteins with restricted expression to the 
testis or placenta, but also expressed in cancer. 
NY-ESO-1 (Jäger et al., 1999) 
MAGE (Daudi et al., 2014) 
SSX (Smith and McNeel, 2010) 
Differentiation antigens 
Cancer proteins expressed during at least one 
stage of cellular differentiation resulting in 
tumour development 
MART-1 (Colella et al., 2000; Yee et al., 2000) 
HER-2/neu (Slamon et al., 2001) 
IL22RA1 (Qi and Ding, 2018) 
Virus-associated antigens 
Viral stain-associated proteins that promote 
cancer initiation and/or progression. 
EBV (Liu et al., 2018) 
HPV (Schäfer et al., 2017) 
ATLA (Hinuma et al., 1982) 
Mutational antigens 
Cancer proteins that result from mutations in 
otherwise “normal” proteins 
P53 (Peace et al., 1991; Deniger et al., 2018) 
BRAF (Tomei et al., 2015) 
EGF (Lynch et al., 2004) 
Over-expressed antigens 
Cancer proteins that are overexpressed in 
cancers, usually conferring tumorigenic effect 
and an immune-suppressor. 
VEGF/VEGFR (Li et al., 2016; Zhu et al., 2017) 
AR (Bupp and Jorgensen, 2018) 









CTA, also known as germ-line antigens, were added to the list of TAAs in 1991 when Van Der 
Bruggen et al. (van der Bruggen et al., 1991) showed expression of melanoma antigen family A, 
1 (MAGE-1) antigen in the MZ2-MEL melanoma cell-line using autologous typing. Subsequently, 
cloning of the gene revealed that the gene encoding MAGE-1, MAGEA1, is a member of the 12 
gene family whose expression is normally restricted to the testis, but can be detected in a wide 
range of tumour-types (De Plaen et al., 1994). Further investigations lead to the discovery of 
other tumour antigens that were encoded by testis-restricted genes, including BAGE (Boël et al., 
1995) and GAGE (De Backer et al., 1999) genes. Other antigens isolated also include NY-ESO-1 
(Türeci et al., 1996), HOM-MEL-40 (Türeci et al., 1998) and SYNSP1 (Chen et al., 1997). Given the 
reactivation and subsequent immunogenicity of testis proteins in tumours, such antigens were 
termed CTAs. Numerous methods have been developed and employed for the discovery of CTAs, 
with nearly 225 genes identified, however, many of these were identified by gene expression 
data alone and have unknown antigenic status. The comprehensive CTA database, including the 
list of proteins with gene names, and mRNA, protein expressed and immune response summary, 
can be found at http://www.cta.lncc.br/. 
The roles of CTAs in the gamete are unclear, although gene expression and knockout studies have 
shown that these proteins have diverse functions. Studies on X-lined CTAs, e.g. MAGEA1 and NY-
ESO-1, have shown their expression in the initial stages of spermatogenesis (Jungbluth et al., 
2000b). Expression of GAGE genes has been detected in OCT4+ primordial germ cells, suggesting 
that the protein may be important in germ stem cell function (Gjerstorff et al., 2007). Studies on 
mice lacking single CTAs frequently showed reduced or even ablated fertility. Furthermore, 
SPATA19 and COX6B2 have been shown to be essential in sperm metabolism (Goldberg et al., 
2010), AKAP3, CABYR, SPA17 and ROPN1 are important in sperm movement and SPO11, SYCE1, 
SYCP1, HORMADI and TEX15 are important for meiosis in sperm cells (Brown et al., 2003; Eddy 
et al., 2003; Chiriva-Internati et al., 2008; Fiedler et al., 2008). The diverse function of CTAs in 
their native setting suggests that they may be important in a number of tumourigenic features. 
The functions of CTAs in cancers have previously been studied, appearing to promote 
tumourigenicity. A CTA called hCGH was detected in a variety of cancers including bladder, 
breast, renal, ovarian, prostate, pancreatic and CRCs (Stenman et al., 2004). hCGH, normally 
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produced in the placenta, is required for progesterone secretion by the corpus leuteum in order 
to promote the formation of blood vessels and capillaries to sustain the developing foetus, thus, 
hCGH may contribute to the process of angiogenesis in tumours (Cole, 2012). The CTA, ATAD2, 
acts as a cofactor for Myc-mediated transcription, where its depletion reduces tumour cell 
proliferation by inhibiting S-phase entry (Ciró et al., 2009), suggesting that ATAD2 may promote 
tumourigenicity. Furthermore, CTAs including PRAME (Epping et al., 2005), CCDC62 (Chen et al., 
2009) and MAGE (Doyle et al., 2010), have been implicated in tumourigenic signalling, whereas 
CEP55 (Chang et al., 2012), TEX14 (Mondal et al., 2012), CASC5, TTK (Cheeseman et al., 2008) and 
NUF2 (DeLuca et al., 2002) are associated with tumour cell division. The tumourigenic properties 
of CTAs make them potential targets for cancer immunotherapy and useful as targets for cancer 
diagnosis. 
1.5. Autoantibodies against TAA for cancer diagnosis 
To counteract high cancer mortality rates, diagnostic tools need to be developed for early stage 
detection of cancers before they reach incurable metastatic stages. Detection of cancer is 
currently typically restricted to morphological and histochemical diagnosis of primary tumour 
samples.  More recently, autoantibodies against autologous TAAs have been investigated as 
potential cancer biomarkers. Using autoantibodies for cancer diagnosis is advantageous as (1) 
serum extraction is minimally invasive; (2) increased autoantibody levels are detected at early 
cancer stages (Zayakin et al., 2013); (3) autoantibody production precedes clinical signs of tumour 
progression by months to years (Caron et al., 2007); (4) autoantibodies are stable serological 
proteins (Anderson and LaBaer, 2005); and (5) autoantibodies persist for long periods in blood 
due to limited proteolysis and clearance from circulation (Pedersen and Wandall, 2011).  
No single autoantibody has been used alone as a cancer biomarker due to low sensitivity and 
specificity of single markers. However, biomarker panels of multiple TAAs can in principle result 
in high sensitivity and specificity, and are therefore sought after to produce biomarker panels to 
detect specific cancer-types at early-stages. According to the WHO, breast, prostate and CRC are 
the most prevalent cancer-types globally (Figure 1.6). As such, autoantibodies that may serve as 
biomarkers for these cancer-types will be discussed: 
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For breast cancer, CA 15-3, CA 27-29, and carcinoembryonic antigen (CEA) are clinically used as 
biomarkers, although they are more informative for advanced disease states. The first 
autoantibody biomarkers for breast cancer include HER2 (Disis et al., 1997), p53 (Crawford et al., 
1982), MUC1 (von Mensdorff-Pouilly et al., 1996), and NY-ESO-1 (Stockert et al., 1998). A panel 
of autoantigens, including HER2, p53, p16 and c-Myc produced sensitivity- and specificity-values 
of 44% and 97.6%, respectively. Using serological analysis of recombinant cDNA expression 
libraries (SEREX), SERAC1, RELT, SOCS and ASB-9 achieved sensitivity- and specificity-values of 
77% and 82.8%, respectively (Zhong et al., 2008). Serological proteome analysis (SERPA) was used 
to assess the autoantibody response of advanced breast cancer patients, where HSP60 
autoantibodies were detected in 47.5% of patients, but only in 4.7% of healthy control (HC) sera 
(Hamrita et al., 2008).  
For prostate cancer, prostate specific antigen (PSA) serum levels are used for diagnosis, although 
its specificity is less than 50%, leading to high false-positive results (Zeliadt et al., 2011). 
Furthermore, the PSA biomarker cannot reliably distinguish between benign and malignant 
prostate cancer (Stamey et al., 1987). Furthermore, PSA levels can increase due to non-cancerous 
conditions e.g. urinary infection (Pan and McCahy, 2012). Using protein microarrays on prostate 
cancer and HC sera, increased autoantibody levels against BRD2, elf-4G1, RPL22, RPL13a and 
XP_373908 were detected in prostate cancer patients, producing sensitivity- and specificity-
values of 81.6% and 88.2%, respectively (Wang et al., 2005). Another microarray study aimed to 
identify autoantigens that distinguish prostate cancer from benign prostate hyperplasia in 
patients with high PSA levels. The potential biomarkers include TLN1, TARDBP, LEDGF, CALD1, 
and PARK7. Alone, PSA produced sensitivity- and specificity-values of 12.2 and 80%, respectively, 
whereas the collective panel produced sensitivity- and specificity-values of 95% and 80%, 
respectively (O’Rourke et al., 2012). Using the cancer-testis antigen microarray (CT100plus) 
containing CTAs and other TAAs, revealed that prostate cancer patients had higher autoantibody 
titres against GAGE1, ROPN1, SPANZA1 and PRKCZ compared to patients with benign prostate 
hyperplasia or disease control (Adeola et al., 2016). 
For CRC, CEA is the only clinically used serological biomarker, however, it has low sensitivity and 
specificity (Liu et al., 2009). Autoantibodies against Fas reportedly show high specificity for early-
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stage CRC. In addition, higher anti-Fas titres were detected in patients with colorectal adenomas 
versus colorectal adenocarcinomas, resulting in sensitivity- and specificity-values of 17% and 
100% for CRC (Reipert et al., 2005), suggesting that Fas may not be useful to detect CRC, but 
rather to confirm the absence of disease. An enzyme-linked immunosorbent assays (ELISA)-based 
assay was used to detect MUC5AC between CRC patients, disease controls and healthy 
volunteers, producing sensitivity- and specificity-values of 73% and 54%, respectively (Kocer et 
al., 2006). Autoantibodies against HSP60 (He et al., 2007), p53 (Cioffi et al., 2004; Yoshizawa et 
al., 2007; Belousov et al., 2008) and Calnuc (Chen et al., 2007) have also been detected in CRC 
patients, although autoantibodies against these autoantigens are also detected in patients with 
other cancer-types, too, indicating that these biomarkers are not specific to CRC. 
Taken together, it is clear that emerging autoantibody biomarkers have applicability in the clinical 
setting, although the current issues regarding specificity and sensitivity need to be addressed. 
The apparent solution involves the use of multiple biomarkers for cancer detection, that, 
according to the literature, improves both the sensitivity and specificity of the test. It is also 
apparent that biomarkers specific to a cancer-type are needed to prevent diagnostic ambiguity. 
Although ELISAs provide effective means of identifying novel antigens, these assays are limiting 
with regards to the number of biomarkers that can be tested, and often involves tedious 
procedures. Thus, alternate robust and rapid assaying methods are required, for example 
proteomics which tests hundreds to thousands of proteins as potential biomarkers for cancer. 
1.6. Methods for cancer autoantigen and autoantibody identification 
Cancer patients produce autoantibodies against proteins that are mutated, misfolded, 
improperly glycosylated, overexpressed, truncated or aberrantly localised within tumour cells. 
Research on CTAs and TAAs, as well as their related autoantibodies, has provided an abundance 
of targets for therapy, prognostication as well as biomarkers of disease and response to therapy. 
Techniques used for the identification of cancer associated autoantibody biomarkers are 
discussed below: 
Western blotting is a widely used technique whereby proteins are separated according to their 
molecular weight by electrophoresis, and then transferred to a membrane; a primary Ab specific 
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to the protein of interest is then used to detect the presence and relative abundance of the target 
protein. Conventional western blotting allows the detection of specific proteins at the level of 
single isotypes. However, it is associated with poor reproducibility, lack of accurate quantitation, 
and a lengthy time to results, whilst non-specific cross-reactivity of mono- and poly-clonal 
primary and secondary antibodies on the blots is common. In the context of biomarker discovery, 
western blotting is used as a validation method rather than a primary method of identifying 
biomarkers as it is time-consuming, laborious, requires a large sample volume, and allows the 
assessment of only a few samples at a time.  
ELISAs, unlike western blotting, are adaptable to high throughput as it is performed in a 96-well 
microtiter plates, whereby plate handling and detection systems can be automated. 
Furthermore, ELISAs can be used to determine the exact amount of protein in a sample, making 
it readily quantitative. The signals can be produced by chromogenic reaction or 
chemiluminescence, which is quantified by spectrophotometry. Considering its rapidity and high-
throughput capability, as well as the generation of quantitative information, ELISA is an excellent 
tool for screening, verification and validation of a small number of biomarkers. However, 
standard ELISAs often have relatively low sensitivity levels and detection usually depends on 
enzymatic amplification of signal at the end of the assay. In addition, ELISA can give false-positive 
outputs due to cross-reactivity of the detecting antibodies and other proteins in the sample. Since 
sensitivity and specificity are prerequisites of any biomarker discovery platform, traditional ELISA 
may not be the ideal choice when it comes to identifying biologically relevant and meaningful 
disease biomarkers. 
Several high throughput techniques have been used to identify novel CTAs and TAAs, which 
include SEREX, phage display, SERPA and protein micro-array technology, which are discussed 
below: 
SEREX was developed by Sahin et al. in 1995, and utilizes human cDNA derived from patients to 
profile autoantibody repertoires from the same patient in a process called autologous typing. The 
approach involves the extraction of mRNA from cancer tissue or tumour cell and the subsequent 
construction of a tumour-derived cDNA expression library into a bacteriophage for infection of 
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E.coli. Recombinant proteins are expressed during the lytic phase and blotted onto a 
nitrocellulose membrane. Sero-reactive proteins can then be identified by sequencing the phage 
cDNA from positive plaques (Sahin et al., 1995) (Figure 1.9). The approach is highly sensitive, 
given the use of DNA detection, compared to direct protein identification-based methods that 
are often limited by absolute protein abundance. Furthermore, the method detects potential 
antigens from patient-derived tissues and identifies several TAAs in one experiment. The first 
cancer testis antigen, NY-ESO-1, was identified by SEREX by analysing TAAs that elicit high titre 
IgG Ab in sera from patients with different types of cancer (Yuan et al., 2016). SEREX has been 
used to identify several TAAs that generate a humoral response in cancers such as those from 
kidney, lung, breast and colon (Martin et al., 2011). However, a crucial limitation of SEREX is that 
it lacks the ability to differentiate or detect PTMs that are likely to play a significant role in 
autoimmune diseases (Ganesan et al., 2016) and cancers (Martin et al., 2011). Furthermore, 
identification of TAAs is limited to those that are expressed by the patient tumour or cell line in 
which the cDNA library was derived, which means that more than one cDNA library may be 
required to identify comprehensive set of TAAs for difference cancers (Martin et al., 2011). 
The phage display approach was developed by Smith, 1985. For the method, a phage display 
library is constructed from cancer tissue, and biopanning, an affinity selection technique which 
selects for peptides that bind to a given target, is used to enrich for target peptides. Several cycles 
of biopanning are performed to enrich for peptides that are specific to cancer sera. Reactive 
phages are cloned to monoclonality and propagated prior to printing on a microarray. The 
microarray is incubated with fluorescently-labelled antibodies against the autoantigen of 
interest. The microarray is also incubated with a fluorescently-labelled Ab specific for the phage 
capsid protein, which is used for antigen signal normalization (Smith, 1985a) (Figure 1.10). Phage 
display is useful for the direct detection of TAAs from tumour tissues or a patient-derived tumour 
cell-line, and simultaneous screening of a large number of antigens against the sera of cancer 
patients relative to the sera of HCs. However, like SEREX, phage display cannot detect alternate 





Figure 1.9. The strategy followed in serological analysis of recombinant cDNA expression libraries 






Figure 1.10. Overview of the phage display protein microarray production strategy. [Adapted from 
(Gunawardana & Diamandis 2007)]. 
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SERPA was developed by Klade et al. in 2001, using a combination of two-dimensional (2D) gel 
electrophoresis and serological analysis. The method involves separating proteins using three 
replicate 2-dimensional electrophoresis (2-DE) gels under identical conditions. Two gels are 
blotted to a nitrocellulose membrane, and probed with cancer or normal sera, whereas the third 
gel is stained with Coomassie blue. Unique immunoreactive spots present in patient and not in 
the healthy sample are identified and excised from the third gel, and subjected to trypsin 
digestion followed by protein/peptide identification using mass spectrometry, and subsequently 
validated using an ELISA (Figure 1.11)  (Klade et al., 2001). The advantages of SERPA includes the 
detection of autoantigens from in vivo material, the identification of tumour-specific PTMs, and 
a parallel analysis of cancer patient and HC plasma. However, the inherent gel-to-gel variability 
and relatively low resolving power of individual gels impacts on the accuracy of spot picking and 
imposes a limitation, which is especially true for low-abundance proteins. Several modifications 
have been suggested to address such limitations, including the triangulation approach involving 
rigorous quality control steps to accurately identify the protein as well as fluorescence-based 2-
dimensional immunoproteomic approaches (Ganesan et al., 2016), but these still so not address 














Figure 1.11. Serological proteome analysis (SERPA). Abbreviations include: 2D = two-dimensional; MS = 




Protein microarrays are easily customisable, miniaturised platforms used to simultaneously 
characterise the biomolecular interactions of hundreds of proteins that are spotted in defined 
locations on a solid support. Microarrays allow the screening of a wide variety of analytes, such 
as antibodies, proteins, DNA, RNA, small molecules, lipids, enzymes, as well as peptides, allowing 
the quantification of analytes that bind to arrayed proteins. Typically, three types of protein 
microarrays are commonly used, including analytical, function and reverse-phase microarrays. 
Analytical protein arrays, or Ab arrays, are ideal for quantification of different proteins in a 
biological sample, monitoring protein expression levels and protein profiling in what amounts to 
miniaturised, highly multiplexed ELISAs. Functional protein arrays can be used for autoantibody 
and immune response profiling, biomolecular interaction profiling and the identification of 
enzyme substrates, amongst others (Duarte and Blackburn, 2017), whilst reverse phase protein 
arrays are suited for detection of altered proteins or other targets that contribute to disease. 
Moreover, protein microarrays can be applied in diagnostic and therapeutic research, through 
new biomarker discovery for disease staging and monitoring, potential drug-target evaluation 
and for identification of new drug targets. 
Microarray slide surface chemistries vary: aldehyde and epoxy-derivatized glass surfaces are used 
for random attachment through amines, whereas nitrocellulose, hydrogel or metal surfaces are 
used for the attachment of affinity-purified proteins. An ideal surface chemistry should resist 
non-specific adsorption, provide sufficient stability for the 3D structures and allow the 
immobilisation of native proteins and provide highly specific linking chemistry that eliminates the 
need for protein pre-purification (Duarte and Blackburn, 2017). 
The E.coli expression system rapidly produces proteins at relatively low costs, require simple and 
rapid culture conditions and are highly scalable. However, inefficient disulphide bond formation, 
insolubility, aggregation and poor folding of proteins have been reported using this method, as 
well as the minimal capability of forming post-translational modifications (Broadway, 2012). 
Yeast protein expression systems, e.g. Saccharomyces cerevisiae (S. cerevisiae) and Pichia 
pastoris (P. pastoris), are common alternatives to prokaryotic expression systems and fold 
efficiently and provide numerous PTMs (Broadway, 2012). However, the major disadvantage of 
yeast expression systems is that it does not mimic protein glycosylation patterns from 
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mammalian cells, with proteins tending to be hyperglycosylated. Moreover, yeast lysis conditions 
are harsh and induce many endogenous proteases, meaning that the extracted recombinant 
proteins can be significantly proteolyzed. Baculoviruses belong to a diverse group of large double-
stranded DNA virus that infect many different species of insects as their natural host. Baculovirus 
stains are highly species-specific. The system shows good expression levels especially for 
intracellular proteins and typically produces soluble and functionally active recombinant proteins 
containing proper folding, disulphide bond formation and oligomerization, in addition to 
performing mammalian-like post-translation modifications. In particular, the glycosylation of 
proteins is more like mammalian cells, which indicates that the protein produced using this 
method is both structurally and functionally similar to its native counterpart (Broadway, 2012). 
Mammalian cells, e.g.  HeLa, human embryonic kidney-derived (HEK293) epithelial cells, Chinese 
hamster ovary cells (CHOs) and African green monkey kidney cells (COS), are preferred by some 
researchers as they produce more “humanised” proteins. Despite producing eukaryotic 
recombinant proteins, mammalian expression systems require more demanding culture 
conditions compared to other systems (Broadway, 2012), and so are significantly more 
challenging for high throughput expression purposes. 
Previously, Hanash et al. (2003) demonstrated the feasibility of manufacturing a natural protein 
microarray using chromatographic techniques and microarray printing technology. Briefly, cell 
lysate from a cancer cell-line is resolved using liquid-based isoelectric focusing into 20 fractions. 
Each fraction is further divided into 92 fractions using reverse-phase liquid chromatography. The 
fractionated proteins are lyophilized and re-suspended in a suitable buffer for printing on a 
nitrocellulose-based array. The protein array is screened using sera from cancer patients and 
healthy individuals as controls. Protein are subsequently identified using mass spectrometry 





Figure 1.12. Overview of the natural protein microarray production strategy. [Adapted from 
(Gunawardana & Diamandis 2007)]. 
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SEREX, phage display, SERPA and cell fractionation methods have provided advanced and 
effective means of identifying numerous novel TAAs that are applicable in the clinical setting, for 
cancer diagnosis and in some cases, cancer treatment. The most significant drawbacks include 
the use of non-native TAAs that are expressed in E.coli or proteins that have been denatured (e.g. 
in SERPA), resulting in missed TAAs due to the loss of conformational epitopes. Thus, to identify 
TAAs that can be used to reproducibly detect cancer, autoantibody and autoantigen detection 
methods should be improved to identify near-native proteins with relevant PTMs. An approach 
proposed in this thesis involves the use of affinity purification-mass spectrometry (AP-MS), 
whereby the plasma-derived IgG molecules are purified from CRC patients using Protein G beads, 
which is subsequently used to capture native cancer antigens from autologous patient lysate. 
Using the relevant controls, potential antigens enriched from cancer-specific AP-MS samples can 
be identified for use as cancer biomarkers (See Chapter 4). 
1.7. Citrullination and cancer 
Aberrant PTMs on cancer proteins can activate an autoimmune response in cancer patients. 
Examples of reported immune-activating PTMs include glycosylation, methylation, 
phosphorylation, sumoylation, adenosine diphosphate-ribosylation, ubiquitination, acetylation 
and citrullination. Although citrullination is not as extensively investigated as other PTMs e.g. 
glycosylation, aberrant citrullination of proteins has been reported for cancer patients (Chang et 
al., 2009; Baka et al., 2011; Assmann et al., 2014). 
Protein citrullination is a calcium-dependent hydrolytic reaction that converts arginine to the 
citrulline amino acid, resulting in the loss of ammonia (Figure 1.13) (Rogers and Simmonds, 1958). 
The reaction is catalysed by the PAD family of proteins, consisting of 5 isozymes (PAD1-4 and 6), 
each with unique and overlapping target substrates, but with tissue-specificity (Table 1.2) 
(Knuckley et al., 2010; Darrah et al., 2012). Under physiological conditions, PADs are not normally 
active unless stimulated by calcium, resulting in the citrullinated of structural proteins e.g. 
vimentin, filaggrin and keratin (Inagaki et al., 1989; Senshu et al., 1995); and proteins involved in 
gene transcription e.g. histones H1, H2A, H3 and H4 (Wang, 2004; Saiki et al., 2009; 





Figure 1.13. PAD-catalysed conversion of peptidyl arginine to peptidyl citrulline. PAD isozymes catalyse 
the calcium-dependent hydrolytic conversion of peptidyl arginine to peptidyl citrulline, with the loss of 
ammonia. 
 
Table 1.2. Substrates and locations of PAD isozymes in humans. Abbreviations include: PAD = protein 
arginine deiminase. [Adapted from (Witalison et al., 2015)] 
Isozyme Known Substrates Location 
PAD1 Keratin and filaggrin Epidermis, hair follicles and the uterus 
PAD2 Myelin basic protein, vimentin, actin and 
histones 
Central nervous system, spleen, skeletal 
muscle and leukocytes, colon and tumours 
PAD3 Filagrin, trichohyalin, apoptosis-inducing 
factor and vimentin 
Epidermis and hair follicles 
PAD4 Histones, ING4, p300, p21, nucleophosmin 
and nuclear lamin C 
Macrophages, neutrophils, mammary glands 
and tumours 
PAD6 Unknown Ovaries, eggs and embryo 
 
 
Neeli et al. were the first to demonstrate the connection between histone acetylation and 
neutrophil extracellular “trap” (NET) release to confer protection against pathogens (Neeli et al., 
2008), although it was later found that deiminated histones were antigens of human 
autoantibodies, aiding in pathogen removal (Dwivedi et al., 2012). Citrullinated proteins, and 
resulting autoantibody responses, have also been associated with autoimmune diseases, 
including rheumatoid arthritis (Schellekens et al., 1998), Alzheimer’s disease (Ishigami et al., 
2005) and cancer (Chang and Fang, 2010). 
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PAD2 and PAD4 expression has been reported to be dysregulated in multiple cancer-types. For 
example, PAD2 levels are reportedly elevated in breast cancer cell-lines (Zhang et al., 2012), 
whereas decreased PAD2 expression is reported for CRC and is associated with poor disease 
prognosis (Funayama et al., 2017). Increased PAD4 levels were reported for cancerous tissues, 
but not in benign tumours or non-cancerous inflammatory disease (Chang et al., 2009). 
Citrullination of cancer proteins culminates in an autoantibody response in lung cancer (Baka et 
al., 2011) and diffuse large B-cell lymphoma patients (DLBCL) (Assmann et al., 2014). 
1.8. Cancer immunotherapy  
Cancer immunotherapy is a biological therapy used to stimulate or suppress the immune system 
to aid in cancer eradication. The various arms of the immune system have been implicated in 
cancer detection and eradication.  
Early In vivo mice experiments showed that T-cell populations cultured with leukaemia cells 
eradicate leukaemia when introduced into mice models (Cheever et al., 1981a, 1981b). Since 
then, clinical trials have provided evidence of a powerful anti-leukaemia response in patients 
treated with allogeneic hematopoietic cells (Wu et al., 2005; Wu and Ritz, 2006). In addition, 
metastatic melanoma patients displayed metastatic regression after treatment with CD8+ T-cells 
specific toward melanoma proteins MART-1 (Yee et al., 2002; Morgan et al., 2006), Melan-A, and 
gp100 (Yee et al., 2002). Cancer-specific monoclonal antibodies can also produce potent anti-
tumour activity in cancer patients.  
Numerous studies have shown clinical efficacy of monoclonal antibodies against HER2-positive 
breast cancer (Piccart-Gebhart et al., 2005; Romond et al., 2005), B-cell lymphomas (Cheson and 
Leonard, 2008), as well as head and neck (Kim et al., 2004), non-small-cell lung (Giaccone, 2005) 
and colorectal (Mendelsohn, 1997) cancers.  Compelling evidence confirms immune reactivity 
toward tumour antigens and other molecules, although patient responses are marginal, possibly 
due to late disease presentation (patients receive immunotherapy after other treatments have 
failed), and/or tumour immune evasion. Of particular interest to this study is tumour immune 
evasion through checkpoint inhibitors mediated by cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and programmed death 1(PD-1), discussed below (see Section 1.9).  
37 
 
1.9. Immune checkpoint inhibitors: CTLA-4 and PD-1 
The discovery of immune checkpoint proteins such as CTLA-4 and PD-1, is regarded as a big step 
forward in cancer immunotherapy. The roles of these checkpoint inhibitors in immune 
deactivation towards tumours since their inhibition can reactivate the immune system against 
cancer. The roles of CTLA-4 and PD-1 in immune deactivation and as cancer vaccine targets are 
further discussed below:  
Besides TCR and MHC interaction (See Section 1.3), T-cell activation requires co-stimulatory 
signals. One essential interaction occurs between CD28 on T-cells and B7-1 or B7-2 molecules on 
APC, which aids T-cell proliferation and survival, the production of growth cytokines (e.g. IL-2), 
and increased energy metabolism (Buchbinder and Desai, 2016). CTLA-4 is a CD28 homologue 
also found in or on T-cells, but has a higher affinity toward B7 molecules than CD28 (Chambers 
et al., 2001; Collins et al., 2002). The interaction between CTLA-4 and B7-1 or B7-2 molecules 
prevents T-cell proliferation and survival, the production of growth cytokines, and increased 
energy metabolism. On naïve T-cells, CTLA-4 is normally located in the cytosolic side of the cell 
membrane (Linsley et al., 1996). However, T-cell activation and stimulatory signals result in 
increased CTLA-4 levels on the T-cell surface (Krummel and Allison, 1996). The ratio of CD28 to 
B7 versus CTLA-4 to B7 binding that determines T-cell activation or no immune response (also 
known as anergy) (Krummel and Allison, 1995) (Figure 1.14). The exact molecular mechanism of 
CTLA-4 remains controversial: molecular studies indicate that CTLA-4 may function by recruiting 
phosphatases to TCRs resulting in signal attenuation (Lee et al., 1998), and/or by modulating cell 
motility and signalling through PI3 kinase (Knieke et al., 2012). Other in vivo studies suggest that 
CTLA-4 captures and removes B7 from the membranes of APC, preventing CD28 and B7 




            
 
Figure 1.14. CTLA-4-mediated inhibition of T-cell. T-cells become activated upon interaction between 
TCRs and peptide antigens presented on MHC molecules, in concert with CD28 and B7-mediated co-
stimulation. (A). A weak TCR stimulus in which CD28 and B7 binding results in IL-2 production, proliferation 
and increased survival. (B) Overstimulating TCRs result in CTLA-4 expression and transport to the cell 
surface. CTLA-4 has a high affinity for B7, and the interaction results in decreased IL-2 production, T-cell 
proliferation and survival. [Adapted from (Buchbinder & Desai 2016)] 
  
PD-1 regulates T-cell activation by binding to its ligands, programmed death ligand 1 (PD-L1) and 
programmed death ligand 2 (PD-L2). Upon binding, the PD-1/PD-L interaction generates signals 
that prevent phosphorylation of key TCR signalling intermediates, reducing T-cell activation 
(Bennett et al., 2003; Parry et al., 2005). Like CTLA-4, PD-1 binding to its ligands also inhibits T-
cell proliferation and survival, but also inhibits IFN-γ, TNF-α and IL-2 production (Keir et al., 2008) 
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(Figure 1.15). PD-1 is normally expressed on T-cells after high levels of stimulation, leading to 
suboptimal control of chronic infections and cancer (Wherry, 2011). 
 
 
Figure 1.15. PD-1-mediated inhibition of T-cells. Prolonged TCR stimulation causes the upregulation of 
PD-1 expression. Tumours cells expressed PD-L1 and PD-L2 (not shown) in response to inflammatory 
cytokines and/oncogenic signalling pathways. This interaction inhibits TCR-mediated T-cell activation, 
leading to decreased cytokine production, as well as T-cell proliferation and survival. [Adapted from 
(Buchbinder & Desai 2016)]. Abbreviations include: PD-1 = programmed death 1; PD-L1 = programmed 
death ligand 1; PD-L2 = programmed death ligand 2; TCR = T-cell receptor; IFNγ = interferon γ. 
 
Both CTLA-4 and PD-1 are also constitutively expressed on Treg cells, resulting in the dampening 
of immune responses. While CTLA-4 expression is restricted to T-cells, PD-1 is more broadly 
expressed on activated T-cells, B-cells and myeloid cells. Also, whilst B7 is restricted to APCs, PD-
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1 ligands are expressed by tumour cells and tumour-infiltrating lymphocytes. Lastly, CTLA-4 
appears to function in the priming phase of T-cell activation in the lymph nodes and spleen, 
whereas PD-1 functions during the effector phase in peripheral tissues. 
Preclinical studies with CLTA-4 and PD-1 blockade led to decreased tumour burden, thus, immune 
checkpoint inhibitors were further developed for cancer patient treatment. Monoclonal 
antibodies that block CLTA-4 and PD-1 have been developed for melanoma, non-small lung-, 
kidney-, prostate- and head and neck-cancers. Agents targeting PD-L1 are also being developed. 
Ipilimumab was the first anti-CTLA-4 blockade to prolong survival in patients with advanced 
melanoma (Hodi et al., 2010; Robert et al., 2011). Long term survival analysis indicated a 3-year 
survival of 22%, 26% and 20% in all patients with sufficient follow-up, in treatment of naïve 
patients, and in previously treated patients, respectively (Schadendorf et al., 2015). PD-1 
blockade has improved survival for metastatic melanoma, non-small cell lung cancer (NSCLC) and 
renal cell carcinoma (RCC) patients (Herbst et al., 2014; Topalian et al., 2014; Garon et al., 2015; 
Gettinger et al., 2015; McDermott et al., 2015). In one trial, advanced melanoma patients treated 
with pembrolizumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody) showed a 
superior response in pembrolizumab-treated versus ipilimumab-treated patients, with response 
rates of 34% and 12%, respectively. In conjunction with this data, patient survival rates were also 
high in pembrolizumab versus ipilimumab treatment, at 74% and 58%, respectively (Farolfi et al., 
2012). Nivolumab is a human IgG4 anti-PD-1 monoclonal Ab that selectively blocks the 
interaction between PD-1 and PD ligands, restoring T-cell immune activity directed against 
cancer. Nivolumab was the first checkpoint inhibitor approved for advanced NSCLC following 
chemotherapy, resulting in increased response rates, survival and progression-free survival when 
compared to intravenous docetaxel alone. Furthermore, nivolumab was better tolerated than 
docetaxel, as nivolumab-induced immune adverse events were more manageable (Keating, 
2015). Stage III/IV melanoma patients achieved a partial tumour response, with a median 
progression free survival of 172 days, with only 18% experiencing grade 2 or 4 adverse events 
(Deeks, 2014).   
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Combination check-point inhibitor treatments, targeting both CTLA-4 and PD-1, have also shown 
strong promise, with clinical trial data in untreated melanoma patients reporting objective 
response rates up to 72% (amongst patients with PD-L1-positive tumours) and with median 
progression-free survival for 11.5 months for ipilimumab plus nivolumab, compared to 2.9 
months with ipimilumiab alone and 6.9 months with nivolumab alone (Larkin et al., 2015). 
However, high grade immune-related adverse events (irAEs) occurred in 55% of those in the 
combination treatment group (Larkin et al., 2015) and similarly high rates if irAEs have been 
reported elsewhere for anti-CTLA-4 and anti-PD-1 treatments (Michot et al., 2016). 
Biomarkers that could predict treatment outcomes would be hugely beneficially in providing 
optimal patient treatment, whilst limiting potential adverse treatment-side-effects. Exhausted T-
cells are defined as T-cell dysfunction that arises during chronic infections and cancer, defined 
poor effector function, sustained expression of inhibitory receptors and a transcriptional state 
distinct from functional effector or memory T-cells (Wherry, 2011). Upregulation of PD-1 on 
exhausted-cells and of PD-L ligands on tumour cells, and/or tumour infiltrating cells, may serve 
as biomarkers that predict patient response to PD-1 or PD-1 ligand vaccines. Preliminary results 
of multiple tumour-types indicate that patients with PD-L1-expressing tumours or infiltrating 
immune cells typically have higher response rates to anti-PD-1 or anti-PD-L1 versus patients with 
low or no PD-L1 expression (Herbst et al., 2014; Taube et al., 2014), however, these results 
remain controversial as patients with NSCLC did not show a correlation between PD-L1 levels and 
treatment outcomes (Borghaei et al., 2015; Brahmer et al., 2015; Herbst et al., 2016; Passiglia et 
al., 2016). It has been more challenging to identify predictive biomarkers for ipilimumab-
treatment, due to low levels CTLA-4 expression, and wide range expression of B7 ligands. 
Retrospective studies have identified markers associated with treatment response, including 
absolute lymphocyte count, increased levels of T-cell activation marker ICOS, and T-cell response 
to NY-ESO-1 (Callahan et al., 2013), although neither biomarker has since been validated. In 
addition, a study concluded that neoantigen presentation on tumours correlates with overall 
survival in CTLA-4-treated melanoma patients (Snyder et al., 2014). Together, it is evident that 
reliable biomarkers for treatment response remain to be discovered in order to enable beneficial 
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management of patient treatment, thereby improving treatment response rate and reducing 






















The underlying hypothesis for the studies described in this thesis is that measurable differences 
in autoantibody repertoires can be detected in CRC and melanoma patients compared to HCs, 
which alone or as part of a biomarker panel, reproducibly detects cancer. In addition, we 
hypothesise that the autoantibody response against aberrant cancer proteins can also be used 
to assess disease prognosis and response to therapy. 
Aims and objectives 
The overall aim of this study is to identify TAAs associated with CRC and melanoma, that can 
reproducibly detect cancer and predict disease prognosis. The specific objectives therefore are: 
i. To develop a robust statistical pipeline that enables the assess the biomarker 
potential of TAAs identified using microarray technology. 
ii. To assess the autoantibody response of CRC patients on the CT100plus microarray, 
and use the established statistical pipeline to identify top biomarker candidates linked 
to disease diagnosis and prognosis. 
iii. To assess the autoantibody response of CRC patients toward citrullinated antigens 
using the CT100plus microarray, and use the established statistical pipeline to identify 
top biomarker candidates linked to disease diagnosis and prognosis. 
iv. To develop and test an AP-MS assay for the detection of TAAs associated with CRC, 
and compare the results to responses observed on the CT100plus microarray. 
v. To assess the autoantibody response of melanoma patients to checkpoint inhibitor 
treatment, and use the established statistical pipeline to identify top biomarker 






Chapter 2  
 
Analysis of CRC patient plasma on the CT100plus microarray  
 
Abstract 
Cancer patients elicit an autoantibody response toward TAA. The aberrant TAAs arise due to 
altered tissue-specific expression patterns, mutations, PTMs, inter alia, and induce autoimmune 
and autoantibody responses in the host. The resulting autoantibody response in cancer patients 
can in principle be used for cancer diagnosis and predicting disease prognosis. In this study, we 
assessed the autoantibody response of 57 CRC patients and 14 HCs on a custom CT100plus 
microarray. Significantly (p-value ≤ 0.05, adjusted p-value ≤ 0.05) higher autoantibody signals 
were detected in CRC patients versus HCs toward CEACAM 1, COL6A1, GRWD1, MAGEA1, 
MAGEA5, MAGEA10, NY-CO-1, SGY-1, SPANXB1 and THEG. Furthermore, receiver operator 
characteristic (ROC) analyses indicate area under the ROC curve (AUC)-, sensitivity- and 
specificity-ranges of 0.81 – 0.86, 0.70 – 0.88 and 0.64 – 0.86, respectively. Combined ROC results 
indicate that CEACAM1 and GRWD1 were the best autoantigen combination, producing 
sensitivity-, and specificity-, and AUC-values of 1.00, 0.77 and 0.94, respectively. Multivariate PCA 
and unsupervised hierarchical clustering analyses resulted in the identification of distinct clusters 
of CRC patients and HCs. Interestingly, COL6A1, THEG and CEACAM7, a homologue of CEACAM1, 
were also later identified by AP-MS (See Chapter 4), providing supporting evidence for biomarker 
identification. Patient clinical information was available for the CRC patients, although no 
significant association was found for patient clinicopathological features and antigenic signal. 
Together, we provide strong evidence using orthogonal methods that CRC patients elicit an 
autoantibody response to COL6A1, THEG and CEACAM1, which have potential use in CRC cancer 





CRC refers to cancers of the colon and rectum. CRC is a major cause of morbidity and mortality 
throughout the world, being the third most common cancer worldwide and the fourth most 
common cause of cancer-related deaths. The likelihood of CRC increases after the age of 40, with 
more than 90 % of CRC cases presented by patients aged 50 years or older. World-wide, CRC 
represents 10.1 % of all cancer incidences in women and 9.4 % in men. Although most CRC cases 
occur in developed countries e.g. the United States, Australia, New Zealand and Western Europe, 
an increase in the incidence number has been observed in developing countries. CRC is generally 
considered a cancer-type associated with the environmental risk factors e.g. cultural, social and 
lifestyle factors. Approximately 5-10% of CRC are hereditary, with the most common inherited 
conditions being hereditary nonpolyposis colorectal cancer (HNPCC) (accounts for ~ 2-6 % of CRC 
cases) and familial adenomatous polyps (FAP) (accounts for ~ 1 % of CRC cases) (Jackson-
Thompson et al., 2006). Genes for hereditary CRC have been identified, with HNPCC being 
associated with genes involved in DNA repair (MLH1 and MSH2) (Papadopoulos et al., 1994), and 
FAP being caused by mutations in the tumour suppressor gene APC (Wilmink, 1997). CRC typically 
starts as a non-cancerous polyp, which develops in the lining of the colon or the rectum. 
Adenomous polyps give rise to adenocarcinomas, which makes up about 96 % of CRC cases 
(Levine and Ahnen, 2006). Once the cancer forms in the large intestine, it can grow through the 
intestinal lining into the wall of the colon or rectum. Cancers which have invaded the wall are 
also able to penetrate the blood or lymph vessels, leading to cancer metastasis (Siegel et al., 
2014).  
CRC diagnosis typically starts with a positive faecal occult blood test, or observed blood in the 
faeces, followed by a colonoscopy. The patient medical history is also collected, including family 
history of CRC, and then a physical exam. Blood tests are often performed, including a complete 
blood count (CBC), as CRC patients tend to have anaemia due to tumour bleeding. Liver enzymes 
are also assessed as CRC can spread to the liver (www.cancer.org). Lastly, the tumour marker, 
CEA, is used for CRC diagnosis, although it reportedly has low sensitivity and specificity (Liu et al., 
2009). An autoantibody response is activated toward cancer-related aberrant proteins, including 
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TSA and TAA. Autoantibodies against Fas show high specificity for early-stage CRC. In addition, 
higher anti-Fas titres were detected in patients with colorectal adenomas versus colorectal 
adenocarcinomas. The resulting sensitivity- and specificity-values of 17% and 100% for CRC 
(Reipert et al., 2005) suggest that Fas may not be useful to detect CRC, but rather to confirm 
absence of disease. An ELISA-based assay was used to detect differential abundance of MUC5AC 
between CRC patients, disease controls and healthy volunteers, producing sensitivity- and 
specificity-values of 73% and 54%, respectively (Kocer et al., 2006). Autoantibodies against HSP60 
(He et al., 2007), p53 (Cioffi et al., 2004; Yoshizawa et al., 2007; Belousov et al., 2008) and Calnuc 
(Chen et al., 2007) have also been detected in CRC patients, although autoantibodies against 
these autoantigens are also detected in patients with other cancer-types, indicating that these 
biomarkers are not specific to CRC.  
The Blackburn lab created a customised cancer antigen microarray, called the CT100plus 
microarray. The microarray is fabricated with biotinylated native cancer-testis antigens and 
tumour associated antigens, printed in triplicate within 8 subarrays. Each subarray contains 5, 10 
and 15 ng/µl Cy5-labelled biotinylated bovine serum albumin (BSA) which is used for downstream 
normalization. Other controls include anti-human IgG antibody, used to confirm the presence of 
human serum/plasma and human IgG, used to confirm the addition of the detection Ab 
(fluorescently labelled anti-human IgG). The negative controls include lysis buffer only, insect cell 
lysate (ICL) and the vector containing the biotin carboxyl carrier protein (BCCP)-tag only (Figure 
7.4).  
The CT100plus microarray is built on a glass slide coated with a hydrogel layer for the covalent 
immobilisation of proteins. The hydrogel layer is a permeable polymer coating that helps 
preserve the three-dimensional (3D) structure of proteins, thus maintaining protein 
conformation and functionality. In-house slide derivatisation resulting in a uniform streptavidin 
layer covalently bound to the hydrogel, which greatly diminishes non-specific binding. 
Biotinylated cancer proteins are produced in insect cells to maintain the eukaryotic integrity of 
proteins. The whole ICL is spotted on the microarray and washed, resulting in the purified cancer 
protein remaining within the spot. The sandwich layout of the CT100plus microarray is depicted 
in Figure 2.1. Previously, the CT100plus microarray has been used to assay the serum samples of 
47 
 
melanoma (Duarte et al, unpublished data) and prostate cancer (Adeola et al., 2016) patients, 
and in this thesis was used to assess the autoantibody profiles of CRC (Chapter 2 and 3) and stage 
IV melanoma (Chapter 5) patients. 
 
 
Figure 2.1. Depiction of the slide surface chemistry of the CT100plis microarray. Individually purified 
BCCP-tagged proteins are immobilized onto custom hydrogel-coated glass slide surfaces such that they 
retain their folded structure and function in an aqueous environment and behave as though they are in 
free solution. 
 
The Blackburn group previously collected plasma (with buffycoat) samples, CRC and normal 
mucosa tissues, and clinical information from 63 CRC patients undergoing colonic resection 
surgery at Groote Schuur Hospital (GSH) (HREC 269/2011). The clinical information was gathered 
within a database format by Dr. Katie Lennard and Dr. Ryan Goosen. Genomic and bacteria-
association studies on the patient-matched CRC tissue samples were conducted by Dr. Katie 
Lennard. The 63 plasma samples were assayed and analysed by Dr. Jessica Duarte on a custom 
CT100plus microarray using a 1000-relative fluorescence units (RFUs) cut-off. In this Chapter, the 
CT100plus-derived CRC data is re-analysed by comparison to HC data to identify the top 10 
antigens for CRC diagnosis. The analysis pipeline includes ROC analysis, hierarchical clustering 
analysis, principle component analysis (PCA), and Kruskal-Wallis and Benjamini-Hochberg 
analysis (Figure 2.2). In addition to the clinical information provided for each patient, the 
microsatellite (MS) status of patients, identified by Dr. Katie Lennard, were also included in the 
analysis. Lastly, the obtained results were compared to AP-MS results (see Chapter 4) to search 




Figure 2.2. Data analysis pipeline. Sixty-three plasma samples were previously assayed (Duarte et al, 
unpublished data) on the CT100plus microarray, and potential CRC biomarkers were identified using a 
1000-RFU cut-off. In this Chapter, the CT100plus-derived CRC data were re-analysed by comparison to HC 
data to identify the top 10 antigens for CRC diagnosis. The analysis pipeline includes ROC analysis, 
hierarchical clustering analysis, PCA, Kruskal-Wallis and Benjamini-Hochberg analysis, described in this 
Figure. Abbreviations include: CRC = colorectal cancer; HC = healthy control; RFU = relative fluorescence 










2.1.  CT100plus microarray quality controls 
A total of 63 plasma samples, derived from individual CRC patients (i.e. single timepoint (TP) per 
patient), were assayed on the CT100plus microarray. Three controls assays were performed, 
using Cyanine 3 (Cy3)-labelled anti-c-Myc Ab (Figure 2.3), pooled negative control plasma (Figure 
2.4), or pooled positive control plasma (Figure 2.5). Each of the 123 recombinant proteins on the 
CT100plus microarray (Figure 7.4) contains a c-Myc tag that can be used to confirm the 
successfully immobilisation of recombinant proteins on the slide surface with an anti-c-Myc 
antibody. It is evident from Figure 2.3 that antigens do not have the same signal intensity across 
the microarray. This is because each of the 123 recombinant proteins is expressed at different 
levels within insect cells and are not pre-normalised prior to array fabrication. Although the signal 
for each antigen is not visibly discernible on the image, protein expression was confirmed by 
Western blot analysis (Beeton-Kempen et al., 2014). The antigens are in a 3D conformation on 
the microarray, and in some cases, the c-Myc tag may be buried with in the protein structure, 
preventing interaction between the c-Myc tag and the anti-c-Myc antibody; thus, signal would 
be reduced for these antigens on the CT100plus microarray. 
 
Figure 2.3. CT100plus microarray c-Myc control. Each of the 123 recombinant proteins on the CT100plus 
microarray contains a c-Myc tag. The microarray was treated with Cy3-labelled anti-c-Myc antibody, which 
was used to confirm the successfully immobilisation of recombinant proteins on the slide surface with an 





Figure 2.4. CT100plus microarray negative control pooled plasma sample. As a negative control, the 
CT100plus microarray was incubated with pooled plasma of HCs. Low or no signal is detected for the 
buffer ICL, and BCCP negative control spots, indicating low levels of non-specific binding. High signal was 
detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive control spots, anti-human IgG was detected 
(boxed in red), and human IgG was detected (boxed in blue). Low or no signal is detected for recombinant 


















































































































































































































































Figure 2.5. CT100plus microarray positive control pooled plasma sample. For the positive control sample, 
the CT100plus microarray was incubated with pooled plasma of cancer patients. Low or no signal is 
detected for the buffer, ICL, and BCCP negative control spots, indicating low levels of non-specific binding. 
High signal was detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive control spots, anti-human IgG 
was detected (boxed in red), and human IgG was detected (boxed in blue). Distinct and varying 
autoantibody signal intensity was detected for recombinant proteins. Abbreviations include: HCs = 
















































































































































































































































Both the positive and negative control assays display low or no signal from buffer, ICL, and BCCP 
negative control spots, indicating low levels of non-specific binding. Furthermore, the 5, 10 and 
15 nanograms per microliter (ng/µl) Cy5-biotin-BSA positive control spots were detected, and 
used for subsequent downstream data normalisation steps; anti-human IgG was detected, 
confirming the addition of patient plasma; and human IgG was detected, confirming the addition 
of detection antibody. Low or no antigen signal was detected for the pooled negative control 
(Figure 2.4), whereas high signals were detected for antigens within the pooled positive control 
(Figure 2.5), indicating a high-quality platform that can be used for the specific detection of 
autoantibodies against CT100plus cancer antigens. 
2.2.  ROC and hierarchical clustering analysis of CRC patients on CT100plus microarray 
The blood plasma samples of CRC patients were previously processed on the CT100plus 
microarray (Duarte et al., unpublished data) as per the methodology described in Chapter 7. The 
raw data files were extrapolated using the ArrayPro software, and data filtering and 
normalisation was performed with the CT100plus software with the following criteria: whole 
array coefficient of variation (CV) ≤ 25%; probe replicate CV ≤ 20%; noise-threshold ≥ 2 standard 
deviations (SDs) above background; maximum threshold = 65355 nm; whole array filtering 
control = 15 ng/µl Cy5-biotin-BSA; 57 patient data files passed the filtering and normalisation 
quality control procedure. The median signal intensity for each antigen was obtained and used 
for subsequent ROC and hierarchical clustering analyses. 
A ROC analysis was performed, which is a sensitivity and specificity report of a tested parameter, 
which in this study refers to antigens. The ROC analysis produces an AUC-value, a measure of the 
discriminating efficacy of antigen for patients from HCs; a sensitivity-value, indicating the fraction 
of patients with high cancer antigen intensity; and a specificity-value, indicating the fraction of 
HCs with no or significantly lower signal intensity for antigens (Metz, 1978; Vining and Gladish, 
1992; Zweig and Campbell, 1993). The higher the AUC-, sensitivity- and specificity-values, the 
better an antigen distinguishes patients from HCs. The ROC curve is widely accepted for selecting 
an optimal cut-off point. The cut-off point is used to determine the presence or absence of a 
disease, where values above the cut-off are disease-positive, and values below the cut-off are 
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considered disease-negative (Akobeng, 2007). An a priori ROC sample size was performed using 
MedCalc software (version 17.2), with a hypothesised AUC-value of 0.80, a null hypothesis value 
of 0.5, and a sample ratio of 0.25. The results produced a α-value (significance) of 0.05 and β-
value (1-Power) of 0.01 for the 57 CRC patients and 14 HCs, indicating that our sample size was 
sufficient for the ROC analysis. 
The ROC analysis was performed in R Studio (1.0.136) using the ROCR package (Sing et al., 2005) 
to produce AUC-, sensitivity- and specificity-values for all 123 CT100plus antigens. A top 10 
protein list was generated from proteins with the highest AUC-values, which included CEACAM 1 
(isoform 1), COL6A1, GRWD1, MAGEA1, MAGEA10, MAGEA5, NY-CO-45, SGY-1, SPANXB1 and 
THEG (Table 2.1). These 10 proteins were selected for further ROC analysis in CombiROC 
(Mazzara et al., 2017) to determine the combination of proteins that produce the highest AUC-, 
sensitivity-, and specificity-values. Here, the CombiROC analysis results indicate that a 
combination of CEACAM1 and GRDW1 produced the highest AUC-, sensitivity- and specificity-
values of 0.94, 1.0 and 0.77, respectively. Figure 2.6 represents the combined ROC curve for 
CEACAM1 (isoform 1) and GRWD1. 
Table 2.1. Sensitivity-, specificity-, AUC-, and cut-off-values for top 10 antigens for CRC patients on the 
CT100plus microarray. Abbreviations include: AUC = area under the receiver operator characteristic 
curve. 
Antigen Sensitivity Specificity AUC Cut-off 
CEACAM 1 (isoform 1) 0.88 0.86 0.86 408 
COL6A1 0.70 0.79 0.82 513 
GRWD1 0.82 0.64 0.82 471 
MAGEA1 0.82 0.71 0.81 452 
MAGEA10 0.72 0.86 0.83 467 
MAGEA5 0.88 0.86 0.88 481 
NY-CO-45 0.72 0.86 0.83 558 
SGY-1 0.82 0.71 0.84 542 
SPANXB1 0.82 0.79 0.84 441 




Figure 2.6. ROC curve for CombiROC-derived top 2 antigens for CRC. The ROC analysis was performed in 
CombiROC (http://combiroc.eu/) for the top 10 proteins; the ROC curve represents the best combination, 
which included CEACAM1 and GRWD1. The resulting sensitivity-, specificity- and AUC-values of 1.0, 0.77 
and 0.94, respectively. The yellow star indicates the optimal cut-off point. Abbreviations include: ROC = 
receiver operator characteristic; CRC = colorectal cancer; AUC = area under the ROC curve. 
 
To visualize the differential signal intensities for the top 10 proteins, a bar graph was constructed 
using the median RFU (± median absolute deviation (MAD)) for all patients and HCs. The signal 
intensity for each of the top 10 antigens was higher in CRC patients when compared to HCs: HCs 
produce a median signal intensity ranging of 0 - 208 RFU for the top 10 antigens; whereas CRC 
patients produce median signal intensities ranging from 548 – 771 RFU (Figure 2.7).  
Further statistical tests were performed in R Studio (1.0.136), and the Kruskal-Wallis test analysis 
was performed with the PMCMR package (Maintainer and Pohlert, 2016): The Shapiro-Wilk 
(Shapiro and Wilk, 1965) results indicate a non-normal data distribution (p-value < 0.05), as such, 
the Kruskal-Wallis (Kruskal and Wallis, 1952) and Benjamini-Hochberg (Benjamini and Hochberg, 
1995) tests were performed, indicating a significant increase (p-value < 0.05; adjusted p-value < 




Figure 2.7. Signal intensities of top 10 antigens for CRC patients and HCs. CRC patient (N = 57) and HC (N 
= 14) samples were processed on the CT100plus microarray. The top 10 antigens were identified; the 
graph displays the median RFU-values for the top 10 antigens across all patients or HCs, and the error bars 
represents the MAD. Abbreviations include: CRC = colorectal cancer; HC = healthy control; N = number of 
patients; RFU = relative fluorescence units; MAD = median absolute deviation. 
 
Table 2.2. Shapiro-Wilk, Kruskal-Wallis and Benjamini-Hochberg tests values for the top 10 antigens for 








CEACAM 1 (isoform 1) 5.10 × 10-6 2.67 × 10-5 1.13 × 10-3 
COL6A1 8.05 × 10-4 2.49 × 10-4 3.40 × 10-3 
GRWD1 1.19 × 10-6 2.49 × 10-4 3.40 × 10-3 
MAGEA1 8.48 × 10-12 3.49 × 10-4 3.40 × 10-3 
MAGEA10 6.15 × 10-10 1.62 × 10-4 2.85 × 10-3 
MAGEA5 8.15 × 10-15 8.39 × 10-6 1.03 × 10-3 
NY-CO-45 1.36 × 10-4 1.46 × 10-4 2.85 × 10-3 
SGY-1 2.37 × 10-4 8.05 × 10-5 1.98 × 10-3 
SPANXB1 5.54 × 10-5 6.21 × 10-5 1.90 × 10-3 





















Healthy controls CRC patients
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To further assess the biomarker potential of the top 10 proteins, a PCA and unsupervised 
hierarchical clustering, were performed in Perseus (version 1.5.4.1). The signal intensity values 
were log2-transformed prior to the analysis.  
The one-dimensional (1D) and two-dimensional (2D) PCA plots display two segregating clusters, 
each representing CRC patients (green) or HCs (orange), although overlap is evident between CRC 
patients and HCs; CRC005 and CRC057 cluster close with HCs, whereas HC1, HC5 and HC12 cluster 
with CRC patients (Figure 2.8). 
Unsupervised hierarchical clustering analysis also produced segregated clusters of CRC patients 
and HCs. In agreement with the PCA analysis, CRC005 and CRC057 clustered with HCs, suggesting 
low autoantibody titres against the top 10 proteins for these patients; whereas HC1 clustered 
with CRC032, CRC046 and CRC060, suggesting higher autoantibody titres against the top 10 






Figure 2.8. PCA between CRC patients and HCs. CRC patient (N = 57) and HC (N = 14) plasma were processed on the citrullinated CT100plus 
microarray, and the 10 with the highest AUC-values were log2-transformed and selected for 1D and 2D PCA multivariate testing using the Perseus 
(version 1.5.4.1). The 1D and 2D PCA plots display CRC patient (green) and HC (orange) clusters, with overlap too. Abbreviations include: PCA = 
principle component analysis; CRC = colorectal cancer; HC = healthy control; AUC = area under the receiver operator characteristic (ROC) curve; 






Figure 2.9. Unsupervised clustering of CRC patients and HCs. CRC patient (N = 57) and HC (N = 14) plasma were processed on the CT100plus 
microarray, and the 10 most significantly upregulated antigens in CRC patients were log2-transformed and selected for unsupervised hierarchical 
clustering using the Perseus software (version 1.5.4.1). Here, the HCs and CRC patients form two major clusters; except for CRC057 and CRC005, 
who cluster with HCs, and HC1 that clustered with CRC patients, CRC0032, CRC046 and CRC060. Abbreviations include: CRC = colorectal cancer; 




2.3. CT100plus antigens associated with CRC patient clinicopathological features 
We were provided with the clinicopathological information for 61 CRC patients whose plasma 
samples were assayed on the CT100plus microarray, summarised in Table 2.3.  
Table 2.3. Clinicopathological features of CRC patients. The clinicopathological data of CRC patients 
tested on the CT100plus microarray are summarised. Abbreviation include: N = number of patients; SD = 
standard deviation; N/A = not available; TNM = tumour, node, metastasis; MSI = microsatellite instability; 
MSI-H = high microsatellite instability; MSI-L = low microsatellite instability; HNPCC = hereditary non-
polyposis colorectal cancer; BMI = body mass index. 
Characteristics Number of patients (N = 61) 
  
Mean age (SD, range) 57 (15.8, 23-84) 
Gender (male/female) (percent) 30/30 (49/49%) 
Ethnicity  
Black 8 (13%) 
Indian 2 (3%) 
Mixed 38 (62%) 
White 8 (13%) 
N/A 5 (8%) 
TNM stage (percent)  
I 6 (9%) 
II 20 (33%) 
III 25 (41%) 
IV 4 (7%) 
N/A 6 (10%) 
MSI status  
MSI-H 13 (21%) 
MSI-L 3 (5%) 
MSS 22 (36%) 
N/A 23 (38%) 
Sporadic 55 (90%) 
HNPCC 6 (10%) 
Family history 7 (11%) 
Anatomical location (percent)  
Proximal colon 13 (21%) 
Distal colon 45 (74%) 
N/A 3 (5%) 
Inflammation (percent) 8/61 (12%) 
Radiotherapy 24/61 (39%) 
Mean BMI (SD, range) 26.8 (4.7, 18.15 – 40.48) 
Hypertensive 8/61 (13%) 
Smoking 12/61 (20%) 




The clinical features include patient age, gender, ethnicity, family history, body mass index (BMI), 
hypersensitivity, smoking and alcohol intake. The pathology information includes cancer stage at 
disease presentation; MS stability or instability status; whether the disease was sporadic or 
classified as HNPCC; family history of CRC; anatomical presentation of the cancer specimen; 
whether inflammation was detected; and whether the patient received radiotherapy – these 
features were used for subsequent statistical analysis to identify associations between 
clinicopathological features and autoantibody detection.  
The baseline-corrected antigen signal values were obtained prior to statistical analysis; here the 
baseline-corrected values were obtained by subtracting the ROC-derived cut-off-values from 
CT100plus-derived median-values for each antigen. The ROC-derived cut-off-values used for 
baseline subtraction is shown in Figure 2.10 for each antigen, resulting in a median-value of 473 
(MAD = 46; Range = 325 - 661). 
 
 
Figure 2.10. ROC-derived cut-off-values for CRC patients. ROC analyses between CRC patients and HCs 
produced cut-off-values for each antigen; each bar represents the cut-off-value per antigen. These values 
were used for baseline-correction for each antigen prior to clinicopathological statistical analysis. 
























Clinicopathological features and autoantibody signal associations were determined using the 
Mann-Whitney U test (Mann and Whitney, 1947) when comparing two groups (e.g. Recurrence), 
and the Kruskal-Wallis test (Kruskal and Wallis, 1952) when comparing three or more groups (e.g. 
Cancer stage). Statistical significance was assessed using the Benjamini-Hochberg test (Benjamini 
and Hochberg, 1995), where an adjusted p-value ≤ 0.05 was deemed significant. All tests were 
performed in R Studio (1.0.136), and the Kruskal-Wallis test analysis was performed with the 
PMCMR package in R (Maintainer and Pohlert, 2016) (Figure 2.11). 
 
 
Figure 2.11. Clinicopathological data analysis pipeline. The CT100plus-derived CRC data were analysed 
by subtracting ROC-derived cut-off values, and subsequently performing Kruskal-Wallis or Mann-Whitney 
U tests, as well as Benjamini-Hochberg tests. Abbreviations include: CRC = colorectal cancer; ROC = 




Although p-values ≤ 0.05 were obtained for associations between clinicopathological features 
(including gender, hypertensive, MS status, recurrence and stage) and autoantibody signal, the 
Benjamini-Hochberg correction test indicated that these changes were non-significant. The 
results for p-values ≤ 0.01 and adjusted p-values are summarised in Table 2.4. 
 
Table 2.4. Clinicopathological features and autoantibody signal with p-values ≤ 0.01. Mann-Whitney U 
and Kruskal-Wallis test indicate a significant difference in antigenic signal for gender, hypertensive state, 
MS status, recurrence and cancer stage, although it is not statistically significant after the Benjamini-
Hochberg test is applied. Abbreviation include: TAA = tumour-associated antigen; MS = microsatellite. 
Clinical feature TAA p-value Adjusted p-values 
Gender ACVR2B 0.007 0.80 
Hypertensive NY-ESO-1 0.009 0.58 
MS status SSX1 0.008 0.59 
 MART-1 0.01 0.59 
Recurrence BAGE2 0.001 0.17 
Stage TSSK6 0.001 0.13 












Discussion and conclusion 
Previously, a group of 63 CRC patient plasma samples were assayed on the CT100plus microarray 
(Duarte et al., unpublished data). Only 57 (N = 57/63; 91%) samples passed quality control tests, 
and were thus used for further analysis. For the analyses, an arbitrary 1000 RFU cut-off was 
applied, derived from the average signal obtained for the pooled negative control sample – all 
antigenic signal above this threshold was considered significant. The most frequently significant 
antigens included SILV (N=19/62. 31%), p53 Q136x (N=13/62, 21%), CDK4 (N=12/62, 19%), 
MAGEA5 (N=12/62, 19%), p53 S6A (N=12/62, 19%), PRKCZ (N=12/62, 19%), 5T4/TPBG (N=12/62, 
19% ), CTAG2/LAGE-1b/LAGE1L (N=11/62, 18%), MAPK1 (N=11/62, 18%), p53 K382R (N=11/62, 
18%), CREB1 (N=10/62, 16%), p53 C141Y (N=10/62, 16%), p53 T18A (N=10/62, 16%), ROPN1A 
(N=10/62, 16%). The aforementioned proteins were identified as potential CRC biomarkers 
relating to diagnosis or therapy.  
The drawback of employing the 1000-RFU cut-off relates to the variation in antigen threshold 
due to variable antigen expression, evident in c-Myc control microarray in Figure 2.3. The effect 
is compounded when considering the variation in protein physicochemical properties between 
antigens. This idea is supported by results for the pooled negative control plasma, which for all 
CT100plus antigens produced a median signal intensity of 519 (MAD = 129; Range: 0 – 2811). 
Thus, the results may be more accurate and informative if the analysis process accounted for the 
variable antigen intensities on the CT100plus microarray. To account for threshold variation, the 
CT100plus microarray data from CRC patients and HCs were compared, and the top candidates 
were selected by employing receiver operating characteristic (ROC) analysis. 
ROC curve analysis is used to identify antigens with a significantly higher expression in cancer 
patients versus HCs. The ROC curve displays the true positive rate (sensitivity) as a function of 
the false-positive rate (1 - specificity) for different cut-off points. Thus, each point on the ROC 
curve represents a sensitivity/specificity pair corresponding to a decision threshold. A perfect 
discriminatory score produces a ROC curve that passes through the upper left corner (sensitivity 
= 1; specificity = 1); thus the closer the ROC curve is to the upper left corner, the better the overall 
accuracy of the test (Zweig and Campbell, 1993). The ROC analysis produces an AUC-value, a 
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measure of the discriminating efficacy of antigen for patients from HCs; a sensitivity-value, 
indicating the fraction of patients with high cancer antigen intensity; and a specificity-value, 
indicating the fraction of HCs with no, or significantly lower, signal intensity for antigens (Metz, 
1978; Vining and Gladish, 1992; Zweig and Campbell, 1993).  
ROC analysis was employed to analyse CT100plus microarray data from 57 CRC patients and 14 
HCs samples, where after further analysis into biomarker potential was performed using the 10 
proteins with the highest AUC-values. It is important to note that the HC samples were not age- 
nor gender-matched to the CRC patients. Furthermore, although none of the HCs were previously 
diagnosed with cancer, tests were not performed to confirm that the HCs were CRC-free. 
However, since our intention here was to acquire preliminary results for a potentially larger 
study, we decided to use the plasma samples available to assess autoantibody profiles between 
CRC patient and HCs.  
The top 10 proteins after ROC analysis were CEACAM 1, COL6A1, GRWD1, MAGEA1, MAGEA10, 
MAGEA5, NY-CO-45, SGY-1, SPANXB1 and THEG, of which only MAGEA5 was significant in a 
minimum of 10 patients when using the 1000 RFU cut-off. Individually, these proteins produced 
AUC-, sensitivity- and specificity-values ranging from 0.81 – 0.86, 0.70 – 0.88 and 0.64 – 0.86, 
respectively (Table 2.1). These 10 proteins were selected for further ROC analysis in CombiROC 
(Mazzara et al., 2017) to determine the combination of proteins that produce the highest AUC-, 
sensitivity-, and specificity-values. Here, the CombiROC analysis results indicate that a 
combination of CEACAM1 and GRDW1 produced the highest AUC-, sensitivity- and specificity-
values of 0.94, 1.0 and 0.77, respectively (Figure 2.6). Literature-reported CRC biomarkers include 
CEA, IL-8, Apo AI, C9, and CA-19-9 producing AUC-values ranging from 0.62 - 0.90 (Murakoshi et 
al., 2011; Lee, 2013; Jin et al., 2014; Zhang et al., 2015). Together, these results indicate that the 
top 10 proteins identified with the CT100plus microarray individually produced AUC-, sensitivity- 
and specificity-values in the same range as the best reported CRC biomarkers, whereas 
combinatorial ROC results outperformed individual and literature-reported potential biomarkers. 
Furthermore, Kruskal-Wallis test with Benjamini-Hochberg post hoc analysis indicated a 
significant difference in antigen signals between CRC patients and HCs, producing p-values and 
adjusted p-values less than 0.05 (Table 2.2), indicating a significant difference in antigen signal 
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intensity between CRC patients and health controls. Furthermore, the PCA and hierarchical 
clustering results display two segregating clusters, each representing CRC patients (green) or HCs 
(orange), although overlap is evident on the 1D and 2D PCA plots. Together, these results indicate 
that the top 10 proteins may be potential CRC biomarkers, although alternate methods e.g. 
validating with another CRC cohort or using tumour tissues for histological confirmation, is 
required for biomarker validation 
In Chapter 4, the development and results of an AP-MS assay is described. The AP-MS assay was 
developed to identify known and novel CRC biomarkers, and amongst others corroborates the 
results described here from the CT100plus microarray. For the AP-MS assay, CRC patient samples 
including CRC002, CRC004, CRC017, CRC021 and CRC031 were assayed using the AP-MS method 
described in Chapter 7. Of the top 10 proteins, THEG and COL1A6 were identified by AP-MS. 
Although CEACAM1, COL1A6, GWRD1 and MAGEA1, MAGEA5, and MAGEA10 were not identified 
by AP-MS, homologues of these proteins were identified, including CEACAM7, COL1A2, WRD8 
and MAGED2 (Table 2.5). These outcomes imply the possibility that the CT100plus microarray 
detects autoantibodies toward homologues of proteins printed on the microarray, although this 
should be further investigated. 
Since COL6A1 and THEG were identified on the CT100plus microarray as well as by AP-MS, these 
proteins were further investigated in literature for their biomarker potential. Additionally, since 
CEACAM1 and CEACAM7 share a high degree of homology (Table 2.5), CEACAM7 was also further 











Table 2.5. Top 10 CRC proteins on CT100plus microarray matched to AP-MS protein list. CRC patient and 
HC plasma were tested on the CT100plus microarray. Data filtering and normalisation was performed 
using the CT100plus application, and the median intensity-values were used for ROC analysis. Antigens 
with the highest AUC-values were selected and compared to proteins identified for CRC patients by AP-
MS (Chapter 4). Protein and homologue identification is summarised with query coverage (%), identity 
(%), and E-value. Abbreviation include: CRC = colorectal cancer; AP-MS = affinity purification-mass 
spectrometry; HC = healthy control; N/A = not applicable. 
Protein AP-MS result Homologue Query coverage (%) Identity (%) E-value 
CEACAM1  No CEACAM7 75 70 8-116 
COL6A1 Yes N/A 100 100 0 
GRWD1 No RWD82 65 28 3-5 
MAGEA1 No MAGED2 67 39 1-49 
MAGEA10 No MAGED2 53 40 2-56 
MAGEA5 No MAGED2 59 39 0.06 
NY-CO-45 No No N/A N/A N/A 
SGY-1 No No N/A N/A N/A 
SPANXB1 No No N/A N/A N/A 
THEG Yes N/A 100 100 0 
 
Collagen alpha-1(VI) chain, also known as COL6A1 (http://www.uniprot.org/uniprot/P12109), is 
a collagen protein that has a cell-binding function. COL6A1 gene expression is reportedly 
increased in CRC cell-lines after 5-aza-2’-deocycitidine treatment (Khamas et al., 2012). It is 
significantly deregulation in CRC tissue samples, determined by label-free mass spectrometry 
(Yang et al., 2012; Sethi et al., 2015) and confirmed by Western blot analysis, and thus proposed 
as to be potential biomarker for CRC (Yang et al., 2012). Although COL6A1 is not extensively 
reported for CRC, it is reportedly upregulated and correlates with a poor prognosis in lung (Chiu 
et al., 2011), renal (Wan et al., 2015) and prostate (Zhu et al., 2015) cancer. COL6A1 was 
previously investigated amongst a panel of proteins by ELISA to detect autoantibodies in breast 
cancer patients versus HCs, although it was not found to be significantly dysregulated (Piura and 
Piura, 2011). According to our knowledge, we show for the first time an autoantibody response 
toward COL6A1 in CRC patients using two orthogonal immunoproteomic assays, which could 
serve as a potential biomarker for diagnosis or disease therapy. 
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Testicular haploid expressed gene, also known as THEG 
(http://www.uniprot.org/uniprot/Q9P2T0), is expressed only in spermatid cells and cancer, 
although its function is unknown. It is a relatively newly proposed CTA, and thus also not 
extensively reported. However, in a study of 22 cell-lines, high levels of THEG mRNA was detected 
in the HCT15 colon cancer cell-line (Chen et al., 2005). According to our knowledge, an 
autoimmune response toward THEG has not previously been reported, thus we show for the first 
time an autoantibody response toward THEG using two orthogonal immunoproteomics assay for 
CRC patients, which could also serve as a potential biomarker for diagnosis or disease therapy. 
Carcinoembryonic antigen (CEA), also known as CEACAM 
(http://www.uniprot.org/uniprot/Q13984), is a widely-used tumour biomarker. Its main 
application is for gastrointestinal cancers, especially in CRC. In 1965, CEA was identified in foetal 
colon and colon adenocarcinoma, but absent from healthy adult colon (Gold and Freedman, 
1965a, 1965b). In 1969, increased serum concentrations of CEA were reported for 35 of 36 
patients with CRC, whereas low levels were detected in healthy volunteers, pregnant women, 
patients with non-gastrointestinal cancer, or benign gastrointestinal disease (Thomson et al., 
1969). Further investigations revealed that CEA levels increase with increasing disease stage 
(Wanebo et al., 1978), although serum levels decrease with liver metastasis likely due to CEA 
uptake by Kupffer cells, which modify CEA by removing its sialic acid residues and the asialo CEA 
is endocytosed and degraded by liver parenchymal cells (Thomson et al., 1969; Begent, 1984). 
CEA concentrations are also higher in well-differentiated CRC neoplasms (Rieger and Wahren, 
1975; Goslin et al., 1981; Bhatnagar et al., 1999), malignancies on the right side of the colon 
(Wanebo et al., 1978; Slater et al., 1979), male smokers (Wilson et al., 1999), and aneuploid CRC 
versus diploid CRC (Rognum, 1986). CEACAM7 is a family member of CEA that is expressed in 
normal colorectal epithelia, although it is downregulated in adenomas and carcinomas 
(Thompson et al. 1997; Schö et al. 2000; Birkenkamp-Demtroder et al. 2005). CEACAM7 
decreased expression in rectal cancers is linked to disease recurrence (Messick et al., 2010), 
whereas elevated serum levels were detected for CRC patients with liver metastasis (Kleivi et al., 
2007). According to our knowledge, an autoantibody response has not been reported against 
CEACAM1 or CEACAM7 in CRC patients. Here, using the CT100plus microarray, we again show for 
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the first time using two orthogonal immunoproteomics methodologies an autoantibody 
response in CRC patients. 
We did not find a significant (adjusted p-value < 0.05) association between patient 
clinicopathological information and autoantibody signal intensity. Although p-values ≤ 0.05 were 
obtained for associations between clinicopathological features (including gender, hypertensive, 
MS status, recurrence and stage) and autoantibody signal, the Benjamini-Hochberg correction 
test indicated that these changes were non-significant. Unlike the melanoma cohort (see Chapter 
5), these patient samples were not collected as part of a clinical cohort. Thus, when considering 
the diversity of the cohort (Table 2.3), and only assessing 123 TAA, this result is plausible. It is 
therefore important that future CT100plus assays include carefully selected patient samples that 
form part of a controlled clinical cohort, which may result in statistically significant associations 
between clinicopathological features and autoantibody signal intensity. 
In conclusion, when comparing CRC patients and HCs, we identified top antigens supported using 
several statistical tests that are either used clinical biomarkers, e.g. CEACAM1, or have been 
associated with CRC cancer, e.g. COL6A1 and THEG. Although CEACAM1 is a known clinical 
biomarker for CRC, autoantibody responses have not been reported against COL1A6 or THEG and 
CEACAM in CRC. It is important to note though that alternate methods e.g. validating with 
another CRC cohort or using tumour tissues for histological confirmation, are required for 









Chapter 3  
 




Cancer patients elicit an autoantibody response toward TAAs which can result from altered tissue 
specific expression patterns, mutations, PTMs, et alia. Protein citrullination is a post-translational 
modification (PTM) resulting from the PAD-induced conversion of arginine to citrulline. 
Citrullinated proteins are known to induce an autoantibody response in patients with rheumatoid 
arthritis, Alzheimer’s disease and cancer. The expression of isozymes PAD2 and PAD4 are 
dysregulated in many cancer-types, including CRC, resulting in alternate PAD substrates. In this 
study, we assessed the autoantibody response of 59 CRC patients and 11 HCs toward citrullinated 
and non-citrullinated antigens on the CT100plus microarray. Only 1 microgram per millilitre 
(µg/ml) PAD4 was required to add the citrulline modification on CT100plus microarray antigens. 
CDK7, MAGEB1, MAGEB5, MAGEB6 and SYCP1 produced a medium (2000 < RFU ≤ 10 000) or high 
signal (relative fluorescent unit (RFU) > 10 000) on the citrullinated microarray, but low signal 
(RFU ≤ 2000) on the non-citrullinated microarray. Significantly (p-value ≤ 0.05; adjusted p-value 
≤ 0.05) higher signal intensities were detected in CRC patients versus HCs for citrullinated CDK7, 
MAGEB1, MAGEB5, MAGEB6 and SYCP1, whereas no significant (p-value > 0.05) difference in 
autoantibody signal was detected on the non-citrullinated microarray for the same patient 
cohort. Furthermore, ROC analyses of these antigens resulted in an AUC-, sensitivity- and 
specificity-ranges of 0.91, 0.87 and 0.89, respectively. PCA results indicate distinct groups of CRC 
patients and HC clusters. Together, here we show for the first time that CRC patients elicit an 





Both the humoral and T-cell arm of the immune system are reportedly activated in response to 
a TAAs and TSAs. In this Chapter, we investigated the autoantibody response to citrullinated 
CT100plus proteins: 
Protein citrullination is a calcium-dependent hydrolytic reaction that converts arginine to the 
citrulline amino acid (Figure 3.1) (Rogers and Simmonds, 1958). The reaction is catalysed by the 
Protein Arginine Deimidase (PAD) family of proteins (Knuckley et al., 2010; Darrah et al., 2012). 
Under physiological conditions, PADs are normally inactive until stimulated by calcium, resulting 
in the citrullination of structural proteins (Inagaki et al., 1989; Senshu et al., 1995), and proteins 
involved in gene transcription (Wang, 2004; Saiki et al., 2009; Christophorou et al., 2014).  
 
 
Figure 3.1. PAD-catalysed conversion of peptidyl arginine to peptidyl citrulline. PAD isozymes catalyse 
the calcium-dependent hydrolytic conversion of peptidyl arginine to peptidyl citrulline, with the expulsion 
of ammonia. Here, the charged amine group (indicated in red) is converted to neutral oxygen (indicated 
in blue). 
 
Citrullinated proteins induce an autoantibody response in patients with rheumatoid arthritis 
(Schellekens et al., 1998), Alzheimer’s disease (Ishigami et al., 2005) and cancer (Chang and Fang, 
2010). Increased PAD4 expression and activity in cancer-cells have previously been reported 
(Denman, 2005; Chang et al., 2009; Doyle et al., 2010) for colorectal, lung, ovarian and uterine 
adenocarcinomas, as well as hepatocellular, oesophageal, renal, uterine and bladder carcinomas 
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(Wang et al., 2010). More recently, growing evidence implicates the role of PAD2 in cancer 
progression, where changes in PAD2 expression correlates cancer progression, depending on the 
cancer-type. For example, in vitro studies showed that PAD2 overexpressed in human squamous 
cell carcinoma (SCC) cell-line resulted in elevated markers for inflammation and epithelial-to-
mesenchymal transition (EMT). In vivo studies supported this finding as transgenic mice with 
overexpressed PAD2 developed neoplastic skin lesions, demonstrating increased expression of 
markers of invasion, inflammation and EMT (McElwee et al., 2014). In contrast, studies of breast 
cancer demonstrated a correlation between PAD2 depletion or inhibition with  cancer migration 
(Horibata et al., 2017). Also, in vitro studies concluded that while the PADI2 (isoform 1) transcript 
is expressed in normal colon tissue, the expression is significantly lower in colon cancer cells. 
Moreover, overexpression of PADI2 in colon cancer cells suppressed cell proliferation, suggesting 
that PADI2 may have a tumour suppressor role in colon cancer. Despite decreased PAD2 
expression in colon cancer, citrullinated proteins have been detected by immunoblot analysis 
(Funayama et al., 2017).  
PAD2 substrates in normal tissues include myelin basic protein (Lamensa and Moscarello, 1993), 
vimentin (Hsu et al., 2014), actin and histones (Zhang et al., 2012). Citrullinated proteins have 
been detected in various cancer cell-lines including colon cancer cells. Cancer-associated 
citrullinated proteins include ENO1, HSP60, KRT8, TUBB, which are associated with tumour 
growth, invasion, and a poor prognosis (Jiang et al., 2013). Altogether, these results provide 
evidence that PAD2 may have alternate substrates in cancer, seemingly associated with cancer 
progression.  
In this study, we aim to identify CRC patient autoantibodies against citrullinated CT100plus 
antigens. Here, we compared autoantibody responses between citrullinated and non-
citrullinated CT100plus antigens to identify autoantibodies against citrullinated antigens. 
Furthermore, we compare these autoantibody responses between CRC patients and HCs to 
determine antigen discriminatory efficiency. Lastly, we identified citrullinated antigens also 





3.1. Citrullinating antigens on the CT100plus microarray 
To determine whether CRC patients produce an autoantibody response to citrullinated 
CT100plus antigens, CRC patient plasma was incubated on a citrullinated version of the 
microarray. For this, the microarray was incubated with PAD4 enzyme, to convert a proportion 
of surface-exposed arginine residues to citrulline, and subsequently incubated with CRC patient 
plasma, followed by fluorescently-labelled anti-human IgG to detect patient autoantibodies. The 
optimal PAD4 concentration was determined before assessing the CRC patient autoantibody 
response to citrullinated antigens. For this assay, the CT100plus microarray was treated with 0, 
0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 µg/ml PAD4 for 2 hours, whereafter citrulline groups were detected 
with fluorescently-labelled rabbit anti-citrulline IgG. Raw GenePix files were used to obtain the 
median of all median RFU-values for the foreground (antigen spot) and background (streptavidin) 
signals, and a line graph constructed to assess the dose-dependent effect of PAD4-induced 
citrullination on the CT100plus microarray (Figure 3.2). 
 
 
Figure 3.2. Detecting citrullinated antigens on the CT100plus microarray. The CT100plus microarray was 
incubated with 0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 µg/ml PAD4 enzyme to determine the optimal concentration 
for protein citrullination. Citrullinated antigens were detected using anti-citrulline antibody, and 
subsequent detected with a fluorescent-labelled secondary Ab (635 nm). The median of the median net 
intensity of all antigens was obtained. Here, we detect a higher foreground signal versus background 




























A higher foreground (antigen spots) intensity versus background (streptavidin) intensity was 
detected, suggesting a higher frequency of citrulline groups present on CT100plus antigen spots 
versus streptavidin. Together, the results indicate that PAD4 citrullinated antigens on the 
CT100plus microarray. It is important to determine the optimal PAD4 concentration required for 
significant increase in citrullination on the CT100plus microarray. For this, the CT100plus 
software-derived median net intensities (median foreground minus median background) were 
obtained for all antigens across the microarray, and a Mann-Whitney U test (Mann and Whitney, 
1947) was performed to assess statistical significance, and a line graph was constructed to 
determine the linear range of detection. Figure 3.3 displays the entire range of PAD4 
concentrations assayed, whereas Figure 3.4 displays the signal intensity within the linear range 
of detection (0.25 – 2 µg/ml PAD4). A significant (p-value = 0.005; Mann-Whitney U test) increase 
in citrulline detection was observed for 1 µg/ml PAD4 versus the untreated microarray, which 




Figure 3.3. Detecting Citrullination after CT100plus software processing. To determine the optimal PAD4 
concentration to citrullinate CT100plus antigens, the microarray was treated with 0.25, 0.5, 1.0, 2.0, 4.0 
and 8.0 µg/ml PAD4 enzyme. Citrullinated antigens were detected using anti-citrulline antibody, and 
subsequently detection with a fluorescent-labelled Ab at 635 nm. The CT100plus software was used to 
filter and normalise raw data. The processed data shows a dose-dependent increase in signal. 



























Figure 3.4. Linear range when detecting PAD4-induced citrullination. The CT100plus microarray was 
treated with 0.25, 0.5, 1, 2, 4 and 8 µg/ml PAD4. The Mann-Whitney U test result showed a significant (p-
value = 0.005) increase in citrullination when using 1 µg/ml PAD4, which falls within the linear range of 
detection. Thus, 1 µg/ml PAD4 was subsequently used to citrullinated CT100plus microarrays before 
analysing CRC patient plasma. Abbreviations include: PAD = protein arginine deiminase. 
 
3.2. CT100plus microarray quality controls 
A significant increase in citrullination was detected when treating with 1 µg/ml PAD4, as such, it 
was used for all subsequent assays. Two control assays were performed, including a c-Myc (Figure 
3.5) and pooled negative control plasma (Figure 3.6). Each of the 123 recombinant proteins on 
the CT100plus microarray (Figure 7.4) contains a c-Myc tag, used to confirm the successfully 
immobilisation of recombinant proteins on the slide surface with an anti-c-Myc antibody. It is 
evident from Figure 3.5 that antigens do not have the same signal intensity across the microarray. 
This is because each of the 123 recombinant proteins are expressed at different levels within 
insect cells. Although the signal for each antigen is not visibly discernible on the image, protein 
expression was confirmed by Western blot analysis (Beeton-Kempen et al., 2014). The antigens 
are in a 3D conformation on the microarray and in some cases the c-Myc tag may be occluded 
within the protein structure, preventing interaction between the c-Myc tag and the anti-c-Myc 



























Figure 3.5. CT100plus microarray c-Myc control. Each of the 123 recombinant proteins on the CT100plus 
microarray contains a c-Myc tag. The microarray was treated with Cy3-labelled anti-c-Myc antibody, which 
was used to confirm the successfully immobilisation of recombinant proteins on the slide surface with an 





Figure 3.6. Citrullinated CT100plus microarray negative control pooled plasma sample. As a negative 
control, the CT100plus microarray was incubated with pooled plasma of HCs. Low or no signal is detected 
for the buffer, ICL, and BCCP negative control spots, indicating low levels of non-specific binding. High 
signal was detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive control spots, anti-human IgG was 
detected (boxed in red), and human IgG was detected (boxed in blue). Low or no signal is detected for 
recombinant proteins. Abbreviations include: HCs = healthy controls; ICL = insect cell lysate; BCCP = biotin 






































































































































































































































The negative control assay displays low or no signal from buffer, ICL, and BCCP negative control 
spots, indicating low levels of non-specific binding. Furthermore, the 5, 10 and 15 ng/µl Cy5-
biotin-BSA positive control spots were detected, and used for subsequent downstream data 
normalisation steps; anti-human IgG was detected, confirming the addition of patient plasma; 
and human IgG was detected, confirming the addition of detection antibody.  
Recombinant proteins were detected on the CT100plus microarray by the anti-C-Myc Ab (Figure 
3.5), with low or no signal is detected for the pooled negative control (Figure 3.6), indicating a 
high-quality platform that can be used for the specific detection of autoantibodies against 
CT100plus cancer antigens. 
3.3. Detecting CRC patient autoantibodies toward citrullinated cancer antigens 
A significant increase in citrulline groups was detected when incubating the CT100plus 
microarray with 1 µg/ml PAD4. As such, this concentration was used for all subsequent assays to 
detect autoantibodies against citrullinated antigens in CRC patients (Groote Schuur Hospital, 
HREC REF Number: 269/2011). Briefly, CT100plus microarrays were pre-treated with 1 µg/ml 
PAD4, and subsequently incubated with CRC patient plasma (1:800) and then with fluorescently-
labelled detection antibody. The microarray images were obtained at 635 nanometres (nm) using 
the automatic gain control (AGC) setting.  
To identify the citrullinated antigens that induce autoantibody response in CRC patients, the 
antigenic signals for the citrullinated and non-citrullinated CT100plus microarrays were 
compared. All data files and images for the non-citrullinated microarray were obtained previously 
(Duarte et al., unpublished data). Here, the CT100plus microarrays were also incubated with CRC 
patient plasma (1:800) and fluorescently-labelled detection Ab only, and microarray images were 
obtained at 635 nm using the AGC setting. The raw data files from the citrullinated and non-
citrullinated CT100plus microarrays were extrapolated using the ArrayPro software, and data 
filtering and normalisation was performed using the CT100plus software with the following 
criteria: whole array CV ≤ 25%; probe replicate CV ≤ 20%; noise-threshold ≥ 2 SD above 
background; maximum threshold = 65355 nm; whole array filtering control = 15 ng/µl Cy5-biotin-
BSA. Here, 43 patient data files passed the filtering and normalisation quality control procedure. 
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The median signal intensity for each antigen was obtained and used for subsequent statistical 
analyses. 
Interestingly, 26/43 (62%) CRC patients produced moderately higher baseline values on the 
citrullinated microarray compared the non-citrullinated microarray, increasing from a median 
antigen RFU of 637 (±120 MAD) to 1100 (±402 MAD), respectively. Thus, a direct comparison, e.g. 
the Mann-Whitney U test, between antigens on the citrullinated and non-citrullinated 
microarrays may lead to false-positive or false-negative results. Comparisons between 
citrullinated and non-citrullinated microarrays were based on signal intensities ranges, which 
were classified as those that were low (0 - 2000 RFU), medium (2001 - 10 000 RFU), or high (> 10 
000 RFU). Here, 11/43 (26%) CRC patients displayed low RFU signals on both array-types; an 
example is shown using CRC042 in Figure 3.7. A total of 21/43 (49%) patients produced medium 
or high signals for antigens on the non-citrullinated microarray, but only 6/43 (14%) retained the 
signal toward the same antigens on the citrullinated microarray; an example is shown for CRC010 
in Figure 3.8. Here, signal is detected for DDX53 on both microarray-types, although a high signal 
is observed on the non-citrullinated microarray whilst a medium signal is observed on the 
citrullinated microarray; this may be due to the conversion of arginine to citrulline on antigen 
surfaces, decreasing autoantibody-epitope affinity. A total of 28/43 (65%) patients elicited a 
medium or high signal intensity to at least one of the citrullinated antigens, but low signal on the 
non-citrullinated microarray. Here, the antigens that produced medium and/or high signal on the 
citrullinated microarray, but low signal on the non-citrullinated microarray, included CDK7 and 
MAGEB6, each detected for 14 (number of patients (N) = 14/43, 33%) patients; MAGEB1 in 12 (N 
= 12/43, 28%) patients; MAGEB5 and SYCP1, each detected for 11 (N = 11/43, 26%) patients; 
MAGEA4v2 and SPANXA1, each detected in 6 (N = 6/43, 14%) patients; SOX1 in 5 (N = 5/43, 12%) 
patients; MAGEA3 and CDK2, each detected in 4 (N = 4/43, 9%) patients; NLRP, p53 S46A and p53 
S6A, each detected in 2 (N = 2/43, 5%) patients; and CDCC33, CTNNB1, GAGE5, MAP9, p53, PBK, 
SILV, and TKTL1, each detected in 1 (N = 1/43, 2%) patient. An example is shown for CRC045 in 
Figure 3.9, which showed increased signal intensity for MAGEB1, MAGEB5 and MABEG6, which 
was detected at lower levels on the non-citrullinated microarray. Together, these results provide 
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Figure 3.7. CT100plus antigenic signal for CRC042 on citrullinated and non-citrullinated microarrays. Microarray images were scanned Images, 
and the data extrapolated, filtered and normalised. The CT100plus microarrays treated with (left image and graph) and without (right image and 
graph) 1 µg/ml PAD4, then subsequently plasma from patient CRC042, and detection antibody. Abbreviations include: RFU = relative fluorescence 
units; PAD4 = protein arginine deiminase isoform 4.  
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Figure 3.8 CT100plus antigenic signal for CRC010 on citrullinated and non-citrullinated microarrays. Microarray images were scanned Images, 
and the data extrapolated, filtered and normalised. The CT100plus microarrays treated with (left image and graph) and without (right image and 
graph) 1 µg/ml PAD4, then subsequently plasma from patient CRC010, and detection antibody. Higher signal intensities were detected for DDX53 
(boxed in red) on the citrullinated microarrays versus non-citrullinated microarray. Abbreviations include: RFU = relative fluorescence units; PAD4 





















































































































































































































Figure 3.9. CT100plus antigenic signal for CRC045 on citrullinated and non-citrullinated microarrays. Microarray images were scanned Images, 
and the data extrapolated, filtered and normalised. The CT100plus microarrays treated with (left image and graph) and without (right image and 
graph) 1 µg/ml PAD4, then subsequently plasma from patient CRC045, and detection antibody. Higher signal intensities were detected for 
MARGEB1, MAGEB5 and MAGEB6 on the citrullinated microarrays versus non-citrullinated microarrays. Abbreviations include: RFU = relative 
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3.4. CRC and healthy individuals: autoantibody responses toward citrullinated CT100plus 
antigens 
 
When assessing a biological molecule for its potential as a biomarker, it is critical that the 
molecule should be absent, or at significantly lower levels, in healthy individuals. We therefore 
compared the autoantibody response between 59 CRC patients and 11 HCs on the citrullinated 
CT100plus microarray. It is important to note that the HC samples were not age- nor gender-
matched to the CRC patients. Furthermore, although none of the HCs were previously diagnosed 
with cancer, tests were not performed to confirm that the HCs were CRC-free. However, since 
our intention here is to acquire preliminary results for a potentially larger study, we decided to 
use the plasma samples available to assess autoantibody profiles between CRC patient and HCs.  
The raw data files from citrullinated and non-citrullinated microarrays were processed through 
the CT100plus application, and the median antigen intensity obtained. Citrullinated antigens with 
high or medium intensity, but low intensity on the non-citrullinated microarray, were identified 
and the top 5 citrullinated antigens, to include CDK7 (N = 14/43, 33%), MAGEB6 (N = 14/43, 33%), 
MAGEB1 (N = 12/43, 28%), MAGEB5 (N = 11/43, 26%), and SYCP1 (N = 11/43, 26%), were used 
for further analysis. For this analysis, ROC analysis was performed, which reports the sensitivity 
and specificity of tested parameter i.e. antigens. An a priori ROC sample size was performed using 
MedCalc software (version 17.2), with a hypothesised AUC-value of 0.80, a null hypothesis value 
of 0.5, and a sample ratio of 0.19. The results produced a α-value (significance) of 0.01 and β-
value (1-Power) of 0.20 for the 59 CRC patients and 11 HCs, indicating that our sample size was 
sufficient for the ROC analysis. 
The ROC analysis was performed in R Studio (1.0.136) using the ROCR package (Sing et al., 2005). 
The ROC analysis produced sensitivity-, specificity-, AUC-, and cut-off-values for the top 5 
antigens (Table 3.1). These 5 proteins were selected for further ROC analysis in CombiROC 
(Mazzara et al., 2017) to determine the combination of proteins that produce the highest AUC-
,sensitivity-, and specificity-values. Here, the CombiROC analysis results indicate that the 
combination of CDK7 and MAGEB6 produced the highest AUC-, sensitivity- and specificity-values 
of 0.88, 1.0 and 0.82, respectively. Figure 3.10 represents the combined ROC curve for CDK7 and 
84 
 
MAGEB6. It is evident that MAGEB1, MAGEB5 and MAGEB6 have higher AUC-values than the 
combined antigens, indicating that these antigens alone outperform CDK7 and MAGEB6 
together. 
Table 3.1. Sensitivity-, specificity-, AUC-, and cut-off-values for top 5 citrullinated antigens, and a 
combination thereof. Abbreviation include: AUC = area under the receiver operator characteristic (ROC) 
curve. 
Antigen Sensitivity Specificity AUC Cut-off 
CDK7 0.75 0.82 0.74 955 
MAGEB1 0.87 0.91 0.89 791 
MAGEB5 0.85 1.00 0.89 790 
MAGEB6 0.83 0.91 0.92 848 
SYCP1 0.78 0.91 0.87 1190 
 
 
Figure 3.10. ROC curve for CombiROC-derived top 2 antigens for CRC patients. The ROC analysis was 
performed in CombiROC (http://combiroc.eu/) for the top 5 proteins (CDK7, MAGEB1, MAGEB5, MAGEB6 
and SYCP1). The ROC curve represents the best protein combination, which included CDK7 and MAGEB6. 
The resulting sensitivity-, specificity- and AUC-values are 1.0, 0.82 and 0.88, respectively. The yellow star 
indicates the optimal cut-off point. Abbreviations include: ROC = receiver operator characteristic; AUC = 
area under the ROC curve. 
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By comparison, it is evident that the signal intensity for the top 5 antigens was higher in CRC 
patients when compared to healthy individuals (Figure 3.11) on the citrullinated microarray. TO 
determine whether the difference was statistically significant, the following statistical tests were 
performed in R Studio (1.0.136): The Shapiro-Wilk (Shapiro and Wilk, 1965) results indicate a non-
normal data distribution (p-value < 0.05), as such, the Mann-Whitney U (Mann and Whitney, 
1947) and Benjamini-Hochberg (Benjamini and Hochberg, 1995) tests were performed, indicating 
a significant increase (p-value < 0.05; adjusted p-value < 0.05) in signal intensity for CRC patients 
versus HCs on the citrullinated CT100plus microarray (Table 3.2).  
It is evident that the signal intensity for the top 5 citrullinated antigens was similar for CRC 
patients and healthy individuals on the non-citrullinated microarray (Figure 3.12). Again, the 
Shapiro-Wilk analysis indicated a non-normal data distribution (p-value < 0.05), as such, the 
Mann-Whitney U and Benjamini-Hochberg tests were performed. Here, no significant (p-value > 
0.05; adjusted p-value > 0.05) change in signal intensity was detected on the non-citrullinated 
CT100plus microarray (Table 3.3).  
 
Figure 3.11. Citrullinated microarray: top 5 antigens citrullinated antigens. CRC patient and HC samples 
were processed on the citrullinated microarray. The top 5 citrullinated antigens were identified; the graph 
displays the median RFU-values for CDK7, MAGEB1, MAGEB5, MAGEB6 and SYCP1 across all CRC patients 
or HCs, and the error bars represents the MAD on the citrullinated microarray. Abbreviations include: CRC 
= colorectal cancer; HC = healthy control; RFU = relative fluorescence units; nm = nanometre; MAD = 


























Table 3.2. Shapiro-Wilk, Kruskal-Wallis and Benjamini-Hochberg tests values for the top 5 citrullinated 
antigens on the citrullinated CT100plus microarray.  
Antigen Shapiro Wilk  
(p-value) 




CDK7 1.04 × 10-13 3.41 × 10-3 4.51 × 10-3 
MAGEB1 1.20 × 10-6 2.80 × 10-5 2.46 × 10-4 
MAGEB5 2.63 × 10-3 6.73 × 10-6 2.31 × 10-4 
MAGEB6 2.43 × 10-8 1.82 × 10-5 2.31 × 10-4 
SYCP1 3.82 × 10-7 5.12 × 10-5 2.88 × 10-4 
 
 
Figure 3.12. Non-citrullinated microarray: top 5 citrullinated antigens. CRC patient and HC samples were 
processed on the citrullinated microarray. The top 5 citrullinated antigens were identified; the graph 
displays the median RFU-values for CDK7, MAGEB1, MAGEB5, MAGEB6 and SYCP1 across all CRC patients 
or HCs, and the error bars represents the MAD on the non-citrullinated microarray. Abbreviations include: 
CRC = colorectal cancer; HC = healthy control; RFU = relative fluorescence units, nm = nanometre; MAD = 



























Table 3.3. Shapiro-Wilk, Mann-Whitney U and Benjamini-Hochberg tests values for the top 5 
citrullinated antigens on the non-citrullinated CT100plus microarray.  
Antigen Shapiro Wilk  
(p-value) 




CDK7 2.54 × 10-4 0.07 0.14 
MAGEB1 1.15 × 10-9 0.14 0.22 
MAGEB5 4.83 × 10-5 0.38 0.50 
MAGEB6 5.28 × 10-9 0.73 0.75 
SYCP1 5.55 × 10-15 0.07 0.14 
 
 
To further assess the biomarker potential of the top 5 citrullinated antigens, PCA and 
unsupervised hierarchical clustering were performed in Perseus (version 1.5.4.1). The signal 
intensity values were log2 transformed prior to the analysis.  
The PCA results display two segregating clusters, each representing CRC patients (green) or HCs 
(orange), although overlap is evident on the 1D and 2D PCA plots. For both plots, CRC patients 
and HCs separately, although CRC064, CRC060, CRC050, CRC039 and CRC050, clustering with 






Figure 3.13. PCA between CRC patients and HCs. CRC patient and HC plasma were processed on the citrullinated CT100plus microarray, and the 
top 5 citrullinated antigens in CRC patients were log2-transformed and selected for 1D and 2D PCA multivariate testing using the Perseus (version 
1.5.4.1). The 1D and 2D PCA plots display distinct CRC patient (green) and HC (orange) clusters. Abbreviations include: PCA = principle component 
analysis; CRC = colorectal cancer; HC = healthy control; 1D = one-dimensional; 2D = two-dimensional. 
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3.5. CT100plus antigens associated with CRC patient clinicopathological features 
The clinicopathological information of 61 CRC patients whose plasma samples were assayed on 
the citrullinated CT100plus microarray are summarised in Table 2.3.  
The clinical features include patient age, gender, ethnicity, family history, body mass index (BMI), 
hypersensitivity, smoking and alcohol intake. The pathology information includes cancer stage at 
disease presentation; MS stability or instability status; whether the disease was sporadic or 
classified as HNPCC; family history of CRC; anatomical presentation of the cancer specimen; 
whether inflammation was detected; and whether the patient received radiotherapy. These 
features were used for subsequent statistical analysis to identify associations between 
clinicopathological features and autoantibody detection.  
The baseline-corrected antigen signal values were obtained prior to statistical analysis. Here, the 
baseline-corrected values were obtained by subtracting the ROC-derived cut-off-values from 
CT100plus-derived median-values for each antigen. The ROC-derived cut-off-values used for 
baseline subtraction is shown in Figure 3.14 for each antigen, resulting in a median-value of 619 





Figure 3.14. ROC-derived cut-off-values for CRC patients. ROC analyses between CRC patients and HCs 
produced cut-off-values for each antigen; each bar represents the cut-off-value per antigen. These values 
were used for baseline-correction for each antigen prior to clinicopathological statistical analysis. 
Abbreviations include: ROC = receiver operator characteristic; CRC = colorectal cancer; HCs = healthy 
controls. 
 
Clinicopathological features and autoantibody signal associations were determined using the 
Mann-Whitney U test (Mann and Whitney, 1947) when comparing two groups (e.g. Recurrence), 
and the Kruskal-Wallis test (Kruskal and Wallis, 1952) when comparing three or more groups (e.g. 
Cancer stage). Statistical significance was assessed using the Benjamini-Hochberg test (Benjamini 
and Hochberg, 1995), where an adjusted p-value ≤ 0.05 was deemed significant. All tests were 
performed in R Studio (1.0.136), and only the Kruskal-Wallis test analysis was performed with the 
PMCMR package (Maintainer and Pohlert, 2016). 
No significant association between clinicopathological features and autoantibody signal were 
identified for CRC patients assayed on the citrullinated CT100plus microarray. Although a p-value 
of ≤ 0.05 was obtained for associations between “smoking” and the signal intensity of MICA, the 
Benjamini-Hochberg correction test indicated that the changes were non-significant. The results 
























Table 3.4. Clinicopathological features and autoantibody signal with p-values ≤ 0.01. Mann-Whitney U 
test indicate a significant difference in antigenic signal for the smoking, although it is not statistically 
significant after the Benjamini-Hochberg test was applied. Abbreviation include: TAA = tumour-associated 
antigen. 
Clinical feature TAA p-value Adjusted p-value 





















Discussion and conclusion 
Arginine is a positively charged amino acid, which when converted to citrulline results in a 
monoisotopic mass difference of +0.984016 Daltons (Da), attaining a neutral charge (Rogers and 
Simmonds, 1958). The shift in charge caused by citrullination affects protein-protein interactions, 
hydrogen bond formation, protein structure, and in some cases, can cause denaturation (Tarcsa 
et al., 1996; Knuckley et al., 2010). In fact, it is hypothesized that citrullination-induced changes 
in protein surface results in protein structure alterations that activate autoimmune responses 
when the protein is released in to the surrounding interstitial tissues. Interestingly, for our assays, 
CRC plasma produced a higher median signal intensity on the citrullinated (1100 RFU, MAD = 
±402) versus non-citrullinated (637 RFU; MAD = ±120) CT100plus microarray, possibly due to 
increased non-specific binding on citrullinated antigens caused by increased hydrophobicity of 
the citrulline compared to arginine.  
For this study, our aim was to assess the autoantibody response of CRC patients to citrullinated 
antigens on the CT100plus microarray. The first objective was to determine the appropriate PAD 
concentration needed to citrullinated antigens on the CT100plus microarray to acquire a 
significant level of citrullination. Since PAD4 was commercially available, and since it catalyses 
the same citrullination reaction as PAD2, it was used to citrullinate antigens on the CT100plus 
microarray. It is expected that surface-exposed arginine amino acids will be converted to 
citrulline on all proteins on the slide surface, including streptavidin, antigens and positive 
controls. From our results, it is evident that the median signal intensity from streptavidin is lower 
than the median signal intensity from antigens (Figure 3.2). There are several reasons why the 
foreground (antigen spots) intensity is greater than the background (streptavidin) intensity: The 
foreground signal may result from the cumulative intensity derived from citrullinated 
streptavidin and antigen present within antigen spot, resulting in a higher foreground versus 
background intensity. Alternatively, the higher foreground signal may be derived from 
citrullinated antigen alone as steric hindrance may prevent streptavidin citrullination within the 
antigen spot. If the foreground signal is derived from antigen alone, there are several possible 
explanations for decreased levels of citrullinated streptavidin versus antigens: (1) The 
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streptavidin-biotin interaction changes streptavidin conformation, limiting PAD4-induced 
citrullination, (2) On average, the number of surface arginine residues is higher for the antigens 
versus streptavidin, or (3) the arginine residues in streptavidin are flanked by amino acids which 
limit PAD-induced citrullination.  Together, the results indicate the successful conversion of 
arginine to citrulline on antigens present on the CT100plus microarray. To determine the 
concentration of PAD4 required, a Mann-Whitney U test was performed comparing untreated 
and the 8 PAD4-treated microarrays, and here we found that 1 µg/ml PAD4 was sufficient for a 
significant (p-value = 0.005) increase in citrullination, which also falls within the linear range when 
detecting citrullination (Figure 3.4). It is important to incubate the microarray with PAD4 in the 
linear range concentration, as a low PAD4 concentration may result in under citrullination 
whereas high PAD4 concentration may result in autocitrullination, which reportedly inactivates 
the PAD4 enzyme (Andrade et al., 2010). Thus, 1 µg/ml PAD4 was used to citrullinate antigens on 
the CT100plus microarray before assaying CRC patient plasma. 
The second objective was to compare the differential CRC patient autoantibody signals on the 
citrullinated and non-citrullinated CT100plus microarray. The comparative analysis showed that 
11/43 (26%) of patients produced low RFU signal for all antigens on both microarray-types; an 
example is shown for patient CRC042 in Figure 3.7, indicating that this patient subgroup does not 
produce autoantibodies against citrullinated or non-citrullinated CT100plus microarray antigens. 
Twenty-one of the 43 (49%) patients elicited a medium or high response on the unmodified 
microarray, but only 6/43 (14%) patients retained the signal toward these antigens on the 
citrullinated microarray. An example of decreased signal is shown for CRC010 (Figure 3.8), who 
produced an autoantibody response toward DDX54 on both array-types, although a high signal 
is observed on the non-citrullinated microarray whilst a medium signal is observed on the 
citrullinated microarray. Decreased autoantibody signal on the citrullinated microarray may 
result from citrullination-induced epitope destruction. Interestingly, 28/43 (65%) patients 
produced a medium and/or high autoantibody response to antigens on the citrullinated 
microarray, although baseline intensity levels were detected on the non-citrullinated microarray. 
An example is shown for CRC045 (Figure 3.9) who produced baseline signals on the non-
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citrullinated microarray, but higher signals intensities for MAGEB1, MAGEB5 and MAGEB6 on the 
citrullinated microarray.  
A critical consideration when selecting a potential biomarker molecule is that the molecule 
should be detectable in patients, but absent or at significantly lower levels in healthy individuals. 
Our final objective was therefore to compare the autoantibody responses of 59 CRC patients and 
11 healthy individuals toward citrullinated antigens on the CT100plus microarray. The top 5 
antigens, to include CDK7, MAGEB6, MAGEB1, MAGEB5, and SYCP1, with medium or high signal 
on the citrullinated, but low signal on the non-citrullinated microarray were analysed: 
The ROC analysis produced sensitivity-values ranging from 0.75 – 0.87; specificity-values ranging 
from 0.82 - 1.0; and AUC-values ranging from 0.74 – 0.92. A combination analysis was also 
performed for all antigens, and the best combination was for CDK7 and MAGEB6, which together 
produced sensitivity-, specificity-, and AUC-values of 1.0, 0.82 and 0.88, respectively (Table 3.1). 
In the literature, ROC assessments are reported for potential and currently used CRC protein 
biomarkers, including CEA, IL-8, Apo AI, C9, and CA-19-9. Here, the AUC-values, either alone or in 
combination, ranged from 0.62 - 0.90 (Murakoshi et al., 2011; Lee, 2013; Jin et al., 2014; Zhang 
et al., 2015). Thus, our citrullinated antigen panel produced similar AUC-values to the best 
performing CRC biomarkers tested. To further assess the selected top 5 antigen panel, a 
multivariate PCA was performed in Perseus (version 1.5.4.1). Distinct groupings of CRC patients 
and HCs formed on the 1D and 2D PCA plots, with overlap between CRC patients and HC1, HC3, 
HC6, HC7 and HC8 (Figure 3.13). Overlap may be expected as a ROC specificity-value of 0.91 was 
obtained, indicating a relatively high, but not perfect, discrimination score. Together, the Mann-
Whitney U test, ROC and PCA results provide evidence for the first time that citrullinated antigens 
discriminate between CRC patients and HCs with high sensitivity and specificity, and may be 
potential CRC diagnostic biomarkers. 
Autoantibody responses to citrullinated and non-citrullinated CDK7, MAGEB6, MAGEB1, 
MAGEB5, and SYCP1 have not been reported previously. CDK7 and MAGE proteins are reportedly 
expressed in CRC, which is summarised below: 
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Cyclin-dependent kinase, or CDK7 (http://www.uniprot.org/uniprot/P50613), is a 
serine/threonine kinase involved in cell cycle control and RNA polymerase II-mediated RNA 
transcription. Cyclin-dependent kinases are activated by binding to cyclin and mediate the 
progression through the cell cycle. A study with multiple cell-lines, including the HCT116 colon 
cancer cell-line, proposed that CDK7 may promote cancer cell-cycle progression and improve cell 
survival, as low doses of CDK7 inhibitors caused delays in cell-cycle progression and diminished 
tumour cell survival. High doses of CDK7 inhibitor caused cell death, which they concluded 
resulted from the inability of CDK7-induced mRNA synthesis (Kelso et al., 2014). Autoimmune 
and autoantibody responses toward non-citrullinated and citrullinated CDK7 have not been 
reported. However, using the solved structure of CDK7 in PyMOL (version 2.0.4), we identified 
arginine residues on the surface of CDK7 (Figure 3.15) available for conversion to citrulline in CRC 
cells or on the CT100plus microarray. In conclusion, CRC-related CDK7 activity has only been 
described for in vitro colon cancer cell-lines but here we provide supporting evidence for the 
citrullinated form of CDK7 in CRC patients. 
 
Figure 3.15. Crystal structure of CDK7 with arginine residues highlighted in red. CDK7 was detected at 
medium and high signal intensities on the citrullinated microarray, but low signal intensities on the non-
citrullinated microarray, indicating that the citrullinated version CDK7 induces an autoantibody response 
in CRC patients. The image represents the crystal structure of CDK7 (PDB: 1UA2). The arginine-residues 
available for PAD-induced citrullination are indicated in red. Abbreviations include: CRC = colorectal 
cancer; PAD4 = protein arginine deiminase isoform 4; PDB = protein data bank. 
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Melanoma antigen gene, also known as MAGE, is a large protein family of highly conserved 
proteins that share the MAGE homology domain. MAGE family members can be divided in to two 
categories: Type I, which are considered CTAs in humans, and include MAGE-A, -B, and -C 
subfamily members; and Type II, which include MAGE-D, -E, -F, -G, -H, -L subfamilies, and are 
expressed in many tissues throughout the body (Weon and Potts, 2015). Jungbluth et al. did not 
detected the expression of MAGEA-1, -3, -4, -6 and -12 in normal nor cancer tissues of colon and 
rectum, which they suggest may be due to the poor sensitivity of immunohistochemistry 
(Jungbluth et al., 2000a). In contrast, a large number of studies identified MAGE mRNA and 
protein expression in CRC cell-lines and tissues (Mori et al., 1996; Li et al., 2005; Chung et al., 
2010; Jeon et al., 2011; Choi and Chang, 2012). Several of these studies observed a significant 
association between increased MAGE expression in patient cancer tissues and liver metastasis 
(Mori et al., 1996; Li et al., 2005; Choi and Chang, 2012). Autoimmune and autoantibody 
responses to cancer antigens have been reported, suggesting that the immune system may be 
an excellent target for cancer diagnosis, screening and treatment. Consistent with this idea, a 
study of 20 CRC patients treated with a MAGEA DC vaccine showed a median progression-free 
survival of 2.4 months, with 2 patients showing progression-free survival for more than 27 
months (Toh et al., 2009). MAGEB1, MAGEB5 and MAGEB6 are not reportedly expressed in CRC, 
but MAGEB1 is reportedly expressed in other gastrointestinal carcinomas, including oesophageal 
SCCs (Nagashima et al., 2002). MAGE-D2 transcripts and the MAGED2 protein are reportedly 
overexpressed in CRC (Hashimoto et al., 2015). Thus, the autoantibody signal detected on the 
CT100plus microarray may be directed against an epitope shared between MAGEB and MAGED2. 
Interestingly, MAGED2 was also identified in our AP-MS results (Chapter 4). Although MAGEB and 
MAGED subfamilies form part of type I and type II MAGEs, respectively, both MAGE-types share 
a MAGE homology domain (MHD) that spans 170 amino acids, which on average is 46% 
conserved amongst all human MAGEs. It is possible that an autoimmune response is raised 
against citrullinated MAGED2, and that the autoantibodies cross react with MAGEB1, MAGEB5 
and MAGEB6 on the CT100plus microarray. Unfortunately, the structures of MAGEB1, MAGEB5 
and MAGEB6 are not reported, and potential surface epitopes could not be identified. In 
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conclusion, although CRC-related MAGE activity has previously been reported, for the first time 
we provide evidence for the detection of citrullinated forms in CRC patients. 
Synaptomenal complex protein 1, or SYCP1 (www.uniprot.org/uniprot/Q15431), is a major 
component of the transverse chromosomes during meiotic prophase. SYCP1 is needed for normal 
assembly of the central element of synaptomenal complexes, normal centromere pairing during 
meiosis, normal meiotic chromosome synapsis during oocyte and spermatocyte development, 
and for normal male and female fertility. SYCP1 is not reportedly expressed in CRC, including 
autoimmune and autoantibody responses. Although, using the solved structure of SYCP1 in 
PyMOL (version 2.0.4), we identified arginine residues on the surface of SYCP1 (Figure 3.16) 
available for conversion to citrulline in CRC cells or on the CT100plus microarray. In conclusion, 
we provide supporting evidence for the citrullinated form in CRC patients. 
 
Figure 3.16. Crystal structure of SYCP1 with arginine residues highlighted in red. SYCP1 was detected at 
medium and high signal intensities on the citrullinated microarray, but low signal intensities on the non-
citrullinated microarray, indicating that the citrullinated version SYCP1 induces an autoantibody response 
in CRC patients. The image represents the crystal structure of SYCP1 (PDB: 4YTO). The arginine-residues 
available for PAD4-induced citrullination is indicated in red. Abbreviations include: CRC = colorectal 
cancer; PAD 4 = protein arginine deiminase isoform 4; PDB = protein data bank. 
 
In Chapter 4, the AP-MS assay was used to identify novel and known TAAs and TSAs of CRC. We 
obtained supporting evidence that a fraction of significantly expressed CT100plus antigens were 
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also identified by AP-MS (Chapter 2 and 4). PAD2 was also detected in the AP-MS data for 2 
patients: CRC002 showed PAD2 expression in Cancer only, whereas CRC004 showed PAD2 
expression in Cancer and Normal. The MaxQuant search was extended to include the detection 
of citrullinated peptides; a total of 58 proteins, 87 peptides and 108 citrullination sites were 
identified. Vimentin and actin were identified, which are normal substrates of PAD2 (Zhang et al., 
2012; Hsu et al., 2014). In addition, citrullinated tubulin, heat shock protein, and fibrinogen were 
also identified which are PAD2 substrates in cancer cell-lines and are associated with  tumour 
growth, invasion, and a poor prognosis (Jiang et al., 2013). In this Chapter, a top 5 antigen panel 
was selected to include CDK7, MAGEB6, MAGEB1, MAGEB5, and SYCP1 as the most frequently 
detected antigens on the citrullinated microarray. Although citrullinated peptides of these 
proteins were not detected by AP-MS, non-citrullinated peptides of the CDK5 and MAGED2 
homologues were identified. CDK5 and CDK7 share 46% homology, whereas MAGED2 shares ~ 
40% homology with MAGEB1, MAGEB5 and MAGEB6. Together, these results suggest that the 
detected CT100plus autoantibody signals may be toward homologues of CT100plus antigens, 
although this should be confirmed through alternate methods. In addition, citrullinated peptides 
may not have been sufficiently enriched, and were therefore below the limit of detection for the 
mass spectrometer. Citrulline-enrichment using Biotin-PEG2-4-glyoxalbenzoic acid (BPG) 
improved the detection from 119 to 3600 citrullinated peptides (Tutturen et al., 2014), 
suggesting that citrullinated peptide-enrichment may be important to detect more citrullinated 
peptides in future studies.  
We found a non-significant (adjusted p-value > 0.05) association between patient 
clinicopathological information and autoantibody signal intensity. Although p-values ≤ 0.05 were 
obtained for associations between “smoking” and the signal intensity for MICA, the Benjamini-
Hochberg multiple testing correction indicated that these changes were non-significant. Unlike 
the melanoma cohort, these patient samples were not collected as part of a clinical cohort. Thus, 
when considering the diversity of the cohort (Table 2.3), and only assessing 123 TAA, this result 
is plausible. It is therefore important that future CT100plus assays include carefully selected 
patient samples that form part of a controlled clinical cohort, which may result in statistically 
significant associations between clinicopathological features and autoantibody signal intensity. 
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In conclusion, to our knowledge, this is the first time citrullinated cancer proteins have been used 
to detect autoantibodies in CRC patients, indicating that citrullinated proteins can be used for 
CRC diagnosis. Thus, it may be critical to consider protein citrullination when developing 























Chapter 4  
 
CRC antigen biomarker identification using the IMMUNOME™ microarray and 
affinity purification-mass spectrometry (AP-MS)  
 
Abstract 
TAAs can induce an autoantibody response in its host; these autoantigens have been identified 
using high-throughput methods including phage display, SEREX and SERPA. These methods 
identify multiple potential antigens in a single experiment; however, the disadvantages include 
the use of non-native TAAs that lead to the loss of important epitopes due to expression in 
Escherichia coli (E.coli), protein denaturation (e.g. in SERPA), and absent PTMs. We previously 
processed a cohort of 62 CRC patient plasma samples on the CT100plus microarray which 
contains 123 TAAs (Chapter 2 and 3). In this Chapter, we processed two CRC plasma samples on 
the SENGENICS IMMUNOME™ microarray functionalized with 1622 native eukaryotic proteins. 
The highest autoantibody signals were toward proteins not present on the CT100plus microarray, 
including NOL4 and TXN2 for patient CRC038, and LGALS1 and KRT19 for patient CRC050. We 
also developed an AP-MS assay to detect autoantibody responses to autologous native tissue 
proteins. For the assay, 5 CRC patient samples were processed, whose plasma were also 
processed on the CT100plus microarray. For 5/5 (100%) patients we identified proteins via AP-
MS that were also detected on the CT100plus microarray. Furthermore, we also identify 
citrullinated proteins associated with cancer progression. In conclusion, we identify common 
TAAs for potential diagnostic use using complementary immunoproteomic techniques that 






Cancer patients can produce autoantibodies to proteins that are mutated, misfolded, improperly 
glycosylated, over-expressed, truncated or aberrantly localised within tumour cells. Research on 
TAAs, as well as their related autoantibodies, has provided an abundance of targets for therapy, 
prognostication, diagnosis, and response to therapy. Several techniques have been used to 
identify TAAs, including SEREX, SERPA and protein micro-array technology (Gunawardana and 
Diamandis, 2007), discussed in Chapter 1. 
Using the CT100plus microarray, we identified the autoantigenic targets of autoantibodies that 
are expressed in CRC patients (Chapter 2 and 3). Since only 123 antigens are assessed on the 
CT100plus microarray, we sought to employ tools or assays that allow the assessment of a wider 
array of protein targets. Thus, we assayed CRC patient samples on the SENGENICS IMMUNOME™ 
microarray, which is functionalized with 1622 proteins and based on the same underlying 
technology used to construct the CT100plus microarray. Thus, we expect robust and reliable 
detection of autoantibodies toward autoantigens. To expand the autoantigen identification 
capabilities even further, AP-MS was used to capture CRC patient IgG and subsequently capture 
native cancer antigens from autologous CRC patient tissue samples. Since patient IgG was used 
to capture antigens from whole tissue lysates, the autoantibody response to the entire CRC 
proteome was assessed. In this chapter, we discuss the results of CRC patient autoantibody 
response on the SENGENICS IMMUNOME™ microarray, and discuss the development and results 









4.1. Autoantibody detection on the SENGENICS IMMUNOME™ microarray 
The SENGENICS IMMUNOME™ microarray contains 1622 proteins, comprised of cancer antigens, 
transcription factors, kinases and signalling proteins (Suwarnalata et al., 2016). The signal 
intensities from SENGENICS IMMUNOME™ microarrays treated with detection Ab only (blank) 
and pooled HCs plus detection Ab were provided by SENGENICS®. The data from the SENGENICS 
IMMUNOME™ microarrays were extrapolated using stringent processing and filtered steps: 
whole array CV ≤ 20%; probe replicate CV ≤ 10%; noise-threshold ≥ 2 SD above background; 
maximum threshold = 65355 nm; whole array filtering control = Cy3-biotin-BSA.  
The autoantibody profiles for the two selected patients were compared between the SENGENICS 
IMMUNOME™ microarray and the CT100plus microarray. A blank SENGENICS IMMUNOME™ 
microarray slide was assessed to determine signal levels from a microarray incubated with Cy3-
conjugated anti-human IgG detection antibody. Here, the median antigen signal intensity was 
144 (MAD = 12) RFU, and most antigens produced signal intensities below 500 RFU, except for 
IGHG1 which produced a signal intensity of 14115 RFU (Figure 4.1), which confirmed the addition 
of Cy3-conjugated anti-human IgG detection antibody. The SENGENICS IMMUNOME™ 
microarray was also incubated with pooled HC plasma - the signal intensities displayed in Figure 
4.2. The median signal intensity was 844 (± 96) RFU, reflecting low non-specific binding between 
the functionalised proteins and plasma proteins. Although 95.7% of antigens displayed low signal 
intensities (200-2000 RFU), 67 antigens produced medium signal intensity (2000-10000 RFU) and 
2 antigens produced high signal intensity (>10000 RFU). As expected, a high signal intensity was 
detected for IGHG1 (15162 RFU), the constant region of the IgG heavy chain, confirming the 
addition of detection Ab which binds to the constant region of human IgG molecules. However, 
a high signal intensity was also detected for RBPJ (10954 RFU), which – according to the array 
manufacturer - always produces a high signal intensity on the microarray, even when assaying 




Figure 4.1. Antigen intensities for a Blank SENGENICS IMMUNOME™ microarray. The SENGENICS 
IMMUNOME™ microarray was incubated with serum albumin buffer (PBS, BSA and Triton™ X-100) and 
Cy3-conjugated anti-human IgG detection antibody. Fluorescence images were obtained at 532 nm, and 
numerical data extrapolated. The net intensity for each antigen was obtained, and the data was 
subsequently filtered using stringent criteria (control CV ≤ 20%; antigen CV ≤ 10%; noise threshold ≥ 2 SD 
above background). The scatter plot displays the median intensity-values for each antigen. The image 
represents only a quarter of the microarray, which contains one of the 4 quadruplicate antigens spots. 
Abbreviations include: PBS = phosphate buffer saline; BSA = bovine serum albumin; Cy3 = cyanine 3; IgG 
= immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD = standard deviation. 
 
 
Figure 4.2. Antigen intensities for the SENGENICS IMMUNOME™ microarray treated with pooled HC 
plasma. The SENGENICS IMMUNOME™ microarray was incubated with pooled HC plasma and Cy3-
conjugated anti-human IgG detection Ab to determine baseline signal intensities for various antigens. 
Fluorescence images were obtained at 532 nm, and numerical data extrapolated. The net intensity for 
each antigen was obtained, and the data was subsequently filtered using stringent criteria (control CV ≤ 
20%; antigen CV ≤ 10%; noise threshold ≥ 2 SD above background). The scatter plot displays the median 
intensity-values for each antigen. The image represents only a quarter of the microarray, which contains 
one of the 4 quadruplicate antigens spots. Abbreviations include: HC = healthy control; Cy3 = cyanine 3; 

















































The plasma samples for CRC038 and CRC050 were previously processed on the CT100plus 
microarray (Duarte et al., unpublished data), and showed high autoantibody signals. These 
patient plasma samples were therefore also assessed on the SENGENICS IMMUNOME™ 
microarray to detect autoantibody signals toward other cancer antigens. Unlike the CT100plus 
microarray, the SENGENICS IMMUNOME™ microarrays were processed manually in a slide 
chamber as the Tecan HS4800 Pro automated microarray hybridization station modules cannot 
accommodate the physical dimensions of the SENGENICS IMMUNOME™ microarray. The 
SENGENICS IMMUNOME™ microarray images were obtained at 523 nm using the AUTOPMT 
setting 
We were limited by the number of SENGENICS IMMUNOME™ microarrays available, and so we 
obtained the immunome profile of 2 patients only: CRC038 and CRC050. When assessing the 
autoantibody response of CRC038 (Figure 4.3) and CRC050 (Figure 4.4) on the CT100plus 
microarray, the median intensity for all antigens across the microarray was 0 (MAD = 0) and 642 
(MAD = 267), respectively. The higher median intensity was likely due to low non-specific binding 
from CRC050 plasma, a phenomenon observed previously for patients within this cohort (Chapter 
2 and 3) and the melanoma cohort (Chapter 5). When assessing the median autoantibody 
response of CRC038 (Figure 4.5) and CRC050 (Figure 4.6) on the SENGENICS IMMUNOME™ 
microarray, the median intensity for all antigens across the microarray was 847 (MAD = 135) and 
9584 (MAD = 1610), respectively. Taken together, the median intensity was higher for CRC050 
than CRC038 on both microarray-types, although the difference was more marked on the 
SENGENICS IMMUNOME™ microarray. These results are supported by the microarray images 
presented for CRC038 (Figure 4.5) and CRC050 (Figure 4.6). The methods for slide preparation 
are different for each microarray-type: all SENGENICS IMMUNOME™ microarray processing, i.e. 
plasma incubation, detection Ab incubation and washes, were performed manually in a 
microarray slide holder, whereas all CT100plus microarray processing is confined and automated 
in the Tecan HS4800 Pro automated microarray hybridization station, resulting in the production 





Figure 4.3. Scatterplot representing the autoantibody intensities for CRC038 on CT100plus microarray. 
The CT100plus microarray was incubated with the blood plasma of CRC038, and subsequently incubated 
with fluorescently-labelled anti-human IgG. Fluorescence images were obtained at 635 nm, and numerical 
data extrapolated using the CT100plus.jar software: Antigen net intensities were obtained, and the data 
was processed and filtered: whole array CV ≤ 25%; replicate probe CV ≤ 20%; noise threshold ≥ 2 SD above 
background). The scatter plot displays the median intensity-values for each antigen. Abbreviations 
include: IgG = immunoglobulin G; nm = nanometres; CV = coefficient of variation; SD = standard deviation. 
 
 
Figure 4.4. Scatterplot representing the autoantibody intensities for CRC050 on CT100plus microarray. 
The CT100plus microarray was incubated with the blood plasma of CRC050, and subsequently incubated 
with fluorescently-labelled anti-human IgG. Fluorescence images were obtained at 635 nm, and numerical 
data extrapolated using the CT100plus.jar software: Antigen net intensity were obtained, and the data 
was processed and filtered: whole array CV ≤ 25%; replicate probe CV ≤ 20%; noise threshold ≥ 2 SD above 
background). The scatter plot displays the median intensity-values for each antigen. Abbreviations 









































When assessing the autoantibody response of CRC038 on the CT100plus microarray (Figure 4.3), 
there was high signal toward SILV; a medium signal toward SPATS1 (isoform a), CT47.11, 
MAGEA4v2, MAPK1, p53 S46A and CRC25A; and low or no signal toward the remaining antigens. 
However, when assessing the autoantibody response of CRC038 on the SENGENICS 
IMMUNOME™ microarray (Figure 4.5), the highest autoantibody response detected was against 
NOL4 (15477 RFU), TXN2 (10218 RFU), PPP2R4 (8956 RFU), SDCCAG8 (7611 RFU) and TFG (7565 
RFU), which are all antigens not present on the CT100plus microarray. When assessing the 
autoantibody response of CRC050 on the CT100plus microarray (Figure 4.4), there was high signal 
toward the mutant form p53 Q136x; a medium signal toward MAGEA11 and cytochrome p450 
3A4; and low or no signal toward the remaining antigens. However, when assessing the 
autoantibody response of CRC050 on the SENGENICS IMMUNOME™ microarray (Figure 4.6), the 
highest autoantibody response was detected was for LGALS1 (34263 RFU), KRT19 (22412 RFU), 
FTH1 (21505 RFU), PLK1 (19694 RFU) and p53 (19253 RFU), which except for p53, are not present 
on the CT100plus microarray. Together, these results indicate that CRC patients produce 
autoantibody signals toward proteins not present on the CT100plus microarray, suggesting that 
the CT100plus microarray content should be expanded to allow for the detection of novel cancer 
specific antigens. These antigens could potentially be used for cancer diagnosis and prognosis, 














Figure 4.5. Microarray image and scatter plot for CRC038 plasma on the SENGENICS IMMUNOME™ 
microarray. The SENGENICS IMMUNOME™ microarray was incubated with the blood plasma of CRC038, 
and subsequently incubated with Cy3-conjugated anti-human IgG detection antibody. Fluorescence 
images were obtained at 532 nm, and numerical data extrapolated. The net intensity for each antigen was 
obtained, and the data was subsequently filtered using stringent criteria (control CV ≤ 20%; antigen CV ≤ 
10%; noise threshold ≥ 2 SD above background). The scatter plot displays the median intensity-values for 
each antigen. The image represents only a quarter of the microarray, which contains one of the 4 
quadruplicate antigens spots. Cy3 = cyanine 3; IgG = immunoglobulin G; nm = nanometres; CV = coefficient 



























Figure 4.6. Microarray image and scatter plot for CRC050 plasma on the SENGENICS IMMUNOME™ 
microarray. The SENGENICS IMMUNOME™ microarray was incubated with the blood plasma of CRC050, 
and subsequently incubated with Cy3-conjugated anti-human IgG detection antibody. Fluorescence 
images were obtained at 532 nm, and numerical data extrapolated. The net intensity for each antigen was 
obtained, and the data was subsequently filtered using stringent criteria (control CV ≤ 20%; antigen CV ≤ 
10%; noise threshold ≥ 2 SD above background). The scatter plot displays the median intensity-values for 
each antigen. The image represents only a quarter of the microarray, which contains one of the 4 
quadruplicate antigens spots. Cy3 = cyanine 3; IgG = immunoglobulin G; nm = nanometres; CV = coefficient 

























4.2. Developing and employing an affinity purification-mass spectrometry (AP-MS) assay  
An AP-MS assay was developed to identify novel and known cancer antigens associated with CRC, 
which we hypothesize could serve as potential biomarkers for CRC diagnosis and prognosis. For 
this assay, IgG from CRC patient plasma was affinity purified using MagReSyn® Protein G 
magnetic beads, whereas IgA, IgG and IgM were captured using MagReSyn® Protein A magnetic 
beads. The Protein G beads were used for assay optimizations and AP-MS experiments, whereas 
Protein A was used in an AP-MS experiment only to compare the results from the two bead-
types. To prevent or decrease IgG contamination during the antigen elution step, IgG (and any 
non-specific proteins from plasma) molecules were cross-linked to Protein A or G using dimethyl 
pimelimidate dihydrochloride (DMP). The IgG-coated Protein A or G beads were subsequently 
incubated with autologous native lysate from CRC patients to capture potential antigens, which 
were eluted under mild conditions and then subjected to mass spectrometric analysis. The assay 
optimization and results are described below: 
The first step in the AP-MS assay was to optimize the correct ratio of CRC patient plasma volume 
to Protein G magnetic beads. For this assay, 0 microliters (µl), 2.5 µl, 5 µl, 15 µl, 30 µl, 60 µl, 90 
µl and 120 µl of CRC010 plasma was added to Protein G beads, and IgG eluted with 2.5 % acetate. 
The bound proteins were quantified using the BCA assay (Figure 4.7), and a fraction of the sample 
was separated on a reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) gel and stained with AQUASTAIN (Figure 4.8). 
From Figure 4.7, it is evident that the protein concentration increases linearly from 0 to 15 µl 
plasma, where after it starts to plateau. This result is supported by the SDS-PAGE gel and 
densiometric analysis of the Ig light chain (Figure 4.8). Proteins bands are seen at 25 kilodaltons 
(kDa) and 55 kDa, corresponding to the molecular weight of light and heavy chains, respectively, 
of IgG (as Protein G reportedly binds only IgG of all Igs) after reducing disulphide bonds - 
indicating that IgGs were successfully enriched from plasma samples, and that 50 µl Protein G 
beads was sufficient to capture most of the Ig from 15 µl patient plasma. Protein bands that do 
not correspond to IgG were also detected, and are evident between 70 and 100 kDa, 130 and 250 
kDa, and 35 and 55 kDa. Although these bands appear faint for 2.5 µl plasma, the intensity is 
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pronounced with an increase in plasma volume, and is likely due to non-specific binding of plasma 
proteins to the Protein G magnetic beads. Densiometric analysis of the 25 kDa band showed that 
the protein levels start to plateau at 15 µl plasma. Thus, to extract most Igs, and to minimize non-
specific binding, a ratio of 15 µl CRC plasma to 50 µl MagReSyn® Protein A or G magnetic beads 
was used for subsequent AP-MS assays. 
 
 
Figure 4.7. CRC patient plasma volume as a function of IgG eluted from Protein G beads. CRC010 patient 
plasma, at 0 µl, 2.5 µl, 5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated with 50 µl MagReSyn® Protein 
G magnetic beads to capture IgG. Bound proteins, including IgG and any non-specific proteins, were eluted 





























Figure 4.8. Relative quantitation of CRC plasma-derived IgG eluted from MagReSyn® Protein G magnetic 
beads. CRC010 patient plasma, at 0 µl, 2.5 µl, 5 µl, 15 µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated with 
50 µl MagReSyn® Protein G magnetic beads to capture IgG. Bound proteins were eluted, and separated 
by SDS-PAGE, and stained with AQUASTAIN. Distinct protein bands formed at 25 kDa and 55 kDa from 2.5 
µl plasma, corresponding to the light and heavy chains, respectively, of IgG. Densitometric analysis was 
performed for the 25 kDa band, and the resulting stain intensity is displayed as a function of plasma 
volume (µl). Abbreviations include: CRC = colorectal cancer; IgG = immunoglobulin G; SDS-PAGE = sodium 


























To determine whether Protein A or G captures more IgG from plasma, and to confirm that the 
major bands identified at 25 kDa and 55 kDa (Figure 4.8) were indeed Igs, plasma from CRC038 
or CRC050 was incubated with MagReSyn® Protein A or G magnetic beads, and the eluents from 
each bead-type were analyzed by Western blot analysis using peroxidase-conjugated anti-human 
IgG antibody, with subsequent densiometric analysis. Here, FP is free protein, and refers to 
removed unbound plasma protein; FPW is free protein in wash, and refers to proteins that were 
removed during wash steps; Ab is antibody, and refers to antibodies (and non-specific binders) 
removed through acid elution. For CRC038, Protein A and G captures 73 % and 78 % of IgG, 
respectively (Figure 4.9); whereas for CRC050 Protein A and G captures 58 % and 93 % of IgG, 
respectively (Figure 4.10). This confirms that Protein A and G captured IgG from CRC plasma, and 



















Figure 4.9. Western blot analysis of IP eluents for CRC038. CRC patient plasma, at 0 µl, 2.5 µl, 5 µl, 15 µl, 
30 µl, 60 µl, 90 µl or 120 µl, was incubated with 50 µl MagReSyn® Protein G magnetic beads to capture 
IgG from CRC038 plasma. Unbound proteins and bound proteins were eluted, and IgG light and heavy 
chains were detected by Western blot. Densitometric analysis was performed for the 25 kDa band, and 
the resulting stain intensity is displayed. Abbreviations include: IgG = immunoglobulin G, FP = free protein, 
















































Figure 4.10. Western blot analysis of IP eluents for CRC050. CRC patient plasma, at 0 µl, 2.5 µl, 5 µl, 15 
µl, 30 µl, 60 µl, 90 µl or 120 µl, was incubated with 50 µl MagReSyn® Protein G magnetic beads to capture 
IgG from CRC050 plasma. Unbound proteins and bound proteins were eluted, and IgG light and heavy 
chains were detected by Western blot. Densitometric analysis was performed for the 25 kDa band, and 
the resulting stain intensity is displayed. Abbreviations include: IgG = immunoglobulin G, FP = free protein, 
FPW = free protein in wash, Ab = antibody.  
 
To minimize IgG contamination during antigen elution, the second aim was to crosslink IgG to 
Protein G with DMP using an adapted protocol from Holzmann et al. (Holzmann et al., 2011). For 
this assay, 50 µl Protein G beads were incubated with 7.5 µl or 15 µl plasma; the two 
concentrations were selected to determine whether the IgG load on the beads affected cross-
linking.  After the wash steps, Protein G-bound proteins were crosslinked with DMP. The beads 
were subsequently incubated with 2.5% acetate (pH 2.87) to elute proteins that were not cross-
linked. As a negative control, Protein G beads were incubated with 15 µl plasma, and after several 
wash steps, bound proteins were eluted with 2.5% acetate (pH 2.87). The resulting eluents were 
quantified using the BCA protein quantitation kit and analysed by SDS-PAGE and AQUASTAIN 




































proteins elute under acidic conditions i.e. 2.5% acetate (pH 2.87). When Protein G-bound 
proteins were cross-linked with DMP, the concentration of eluted protein decreases to 0 (0%) 
and 17 µg/ml (1%) for 7.5 µl and 15 µl plasma, respectively (Figure 4.11). This result was 
supported by the SDS-PAGE and AQUASTAIN analysis of eluted proteins: the negative control 
displayed protein bands at ~25 kDa and ~55 kDa, corresponding to the molecular weight of the 
light and heavy chain of IgG, respectively. The DMP-treated samples did not appear to have any 
protein bands seen in the negative control (Figure 4.12). Together, these results indicate that IgG 
and any other non-specific proteins from plasma are crosslinked to Protein G, decreasing the 
amounts of non-specific proteins to be analysed on the mass spectrometer. 
 
 
Figure 4.11. Protein quantitation of eluents after crosslinking IgG to MagReSyn® Protein G magnetic 
beads with DMP. IgG was crosslinked to Protein G beads with DMP to prevent, or decrease, IgG 
contamination when eluting potential cancer antigens. Here, 7.5 µl or 15 µl plasma was incubated with 
50 µl Protein G magnetic beads, and cross-linked using DMP. Beads incubated with 15 µl plasma, with no 
crosslinking were used as a negative control. All proteins that were not crosslinked were eluted and 
quantified using the BCA protein quantification kit. Abbreviations include: IgG = immunoglobulin G; DMP 


































Figure 4.12. SDS-PAGE and AQUASTAIN of eluents after crosslinking IgG to MagReSyn® Protein G 
magnetic beads with DMP. IgG and Protein G were crosslinked with DMP to prevent, or reduce, IgG 
contamination when eluting potential cancer antigens. Here, 7.5 µl or 15 µl plasma was incubated with 
50 µl Protein G magnetic beads, and cross-linked using DMP. Beads incubated with 15 µl plasma, with no 
crosslinking was used as a negative control. All proteins that was not cross-linked was eluted and 
separated on an SDS-PAGE gel and stain with AQUASTAIN. Abbreviations include: SDS-PAGE = sodium 
dodecyl sulphate polyacrylamide gel electrophoresis; IgG = immunoglobulin G; DMP = dimethyl 
pimelimidate dihydrochloride. 
 
The next step was to incubate the IgG-bound beads with autologous tissue lysate to capture and 
enrich for potential cancer antigens. Therefore, the third aim was to produce native protein 
lysates from CRC tissues. Since we were limited with the amount of fresh frozen tissues available 
for assay optimization, SHSY5Y neuroblastoma cells were used to test the efficacy of the buffer 
with the various detergents. The buffer system contained 20 mM 4-(2-hydroxyethyl) piperazine-
1-ethanesulfonic acid (HEPES) (pH 7.9), 1 mM MgCl2, 5 mM EDTA, 1 unit per microliter (U/µl) 
benzonase, 1× protease inhibitor, and a detergent. Detergents tested included 1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 1% IGEPAL® CA-630, 1% 
Triton™ X-100, a mixture of detergents (0.25% CHAPS, 0.5% IGEPAL® CA 630, and 0.5% Triton™ 
X-100), or a negative control without detergent. Three lysis conditions were also assessed for 
protein yield: lysis buffer only refers to lysates generated by incubating with lysis buffer and on 
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ice with intermittent vortexing only; lysis buffer &  PE refers to lysates generated by incubating 
with lysis buffer and homogenizing using a Potter-Elvehjem homogenizer, and then incubated on 
ice with intermittent vortexing; lysis buffer & shaking refers to lysates generated by incubating 
with lysis buffer and homogenizing with a Potter-Elvehjem homogenizer, and then continuous 
vortexing at 4 degree Celsius (°C). From Figure 4.13 it is evident for the lysis buffer only samples 
that the buffer containing Triton™ X-100 produced the highest protein yield, followed by “mix”, 
IGEPAL® then CHAPS, with no protein detected in the buffer without detergent. However, for the 
lysis buffer & PE samples, the protein concentration increased for all buffers, excluding CHAPS. 
Here, again the buffer containing Triton™ X-100 produced the highest concentration of protein, 
followed by IGEPAL®, “mix”, CHAPS, and lowest concentration of protein was detected for the 
buffer without detergent. The condition producing the highest concentration was lysis buffer & 
shaking, which resulted in similar protein levels for all detergent-types used, except for the buffer 
without detergent which produced a significantly lower protein concentration. Since the highest 
protein concentration was produced using Triton™ X-100, the buffer containing Triton™ X-100 
was used for subsequent assays. Since lysis buffer & shaking produced the highest concentration 






Figure 4.13. Protein quantitation of SHSY5Y cell-line lysates. SH-SY5Y human neuroblastoma cells were 
lysed with non-denaturing lysis buffers containing different detergents, including 1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 1% IGEPAL® CA-630, 1% Triton™ X-
100, a mixture of detergents (0.25% CHAPS, 0.5% IGEPAL® CA 630, and 0.5% Triton™ X-100), and a 
negative control with no detergent (No det). Various lysis conditions were also assessed for protein yield: 
lysis only refers to lysates generated by incubating with lysis buffers and incubated on ice with 
intermittent vortexing only; lysis + homogenization refers to lysates generated by incubating with lysis 
buffers and homogenizing using a Potter-Elvehjem homogenizer, and then incubated on ice with 
intermittent vortexing; lysis + shaking refers to lysates generated by incubating with lysis buffers and 
homogenizing with a Potter-Elvehjem homogenizer, and then continuous vortexing at 4 °C.  
 
After the Protein A or G beads were incubated with CRC patient plasma and autologous tissue 
lysate, and the beads were thoroughly washed to remove proteins that bind non-specifically, the 
antigens and any remaining non-specifically bound proteins were eluted. Here, proteins were 
eluted using on-bead tryptic digestion, a method adapted from Turriziani et al. (Turriziani et al., 
2014), to elute tryptic fragments that were further used for mass spectrometry analysis. 
Next, we determined the number of proteins identified from an AP-MS experiment using Protein 
A or Protein G magnetic bead-types. The AP-MS experiment was performed with either Protein 
A or G magnetic beads, using the blood plasma, and native cancer and tissue lysates, from 
CRC004. Here, Cancer refers to antigens and non-specific binders eluted from AP-MS assays using 
blood plasma and native cancer tissue lysate. The negative controls included Plasma, which refers 
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from an AP-MS assay with CRC004 plasma and paired normal tissue. The raw files were processed 
through MaxQuant (version 1.5.3.12) using intensity-based absolute quantification (iBAQ) 
(Schwanhüusser et al., 2011) and match between runs, with a minimum of two unique peptides. 
The iBAQ quantitation values were median normalised. Cancer and normal tissues were collected 
for the CRC patients. The normal mucosa was excised from tissues flanking the cancer tissue, and 
it is therefore possible that normal tissue may have been in the process of transforming to cancer 
tissue. Thus, for the analysis, we identified cancer-derived proteins that were present in Cancer 
only samples (i.e. Cancer-unique), to identify potential cancer antigens unique to cancer tissues, 
or proteins detected at ≥ 2-fold iBAQ in Cancer than Normal (i.e. Cancer-enriched), to identify 
potential cancer antigens that may also be present in transformed normal mucosa. For the 
analysis, Cancer-unique and Cancer-enriched protein groups identified using Protein A or G bead-
types were compared to determine whether common protein groups were enriched using the 
two bead-types. The data analysis pipeline is outlined in Figure 4.14.  
The iBAQ quantitation values were median normalised and is presented as a boxplot in Figure 
4.15. Protein A magnetic beads captured 994, 898 and 117 proteins for Cancer, Normal and 
Plasma, respectively; the number of shared proteins is indicated in Figure 4.16, whereas Protein 
G magnetic beads captured 945, 812 and 499 proteins for Cancer, Normal and Plasma, 
respectively; the number of shared proteins is indicated in Figure 4.17. A total of 317 Cancer-
enriched proteins were identified from Protein A and G, of which70 (22%) proteins were shared 
between the bead-types, whereas 170 (54%) and 77 (24%) were unique to Protein A or G, 
respectively (Figure 4.18). A total of 268 Cancer-unique proteins were identified from Protein A 
and G, of which 80 (30%) proteins were common between the bead-types, whereas 75 (28%) and 
113 (42%) were unique to Protein A or G, respectively (Figure 4.19). Together, these results 
indicate that peptides and proteins were identified from plasma and tissue lysates using Protein 
A or G magnetic beads. Both bead-types identified more proteins for Cancer versus Normal, with 
the lowest number of proteins identified for Plasma. Furthermore, 70 and 80 proteins were 
commonly identified as enriched or unique, respectively, to Cancer for Protein A and G. It would 
be ideal to compare the AP-MS results to the CT100plus microarray results, and since an IgG 
autoantibody response was detected on the CT100plus microarray, and that Protein G binds all 
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IgG subtypes but Protein A binds weakly to a subgroup of IgG subtypes, we continued to use 
Protein G magnetic beads for further assays. 
 
Figure 4.14. AP-MS data analysis pipeline. Cancer (AP-MS with plasma and CRC tissue), Normal (AP-MS 
with plasma and normal mucosa) and Plasma (AP-MS with plasma only) samples of CRC004 were 
processed using Protein A or Protein G beads, and analysed using the Q Exactive mass spectrometer. The 
raw files were processed through MaxQuant (version 1.5.3.12) using intensity-based absolute 
quantification (iBAQ) and match between runs. Subsequent data filtering included the removal of reverse 
hits, contaminants and protein groups with < 2 peptides, and the data was normalised using median iBAQ 
values. Plasma proteins were removed from Cancer and Normal for Protein A and Protein G samples. 
Cancer-enriched, defined as proteins detected at ≥ 2-fold iBAQ in Cancer than Normal, and Cancer-unique, 
defined as cancer-derived proteins that were present in Cancer only, were subsequently identified. 




Figure 4.15. Box plot of median-based iBAQ normalisation. Cancer (AP-MS with plasma and CRC tissue), 
Normal (AP-MS with plasma and normal mucosa) and Plasma (AP-MS with plasma only) samples of 
CRC004 were processed using Protein A or Protein G beads, and analysed using the Q Exactive mass 
spectrometer. The raw files were processed through MaxQuant (version 1.5.3.12) using iBAQ and match 
between runs. Subsequent data filtering included the removal of reverse hits, contaminants and protein 
groups with < 2 peptides, and the data was normalised using median iBAQ values. Abbreviations include: 
AP-MS = affinity purification-mass spectrometry; iBAQ = intensity-based absolute quantification. 
 
 
Figure 4.16. Number of proteins identified for AP-MS with MagReSyn® Protein A magnetic beads for 
CRC004. For the AP-MS assay, Igs from CRC004 were captured using Protein A magnetic beads, and 
proteins were subsequently captured from CRC004 cancer and paired normal native lysate. The captured 
proteins were eluted, analysed by mass spectrometry. The negative controls included Plasma, which 
refers to proteins from Protein A magnetic beads incubated with CRC004 plasma; and Normal, which 
refers to proteins from Protein A magnetic beads incubated with CRC004 plasma and paired normal tissue. 




Figure 4.17. Number of proteins identified for AP-MS with MagReSyn® Protein G magnetic beads for 
CRC004. For the AP-MS assay, Igs from CRC004 were captured using Protein G magnetic beads, proteins 
were subsequently captured from CRC004 cancer and paired normal native lysate. The captured proteins 
were eluted, analysed by mass spectrometry. The negative controls included Plasma, which refers to 
proteins from Protein G magnetic beads incubated with CRC004 plasma; and Normal, which refers to 
proteins from Protein G magnetic beads incubated with CRC004 plasma and paired normal tissue. 




Figure 4.18. Cancer-enriched proteins shared proteins between Protein A and G. For the AP-MS assay, 
Igs from CRC004 were captured using Protein A or G magnetic beads, and proteins were subsequently 
captured from CRC004 cancer and paired normal native lysate. Proteins were identified using MaxQuant 
software (version 1.5.3.12). Proteins identified in the Plasma data were removed from Cancer and Normal 
data, and proteins with higher signal in Cancer versus Normal (i.e. Cancer-enriched) were identified, 
displayed in the Venn diagram. Abbreviations include: AP-MS = affinity purification-mass spectrometry; 





Figure 4.19. Cancer-unique shared proteins between Protein A and G. For the AP-MS assay, Igs from 
CRC004 were captured using Protein A or G magnetic beads, and proteins were subsequently captured 
from CRC004 cancer and paired normal native lysate. Proteins were identified using MaxQuant software 
(version 1.5.3.12). Proteins identified in the Plasma and Normal data were removed from Cancer data, 
and proteins specific to Cancer (i.e. Cancer-unique) were identified, and displayed in the Venn diagram. 
Abbreviations include: AP-MS = affinity purification-mass spectrometry; Igs = immunoglobulins. 
 
Cancer-enriched and Cancer-unique proteins from AP-MS experiments with Protein A and 
Protein G were analysed using the functional association network software search tool for the 
retrieval of interacting genes/proteins (STRING) (version 10.5) (https://string-db.org/). The 
settings included active interaction sources from textmining, experiments, databases and co-
expression, and a medium (0.4) minimum interaction score. The edges indicate evidence of 
interaction, whereas nodes contain query proteins. Although some proteins do not interact 
physically with other proteins in the network, the possibility of the co-expression or predicted 
linkage is plausible. The network generated from STRING indicates multiple links between input 
proteins, and ACLY is a central protein linked to ABCC3, ADH1B, AGPS, CSK, EFTUD1, MCCC2, 





Figure 4.20. String analysis of Cancer proteins common for Protein A and Protein G. Cancer-enriched and Cancer-unique proteins were identified 
for AP-MS samples with Protein A and Protein G and analysed using STRING (https://string-db.org).  
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We next performed the AP-MS assay using Protein G magnetic beads for 4 additional CRC patient 
samples for whom we had the highest amount of tissue specimen available. The patients included 
CRC002, CRC017, CRC021 and CRC031, for which the Cancer, Normal and Plasma protein elutions 
were analysed by mass spectrometry. Thus, a total of 5 patient samples were analysed by AP-
MS. Of the 5 patients tested, CRC017, CRC021 and CRC031 had polyethylene glycol (PEG) 
detected in the mass spectrum. PEG is a charged molecule derived from detergents, e.g. Triton™ 
X-100, Tween® 20 or IGEPAL® CA-630, used in non-denaturing buffers like the buffer used to 
produce native lysate from CRC tissues. Since it is charged, PEG is detected in samples analysed 
by mass spectrometry. At high levels, PEG suppresses the signal intensity from peptides-derived 
ions, resulting in lower levels, or no peptide, detected. Thus, patients whose spectra contained 
high levels of PEG were not used for quantitative analysis, although, these were used to identify 
proteins detected on the CT100plus microarray and to assess citrullination. 
Potential cancer antigens identified by AP-MS and CT100plus microarray: 
We next compared the proteins identified in the AP-MS experiment and CT100plus microarray. 
For this comparison, CT100plus microarray antigen signal intensities greater than or equal to cut-
off-value (Figure 2.10) and present in the AP-MS results, without any data filtering were 
identified. We also identified homologues of significant CT100plus antigens for CRC002 and 
CRC004. CT100plus antigens and antigen homologues identified by AP-MS for CRC002 are 
summarised in Table 4.1 and Table 4.2, respectively, whereas CT100plus antigens and antigen 
homologues identified by AP-MS for CRC004 are summarised in Table 4.3 and Table 4.4. 
CT100plus antigens identified by AP-MS for CRC017, CRC021 and CRC031 are summarised in 
Table 4.5, Table 4.6 and Table 4.7, respectively. Since different CRC patients were assayed on the 
SENGENICS IMMUNOME™ microarray and the AP-MS assays, comparisons could not be made 





Table 4.1. Proteins matched between CT100plus microarray and AP-MS for CRC002. For CRC002, 
significant (> cut-off) cancer antigens on CT100plus microarray were searched against same patient AP-
MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry. 
Protein Cancer Normal Plasma 
CALM1 Yes Yes No 
COL6A1 Yes Yes No 
CTNNB1 Yes Yes No 
ITGB1 Yes Yes No 
LDHC Yes Yes Yes 
MAPK1 Yes Yes No 
MAPK3 Yes Yes No 
SPAG9 Yes Yes No 
THEG Yes Yes No 
 
Table 4.2. Proteins homologues matched between CT100plus microarray and AP-MS for CRC002. For 
CRC002, significant (> cut-off) cancer antigens on CT100plus microarray were searched against same 
patient AP-MS results. Abbreviations include: AP-MS = affinity purification mass-spectrometry, N/A = not 
available. 
Protein Homologue Cancer Normal Plasma Query cover E-value Identity 
CEACAM1 CEACAM7 Yes Yes No 84% 2.00e-120 70% 
COX6B2 COX6B1 Yes Yes No 96% 2.00e-35 54% 
MAGEA1 MAGED2 Yes No No 30% 1.00e-48 41% 
MAGEA10 MAGED2 Yes No No 32% 1.00e-55 40% 
MAGEA11 MAGED2 Yes No No 38% 1.00e-54 41% 
MAGEA2 MAGED2 Yes No No 35% 3.00e-36 38% 
MAGEA3 MAGED2 Yes No No 38% 7.00e-45 40% 
MAGEA4v2 MAGED2 Yes No No N/A N/A N/A 
MAGEA4v3 MAGED2 Yes No No N/A N/A N/A 
MAGEA4v4 MAGED2 Yes No No N/A N/A N/A 
MAGEA5 MAGED2 Yes No No N/A N/A N/A 
MAGEB1 MAGED2 Yes No No 33% 2.00E-55 43% 
MAGEB5 MAGED2 Yes No No 32% 3.00E-46 40% 
MAGEB6 MAGED2 Yes No No 32% 1.00E-52 42% 
PRKCZ PRKCD Yes No No 79% 3.00E+113 40% 
ROPN1 ROPN1B Yes Yes No 100% 4.00E-157 96% 






Table 4.3. Proteins matched between CT100plus microarray and AP-MS for CRC004. For CRC004, 
significant (> cut-off) cancer antigens on CT100plus microarray were searched against same patient AP-
MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry. 
Protein Cancer Normal Plasma 
CALM1 Yes Yes Yes 
COL6A1 Yes Yes Yes 
CTNNB1 Yes Yes Yes 
ITGB1 Yes Yes Yes 
LDHC Yes No No 
MAPK1 Yes Yes Yes 
MAPK3 Yes Yes No 
SPAG9 Yes No No 
THEG Yes Yes Yes 
 
Table 4.4. Proteins homologues matched between CT100plus microarray and AP-MS for CRC004. For 
CRC004, significant (> cut-off) cancer antigens on CT100plus microarray were searched against same 
patient AP-MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry, N/A = not 
available. 
Protein Homologue Cancer Normal Plasma Query cover E-value Identity 
CEACAM 1 CEACAM7 Yes Yes Yes 84% 2.00e-120 70% 
COX6B2 COX6B1 Yes Yes Yes 96% 2.00e-35 54% 
MAGEA1 MAGED2 Yes No No 30% 1.00e-48 41% 
MAGEA10 MAGED2 Yes No No 32% 1.00e-55 40% 
MAGEA11 MAGED2 Yes No No 38% 1.00e-54 41% 
MAGEA2 MAGED2 Yes No No 35% 3.00e-36 38% 
MAGEA4v2 MAGED2 Yes No No N/A N/A N/A 
MAGEA4v3 MAGED2 Yes No No N/A N/A N/A 
MAGEA4v4 MAGED2 Yes No No N/A N/A N/A 
MAGEA5 MAGED2 Yes No No N/A N/A N/A 
MAGEB1 MAGED2 Yes No No 33% 2.00e-55 43% 
MAGEB5 MAGED2 Yes No No 32% 3.00e-46 40% 
MAGEB6 MAGED2 Yes No No 32% 1.00e-52 42% 
ROPN1 ROPNB1 Yes Yes No 100% 4.00e-157 96% 
ROPN1A ROPNB1 Yes Yes No 100% 2e-120 96% 
 
Table 4.5. Proteins matched between CT100plus microarray and AP-MS for CRC017. For CRC017, 
significant (> cut-off) cancer antigens on CT100plus microarray were searched against same patient AP-
MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry. 
Protein Cancer Normal Plasma 
CALM1 Yes Yes No 
MAPK3 Yes No No 
THEG Yes Yes Yes 
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Table 4.6. Proteins matched between CT100plus microarray and AP-MS for CRC021. For CRC021, 
significant (> cut-off) cancer antigens on CT100plus microarray were searched against same patient AP-
MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry. 
Protein Cancer Normal Plasma 
CALM1 No Yes No 
COL6A1 Yes Yes Yes 
CTNNB1 No Yes No 
ITGB1 No Yes No 
LDHC Yes Yes No 
MAPK3 No Yes No 
THEG No Yes No 
 
Table 4.7. Proteins matched between CT100plus microarray and AP-MS for CRC031. For CRC031, 
significant (> cut-off) cancer antigens on CT100plus microarray were searched against same patient AP-
MS results. Abbreviations include: AP-MS = affinity purification-mass spectrometry. 
Protein Cancer Normal Plasma 
COL6A1 Yes No No 
CTNNB1 Yes No No 
THEG Yes No Yes 
 
Potential cancer antigens identified by AP-MS: 
The next step was to identify autoantigens from the AP-MS data that were not present on the 
CT100plus or SENGENICS IMMUNOME™ microarrays. Here, autoantigens specific to Cancer-
unique or Cancer-enriched proteins were matched to the AAgAtlas human autoantigen database 
(version 1.0) with “cancer” as the disease-term. The gene symbols in the AAgAtlas human 
autoantigen database (version 1.0) matched to 2981 UniProt accession numbers, which was used 
for further analysis. Due to PEG contamination in CRC017, CRC021 and CRC031, only CRC002 and 
CRC004 were used for further analysis.  
The data analysis pipeline is described in Figure 4.14. Briefly, the raw files were processed 
through MaxQuant (version 1.5.3.12) using iBAQ (Schwanhüusser et al., 2011) and ‘match 
between runs’, with a minimum of two unique peptides. After the filtering was applied, for 
CRC002 we identified 1440, 1420 and 303 proteins for Cancer, Normal and Plasma, respectively; 
whereas for CRC004 we identified 1307, 1152 and 883 proteins for Cancer, Normal and Plasma, 
respectively. The iBAQ quantitation values were median normalised, presented as a boxplot in 
Figure 4.21.  
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Cancer and normal tissues were collected for the CRC patients. The normal mucosa was excised 
from tissues flanking the cancer tissue, and it is therefore possible that normal tissue may have 
been in the process of transforming to cancer tissue. Thus, for the analysis, we identified cancer-
derived proteins that were present in Cancer only samples (i.e. Cancer-unique), to identify 
potential cancer antigens unique to cancer tissues; or proteins detected at ≥ 2-fold iBAQ in Cancer 
than Normal (i.e. Cancer-enriched), to identify potential cancer antigens that may also be present 
in transformed normal mucosa.  
 
 
Figure 4.21. Box plot of median-based iBAQ normalisation. Cancer (AP-MS with plasma and CRC tissue), 
Normal (AP-MS with plasma and normal mucosa) and Plasma (AP-MS with plasma only) samples of 
CRC002 and CRC004 were processed by AP-MS. The raw files were processed through MaxQuant (version 
1.5.3.12) using iBAQ and match between runs. Subsequent data filtering included the removal of reverse 
hits, contaminants and protein groups with < 2 peptides, and the data was normalised using median iBAQ-
values. Abbreviations include: CRC = colorectal cancer; iBAQ = intensity-based absolute quantification; AP-
MS = affinity purification-mass spectrometry. 
 
Cancer-unique and Cancer-enriched proteins were identified for CRC002 and CRC004. A total of 
68 and 193 Cancer-unique proteins were identified for CRC002 and CRC004, respectively. There 
were no protein shared between CRC002, CRC004 and AAgAtlas, although 1 and 8 proteins 
matched to AAgAtlas for CRC002 and CRC004, respectively (Figure 4.22). Furthermore, 17 Cancer-
unique proteins were shared between CRC002 and CRC004 only. Cancer-enriched proteins were 
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also identified for CRC002 and CRC004. A total of 98 and 146 Cancer-unique proteins were 
identified for CRC002 and CRC004, respectively. Here, there was no protein shared between 
CRC002, CRC004 and AAgAtlas, although 1 and 1 proteins matched to AAgAtlas for CRC002 and 
CRC004, respectively. Furthermore, 1 Cancer-unique protein was shared between CRC002 and 
CRC004 (Figure 4.23).  
 
Figure 4.22. Cancer-unique proteins matched to the AAgAtlas autoantigen database. Cancer-unique 
proteins, defined as proteins characterised with at least 2 unique peptides specific to the Cancer sample, 
for CRC002 and CRC004 were matched it to the AAgAtlas human autoantigen database (version 1.0). The 
Venn diagram represents the number of proteins that are unique to, or overlap between, Cancer-unique 
and the AAgAtlas proteins. 
 
 
Figure 4.23. Cancer-enriched proteins matched to the AAgAtlas autoantigen database. Cancer-enriched 
proteins, defined as proteins with higher expression in Cancer versus Normal (and Plasma-specific 
proteins removed), for CRC002 and CRC004 were matched to the AAgAtlas human autoantigen database 
(version 1.0). The Venn diagram represents the number of proteins that are unique to, or overlap 
between, Cancer-enriched and the AAgAtlas proteins. 
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Citrullinated peptides detected in AP-MS assays: 
In Chapter 3, the autoantibody response of CRC patients to citrullinated CT100plus microarray 
proteins was investigated. Here, autoantibody signals were detected against citrullinated 
versions of the proteins, indicating that a PAD enzyme might be present and active in the CRC 
tissues. From the AP-MS results, PAD2 was detected for Cancer sample of CRC002, and the Cancer 
and Normal samples of CRC004, but it was not detected for the remaining patient samples. To 
assess PAD activity, the raw spectra for each patient were processed through MaxQuant 
(1.5.3.12) to include the detection of citrulline residues. Stringent quality control conditions were 
used: Andromeda score > 40; Δ-score > 8; posterior error of probability (PEP) score < 0.01; and a 
localisation score of > 0.75. After the quality control measures were applied, a total of 58 
proteins, 87 peptides and 108 citrullination sites were identified. Here, vimentin and actin were 
identified, which are normal substrates of PAD2 (Zhang et al., 2012; Hsu et al., 2014). We also 
identified citrullinated tubulin, heat shock protein and fibrinogen, which are PAD2 substrates in 
cancer cell-lines and associated with tumour growth, invasion, and a poor prognosis (Jiang et al., 
2013). Although the citrulline modification may be expected for Cancer and Normal samples, as 
PAD2 is reportedly expressed in colon tissues, 15 citrullinated proteins were also detected in the 
Plasma sample. The list of proteins identified from citrullinated peptides for the Cancer, Normal 
and Plasma samples is summarised for each patient in Appendix B (Table B2 – B16). Together, 










Discussion and conclusion 
Cancer is a heterogenous disease capable of forming and spreading in most tissues of the human 
body. Cancer diagnosis usually involves invasive extraction techniques required for histological 
confirmation. The operations performed are risky and expensive, with a long waiting time in 
public sector hospitals in South Africa. It is therefore important to create a cost-effective, non-
invasive cancer diagnostic tools that also indicates disease prognosis. With these in questions 
mind, the Blackburn lab created the CT100plus microarray, a tool that detects autoantibody 
signals from the blood of cancer patients, detectable in the (picogram per millilitre) pg/ml range. 
The CT100plus microarray is functionalised with native TSA and TAA, which include CTA. Thus, 
the autoantibody signals detected for patients are specific to aberrant cancer proteins, and 
should therefore be detected in cancer patients only (Beeton-Kempen et al., 2014). Despite the 
technological advancements of microarrays, autoantibody signals are not identified in all 
patients. Furthermore, none of the biomarkers have yet been associated with cancer prognosis. 
We therefore sought to assess a wider range of proteins functionalized similarly to CT100plus 
platform, for example, the SENGENICS IMMUNOME™ microarray.  
Like the CT100plus microarray, the SENGENICS IMMUNOME™ microarray is functionalized with 
replicates of 1622 full-length, correctly folded proteins that contain conformational and linear 
epitopes, as well as carrying eukaryotic PTMs. The processed data of the blank SENGENICS 
IMMUNOME™ microarray indicates signal intensity below 500 RFU for all proteins, although a 
high signal intensity for IGHG1, confirming the addition of the detection antibody, Cy3-
conjugated anti-human IgG. The slide incubated with pooled HC plasma produced high signal for 
IGHG1 (15162 RFU) and RBPJ (10954), and although 95.7% of the proteins produced low signal 
intensity (200-2000 RFU), 67 proteins produced medium signal intensity (2000-10000 RFU). The 
medium and high signal intensities may be due to genuine Ab signals present at low frequencies 
in the HC pooled sample; notably, young HC sera show very low binding to either the CT100plus 
or SENGENICS IMMUNOME™ microarrays (J. Blackburn, personal communication), but the 
average age of the commercial HC pooled sample is not described in the product sheet. 
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When assaying the CRC patient plasma, we were limited by cost to only 2 SENGENICS 
IMMUNOME™ microarrays, and assayed the plasma of CRC038 (Figure 4.3) and CRC050 (Figure 
4.4) only, as these patient samples displayed high autoantibody signal on the CT100plus 
microarray. Since the 2 microarrays tested produced variable responses, it was a challenge to set 
a baseline threshold, and so we opted to assess the top 5 antigens with the highest signal 
intensity for each microarray.  The highest signal intensity detected on the SENGENICS 
IMMUNOME™ microarray for both patients was toward proteins not present on the CT100plus 
microarray, except for p53 which was detected in CRC050. The highest signal intensity for CRC038 
was NOL4 (15477 RFU), TXN2 (10218 RFU), PPP2R4 (8956 RFU), SDCCAG8 (7611 RFU) and TFG 
(7565 RFU); whereas the highest signal intensity for CRC050 was LGALS1 (34263 RFU), KRT19 
(22412 RFU), FTH1 (21505 RFU), PLK1 (19694 RFU) and p53 (19253 RFU). Although the CT100plus 
microarray did not detect significant levels (>1000 RFU) of p53 for CRC050, high signal was 
detected against the p53 Q136x mutant form. Together, these results indicate that CRC patients 
produce autoantibody signals against proteins not present on the CT100plus microarray, implying 
that the CT100plus antigen content should be expanded, or that the SENGENICS IMMUNOME™ 
microarray should be used, to identify antigens linked with CRC diagnosis and disease prognosis. 
Importantly, more patient samples should be analysed to obtain enough power to obtain 
statistically significant correlations between autoantigens to CRC diagnosis and prognosis. 
Although assessing the autoantibody response to 1622 proteins on the SENGENICS 
IMMUNOME™ microarray is an improvement from the 123 proteins on the CT100plus 
microarray, here we aimed to develop an assay that assessed the autoantibody response toward 
the CRC proteome. Several techniques have already been used to identify cancer antigens, 
including SEREX (Sahin et al., 1995), SERPA (Klade et al., 2001), phage display (Smith, 1985b), and 
natural protein microarrays (Qiu et al., 2004). Although these techniques have led to the 
discovery of cancer autoantigens, they are limited as most proteins are not identified in their 
native state and/or lack the correct PTMs, suggesting that TAAs or TSAs may be missed as 
conformational epitopes may be lost. We therefore sought to use a modified AP-MS assay, where 
CRC patient IgGs were captured using Protein G beads. The IgG-functionalized beads were used 
to capture cancer antigens from autologous native tissue lysates, which were subsequently 
134 
 
eluted and identified using mass spectrometry. Here, assay optimisation was performed, and 
protein quantitation (Figure 4.7) and SDS-PAGE (Figure 4.8) confirmed that 50 µl Protein G 
magnetic beads captured most of the IgG present in 15 µl CRC plasma. Western blot analysis with 
an anti-human IgG detection Ab confirmed that the 25 kDa band identified by SDS-PAGE was 
indeed IgG, and that Protein G captured more IgG than Protein A for CRC038 (Figure 4.9) and 
CRC050 (Figure 4.10). This result is supported by the reports that Protein G has a higher affinity 
for all IgGs, when compared to Protein A. Since the IgG response is assessed on the CT100plus 
and SENGENICS IMMUNOME™ microarrays, Protein G magnetic beads were used for subsequent 
assays.  
In order to decrease the level of plasma protein contamination during the antigen elution step, 
IgG (and proteins that bind non-specifically) from plasma were crosslinked to Protein G beads. 
Although protein quantitation (Figure 4.11) and SDS-PAGE (Figure 4.12) analyses indicate that 
little or no protein was detected after cross-linking, proteins were detected by mass 
spectrometry. The high number of Plasma proteins could be rationalized by the nature of the 
antigen elution step: after Protein G and IgG were crosslinked, proteins were eluted for 30 
minutes in a mild elution buffer containing trypsin. Thus, even though Plasma proteins were 
crosslinked to Protein G beads, Plasma peptides may have subsequently eluted due to trypsin 
digestion. However, DMP crosslinks at primary amines present on lysine residues and peptide N-
termini, decreasing the number of lysine residues available for trypsin digestion. Thus, although 
Plasma peptides are detected by mass spectrometry, crosslinking plasma proteins may have 
decreased non-specific peptide signal by preventing proteins from eluting due to the presence of 
2 M urea, and due to the unavailability of crosslinked lysine residues for trypsin cleavage. 
After the crosslinking step, the IgG-functionalised Protein G beads were incubated with native 
CRC tissue lysate. Since CRC tissue was precious and limited, an SHSY-5Y human neuroblastoma 
cell-line was first used to optimize lysis buffer composition and lysis conditions. The lysis buffer 
included HEPES (pH 7.4), which is a Good’s buffer characterised by its high compatibility with 
biological analysis, good solubility in water and minor salt effects (Good et al., 1966). Benzonase 
was added to digest nucleic acids. Protease inhibitors were added to avoid premature protein 
degradation. Most critical for the isolation of native proteins was the use of detergents – we 
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tested Triton™ X-100, IGEPAL® CA 630 and CHAPS, which are non-denaturing detergents. Varying 
lysis conditions were also tested, and from the results, it is evident that the buffer containing 
Triton™ X-100 with continuous vortexing at 4 °C produced the highest yield of protein from SHSY-
5Y cell-line, and it was therefore used to produce native CRC tissue lysates. For the AP-MS assays, 
200 micrograms (µg) native CRC lysate was tested which was sufficient to identify proteins by 
mass spectrometry. 
Since IgG bind to both Protein A and G, the AP-MS assay with CRC004 was performed to 
determine the specificity of each bead-type. The results showed high levels of presumed non-
specific binding for the negative controls, as 117 and 453 protein groups were identified for the 
Plasma sample from Protein A and G, respectively. Since 94.0 % and 98.7 % of Plasma proteins 
from Protein A and G, respectively, were identified in the Cancer and/or Normal samples. These 
Plasma proteins were therefore removed from Cancer and Normal samples for downstream 
analysis. Furthermore, for the Normal sample, 898 and 812 protein groups were detected for 
Protein A and G, respectively. Together, these results indicate that further steps should be taken 
to decrease non-specific binding in the AP-MS experiments. It is expected that the difference in 
physicochemical properties of Protein A and G should affect non-specific binding. Despite this, 
70 and 80 protein groups are shared between Cancer-enriched and Cancer-unique, respectively, 
indicating that the same CRC lysate proteins bound to IgG for each bead-type. To obtain support 
that cancer antigens might be enriched in the AP-MS assay, proteins that displayed significant 
signal intensity (> cut-off) on the CT100plus microarray were searched for in the AP-MS protein 
list. 
For all patients, significant proteins (greater than cut-off value) detected on the CT100plus 
microarray were also detected by AP-MS. For CRC002, 9 proteins that displayed significant 
intensity on the CT100plus microarray were also detected by AP-MS (Table 4.1), whereas the 
homologues of 17 CT100plus antigens were detected by AP-MS (Table 4.2). For CRC004, 9 
proteins that displayed significant intensity on the CT100plus microarray were also detected by 
AP-MS (Table 4.3), whereas the homologues of 15 CT100plus antigens were detected by AP-MS 
(Table 4.4). It is possible that antigens detected on the CT100plus microarray share an epitope 
present on the homologues identified by AP-MS. Despite PEG contamination issues, 3, 7 and 3 
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significant CT100plus antigens were also identified by AP-MS for CRC017 (Table 4.5), CRC021 
(Table 4.6) and CRC031 (Table 4.7), respectively. There are several possible reasons why antigens 
with significant intensity on the CT100plus microarray were not detected in the AP-MS assay: (1) 
Cancer is a heterogenous composition of abnormal cells, and only a ~3 mm3 section of cancer 
specimen was assessed in the AP-MS assays. It is therefore possible that tissue sections that 
contain other antigens of interest were not assessed; (2) The peptides for the unidentified 
significant CT100plus proteins do not ionize well, and were therefore not detected by the mass 
spectrometer; (3) The unidentified significant CT100plus protein levels were too low to be 
detected by the mass spectrometer. Notwithstanding this, for the first time, we have 
demonstrated that antigens detected through protein microarray-based autoantibody assays in 
CRC patients can also be detected by an alternate method i.e. AP-MS.  
To further assess the proteins identified by AP-MS, Cancer-unique and Cancer-enriched proteins 
were searched against the AAgAtlas human autoantigen database (version 1.0) with “cancer” as 
the disease-term (Wang et al., 2017). For Cancer-unique, there was no protein shared between 
CRC002, CRC004 and AAgAtlas, although 1 (PARP1) and 8 (RRL12, VWf, PDLI1, RO60, IF2B2, 
B2MG, HYES and MRP3) proteins matched to AAgAtlas for CRC002 and CRC004, respectively 
(Figure 4.22). Furthermore, 17 Cancer-unique proteins were shared between CRC002 and 
CRC004 only.  For Cancer-enriched, 0 proteins were shared between CRC002, CRC004 and 
AAgAtlas, although 1 (SYG) and 1 (HNRNPL) proteins matched to AAgAtlas for CRC002 and 
CRC004, respectively (Figure 4.23). Furthermore, 1 Cancer-enriched protein was shared between 
CRC002 and CRC004 only. These results indicate that potential CRC antigens were identified that 
are not present on the CT100plus or SENGENICS IMMUNOME™ microarray. It is essential that 
more patient samples are assayed in order to obtain enough power to produce statistically 
significant results. Once a selected group of proteins for cancer diagnosis and prognosis are 
identified by AP-MS, the proteins of interest should be expressed in insect cells and printed on 
the CT100plus microarray to confirm that an autoantibody response is detected in the CRC 
patients. 
For the AP-MS analysis, citrullination detection was included in the MaxQuant search. Although 
PAD2 was detected for only CRC002 and CRC004, citrullinated peptides were detected for all 
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samples tested. Although cancer-associated citrullinated peptides were detected in the AP-MS 
data, we did not the detect citrullinated peptides of proteins (CDK7, MAGEB1, MAGEB5, MAGEB6 
and SYCP1) associated with an autoantibody response on the citrullinated CT100plus microarray. 
However, homologues of CDK7, MAGEB1, MAGEB5, MAGEB6 were identified including CDK5, 
MAGED2, suggesting that we may have in fact detected autoantibody signals toward citrullinated 
homologues on the citrullinated CT100plus microarray. There are several alternative 
explanations for not detecting CDK7, MAGEB1, MAGEB5, MAGEB6 and SYCP1 by AP-MS: (1) if the 
citrullinated epitope interacts with an autoantibody, steric hindrance could prevent tryptic 
cleavage of the citrullinated peptide during the on-bead elution step; (2) citrullinated peptides 
do not ionize well and may not be detected by the mass spectrometer; or (3) The citrullinated 
peptide may not have been sufficiently enriched, and was therefore below the limit of detection 
for the mass spectrometer. Previous studies reported that citrulline-enrichment, e.g. using 
Biotin-PEG2-4-glyoxalbenzoic acid (BPG), improved the detection from 119 to 3600 citrullinated 
peptides (Tutturen et al., 2014), suggesting that citrullinated peptide-enrichment may be 
important to detect more citrullinated peptides in future studies.  
In conclusion, we have detected autoantibody responses in CRC patients using both the 
CT100plus and SENGENICS IMMUNOME™ microarrays. Furthermore, for all for 5 patients 
studied, cancer antigens detected on the CT100plus microarray were also detected by AP-MS. 
Several AP-MS-identified proteins that are not present on the CT100plus microarray matched to 
the AAgAtlas database. Lastly, citrullinated cancer proteins were detected by AP-MS, and whilst 
the citrullinated CT100plus antigens were not identified by AP-MS, homologues of these proteins 
were identified. These results are promising, but it will be important to assess at least 15 more 








Chapter 5  
 
A temporal CT100plus autoimmune assessment of stage IV melanoma patients 
treated with checkpoint inhibitors 
 
Abstract 
Melanoma is curable if detected early, whereas advanced melanoma is associated with high 
mortality rates. Immunotherapy with checkpoint inhibitors pembrolizumab, nivolumab and 
ipilimumab has improved survival in advanced stage melanoma patients. Biomarkers that predict 
treatment outcomes are hugely beneficial in providing optimal patient treatment, whilst limiting 
potential adverse treatment-side-effects. In this study, we assessed the autoantibody response 
of 52 melanoma patients before and after treatment with checkpoint inhibitors. Significantly (p-
value ≤ 0.05, adjusted p-value ≤ 0.05) higher autoantibody signals were detected in melanoma 
patients versus HCs toward CEACAM 1, DPPA2, FGFR2, ITGB1, MAGEA10, NANOG, PIM1, 
SPANXB1, THEG and XAGE1B, which produced AUC-, sensitivity- and specificity-ranges of 0.79-
0.87, 0.77 – 1.00 and 0.64 – 0.79, respectively. The combined ROC result indicates that CEACAM1 
and FGFR2 were the best antigen combination, producing AUC-, sensitivity-, and specificity-
values of 0.93, 0.96 and 0.94, respectively. Multivariate PCA and supervised hierarchical 
clustering analyses resulted in distinct groups of melanoma patients and HC clusters. Patient 
treatment information was available for the melanoma patients, although the longitudinal 
assessment indicates that no significant association was found for patient treatment-type and 
antigenic signal. In conclusion, although no association was found between immunotherapy 







Melanoma is a type of skin cancer that develops from melanocytes - a cell-type of the epidermis 
that produces the UV-protective melanin pigment. Although melanomas account for ~1 % of all 
cancer cases, it is responsible for most skin-cancer-related deaths, particularly after having 
metastasized. In fact, worldwide statistics revealed approximately 133 000 new cases of 
melanoma per year (Boyle and Levin, 2014), with 3.1 million active disease cases (GBD 2015 
Disease and Injury Incidence and Prevalence Collaborators, 2016), and 59 800 melanoma-related 
deaths in 2015 alone (GBD 2013 Mortality and Causes of Death Collaborators 2015), with the 
highest rates reported per year from Australia and New Zealand (WHO, 2012; Boyle and Levin, 
2014). In 2014, the Australian melanoma mortality rate was reportedly 5.5 deaths per 100 000 
persons (8.1 for males; 3.3 for females), estimating to have increased to 6.3 deaths per 100 000 
persons (9.5 for males; 3.6 for females) in 2017 (Whiteman et al., 2008). This increased incidence 
was associated with increased recreational exposure to UV radiation and/or early stage detection 
of lesions. Although the incidence rates have increased, the overall trend shows that melanoma 
incidence is beginning to stabilize. Furthermore, the 5-year survival rate from 1988 to 2013 
increased from 86% to 90%, likely associated with protection from ultraviolet (UV) light, early 
disease detection, improved chemo- and immuno-therapy, and surgery techniques (Clegg, 2002; 
Azoury and Lange, 2014).  
In this study, we use the CT100plus microarray to investigate the autoantibody response of 
advanced stage melanoma patients from the Olivia Newton-John Cancer Research Institute 
(ONJCRI) in Australia. For the Australian population, the age-standardized incidence and 
mortality rate increases with age for men and women, with a preponderance toward men 
(www.aihw.gov.au/acim-books). Melanoma typically forms on the legs of women and the trunks 
of men, differences unlikely due to UV exposure as these regions of the body are not necessarily 
exposed to sun light. Furthermore, mortality studies show that women tend to have thinner 
tumours and higher survival rates, suggesting the potential influence of X-linked gene expression 
or hormonal factors (de Vries et al., 2008). 
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Despite progress in the melanoma field, 13 941 new cases (8392 males; 5549 females), and 1839 
deaths (1280 males; 559 females) are predicted in 2017 for Australia alone 
(www.aihw.gov.au/acim-books). These estimates suggest that further melanoma research into 
early detection, recurrence and therapeutic response is needed, especially research that assesses 
the immune response because immunotherapy has significantly increased the 5-year relative 
survival rate. 
Preclinical studies with CLTA-4 and PD-1 blockade led to decreased tumour burden, thus immune 
checkpoint inhibitors have been further developed for cancer patient treatment. Monoclonal 
antibodies that block CLTA-4 and PD-1 have been developed for melanoma, lung, kidney, 
prostate and head and neck cancers. Agents targeting PD-L1 are also under development. 
Ipilimumab, was the first anti-CTLA-4 treatment to prolong survival in patients with advanced 
melanoma (Hodi et al., 2010; Robert et al., 2011). Long-term survival analysis indicated a 3-year 
survival of 22%, 26% and 20% in all patients with sufficient follow-up, in treatment naïve patients, 
and in previously treated patients, respectively (Schadendorf et al., 2015). PD-1 blockade has 
improved survival for metastatic melanoma, NSCLC and RCC patients (Herbst et al., 2014; 
Topalian et al., 2014; Garon et al., 2015; Gettinger et al., 2015; McDermott et al., 2015). In one 
trial, advanced melanoma patients treated with pembrolizumab (anti-PD-1 antibody) and 
ipilimumab (anti-CTLA-4 antibody) showed a superior response in pembrolizumab-treated versus 
ipilimumab-treated patients, with response rates of 34% and 12%, respectively. In conjunction 
with these data, patient survival rates were also high in pembrolizumuab versus ipilimumab 
treatment, at 74% and 58%, respectively (Farolfi et al., 2012). Nivolumab is a human IgG4 anti-
PD-1 monoclonal Ab that selectively blocks the interaction between PD-1 and PD ligands, 
restoring T-cell immune activity directed against cancer. Nivolumab was the first checkpoint 
inhibitor approved for advanced NSCLC following chemotherapy, resulting in increased response 
rates, survival and progression-free survival when compared to intravenous docetaxel. 
Nivolumab was better tolerated than docetaxel, as nivolumab-induced immune adverse events 
were more manageable (Keating, 2015). Stage III/IV melanoma patients achieved a partial 
tumour response, with a median progression free survival of 172 days, with only 18% 
experiencing grade 2 or 4 adverse events (Deeks, 2014).   
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Biomarkers that predict treatment outcomes would be hugely beneficially in providing optimal 
patient treatment, whilst limiting potential adverse treatment-side-effects. Upregulation of PD-
1 on exhausted T-cells and of PD-L ligands on tumour cells, and/or tumour infiltrating cells, may 
serve as biomarkers that predict patient response to PD-1 or PD-1 ligand vaccines. Preliminary 
results of multiple tumour-types indicated that patients with PD-L1-expressing tumours or 
infiltrating immune cells typically have higher response rates to anti-PD-1 or anti-PD-L1 versus 
patients with low or no PD-L1 expression (Herbst et al., 2014; Taube et al., 2014). However, PD-
L1 expression on tumours does not correlate with treatment outcomes for all cancer-types, as 
PD-L1 levels in squamous NSCLC did not correlate with patient response to immunotherapy 
(Borghaei et al., 2015; Brahmer et al., 2015; Herbst et al., 2016; Passiglia et al., 2016). It has been 
more challenging to identify predictive biomarkers for ipilimumab-treatment, due to low levels 
of CTLA-4 expression, and the wide range expression of B7 ligands. Retrospective studies have 
identified markers associated with treatment response, including absolute lymphocyte count, 
increased levels of T-cell activation ICOS, and T-cell response to NY-ESO1 (Callahan et al., 2013), 
although none of these biomarkers have since been validated. In addition, another study 
concluded that neoantigen presentation on tumours correlates with overall survival in CTLA-4-
treated melanoma patients (Snyder et al., 2014). Together, it is evident that reliable biomarkers 
for treatment response are required which would be beneficial in managing patient treatment, 
thereby improving treatment response rates and reducing immune related adverse events.  
The Blackburn group gained access to plasma and serum samples of 52 advanced stage 
melanoma patients before and at various timepoints (TPs) after treatment, amounting to 304 
plasma and/or sera samples, from the ONJCRI. The samples were collected from clinical cohorts 
(HREC/14/Austin/425 - Biomarkers in Cancer) where patients were treated with checkpoint 
inhibitors; ipilumumab, nivolumab, pembrolizumab, combinations thereof or placebos. Here, 
melanoma patients and HCs were compared using the CT100plus microarray platform to identify 
advanced state melanoma-associated TAA; and the treatment information was used to correlate 





5.1. CT100plus microarray quality controls 
A total of 304 samples, corresponding to 52 stage IV melanoma patients (Table 5.3 – 5.10), were 
assayed on the CT100plus microarray. Three controls were performed, including a c-Myc (Figure 
5.1), pooled negative control plasma (Figure 5.2), or pooled positive control plasma (Figure 5.3). 
Each of the 123 recombinant proteins on the CT100plus microarray (Figure 7.4) contains a c-Myc 
tag that is used to confirm the successful immobilisation of recombinant proteins on the slide 
surface. It is evident from Figure 5.1 that antigens do not all have the same intensity across the 
microarray. This is because each of the 123 recombinant proteins is expressed at different levels 
within insect cells. Although the signal for every antigen is not visibly discernible on the image, 
protein expression and biotinylation was confirmed by Western blot analysis (Beeton-Kempen et 
al., 2014).  
Both the positive and negative control assays display low or no signal from buffer, ICL, and BCCP 
negative control spots, indicating low levels of non-specific binding. Furthermore, the 5, 10 and 
15 ng/µl Cy5-biotin-BSA positive control spots were detected, which was used in subsequent data 
normalisation steps; anti-human IgG was detected, confirming the addition of patient plasma; 
and human IgG was detected, confirming the addition of detection antibody. Low or no signal is 
detected for the pooled negative control (Figure 5.2), whereas high signal is detected for the 
pooled positive control (Figure 5.3), indicating a high-quality platform that can be used for the 





Figure 5.1. CT100plus microarray c-Myc control. Each of the 123 recombinant proteins on the CT100plus 
microarray contains a c-Myc tag. The microarray was treated with Cy3-labelled anti-c-Myc antibody, which 
was used to confirm the successfully immobilisation of recombinant proteins on the slide surface with an 

















Figure 5.2. CT100plus microarray negative control pooled plasma sample. As a negative control, the 
CT100plus microarray was incubated with pooled plasma of HCs. Low or no signal is detected for the 
buffer, ICL, and BCCP negative control spots, indicating low levels of non-specific binding. High signal was 
detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive control spots, anti-human IgG was detected 
(boxed in red), and human IgG was detected (boxed in blue). Low or no signal is detected for recombinant 
proteins. Abbreviations include: HCs = healthy controls; ICL = insect cell lysate; BCCP = biotin carboxyl 









































































































































































































































Figure 5.3 CT100plus microarray positive control pooled plasma sample. For the positive control sample, 
the CT100plus microarray was incubated with pooled plasma of cancer patients. Low or no signal is 
detected for the buffer, ICL, and BCCP negative control spots, indicating low levels of non-specific binding. 
High signal was detected for the 5, 10 and 15 ng/µl Cy5-biotin-BSA positive control spots, anti-human IgG 
was detected (boxed in red), and human IgG was detected (boxed in blue). Distinct and varying 
autoantibody signal intensity was detected for recombinant proteins. Abbreviations include: HC = healthy 
controls; ICL = insect cell lysate; BCCP = biotin carboxyl carrier protein; IgG = immunoglobulin G; Cy5 = 







































































































































































































































5.2. Batch-to-batch normalisation 
A total of 307 samples were processed on the CT100plus microarray, consisting of 304 advanced 
melanoma patient samples, and the 3 controls described in Section 5.1. Due to the large cohort 
size, the samples were assayed in two separate batches using two separate microplate sources. 
Furthermore, to improve microarray image and data quality, images that failed visual and 
CT100plus software assessments were re-assayed in two separate batches. Thus, the resulting 
data are derived from four sample batches, which will further be referred to as batch B1, B2, B3 
or B4.  
A batch-effect was observed for all samples processed in separate batches, and patient 14 is here 
used as an example. For patient 14, sera samples were processed for nine TPs (14A-I) in batch 
B1, although samples 14B and 14C were re-assayed in batch B3 to further improve the quality of 
the microarray images. To assess the batch-effect, the signal intensity of cytochrome p450 3A4 
was plotted for patient 14 across various TPs either from the same batch (blue line) or separate 
batches (orange line) in Figure 5.4. Here, it is evident that assaying samples in separate batches 
(orange line) results in a greater signal intensity variation between time points, compared to the 
same samples processed together (blue line). To assess the batch-effect for all proteins on the 
CT100plus microarray, a volcano plot was constructed in RStudio (version 1.0.136) using the 
ggplot2 package for proteins between all batches. Blue dots indicate a significant difference 
(adjusted p-value ≤ 0.05, fold-Δ ≥ 0.25) in signal intensity between batches, whereas the red dots 
indicate a non-significant (adjusted p-value > 0.05, fold-Δ < 0.25) difference in signal intensities. 
Here, it is evident that many of the proteins are significantly different between batches, and 
furthermore, significant differences were observed between B1 and B2, B3 as well as B4 (Figure 
5.5), a rare and unusual result for CT100plus microarray data, especially since low baseline signal 





Figure 5.4. Temporal assessment of cytochrome P450 3A4 for patient 14 pre-normalisation. The samples 
of patient 14 were assayed in the same and separate batches, and here use to assess batch-to-batch 
effects with cytochrome p450 3A4 as an example. It is evident that assaying samples in separate batches 
(orange line) results in a greater variation in signal intensity compared to processing the samples within 




























Figure 5.5. Volcano plot for the CT100 antigens pre-normalisation. A volcano plot was constructed in 
RStudio (version 1.0.136) to determine significant fold-changes (fold-Δ) in signal intensities between 
sample batches. Blue dots indicate a significant difference (adjusted p-value ≤ 0.05, fold-Δ ≥ 0.25) in signal 
intensity between batches, whereas the red dots indicate a non-significant (adjusted p-value > 0.05, fold-
Δ < 0.25) difference in signal intensities. Here, it is evident that all antigen signals are dysregulated 
between batches, and furthermore, significant differences were detected between B1 and B2, B3 as well 
as B4, despite similar intensities viewed on the CT100plus images. 
 
To account for batch-to-batch variation, we used an adapted normalisation method based on the 
total intensity-based module (Quackenbush, 2001). The total intensity-based module assumes 
that post-normalisation, all microarrays have the same total intensity-value for positive control 
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spots, given by ∑ 𝑋𝑖
𝑁spots
𝑖=1
 .Microarray k is normalised using the normalisation factor 𝑎𝑘, given by 
Equation 5.1, where ∑ 𝑋𝑖𝑘
𝑁spots
𝑖=1
 is the total intensity of all positive control spots on array k prior 
to normalisation (Wang, 2013).  
Equation 5.1. Normalisation factor for array-to-array normalisation. 
 
 
For batch-to-batch normalisation, the equation has been adapted to assume that post-
normalisation the median of the median pixel intensity of all antigens across on a microarray is 
the same across all batches. Batch i is normalised using the normalisation factor 𝑎𝑖 given by 
Equation 5.2. 
 
Equation 5.2. Normalisation factor for batch-to-batch normalisation. 




𝛼𝑖 : Normalisation factor for array i 
µ : Median 
X : Set of median foreground pixel intensities for all microarrays 
i : Microarrays from 1,2,3 . . . n 
 
After batch-to-batch normalisation, it is evident that the signal intensity for patient 14 across all 
TPs are now similar (grey line) to the signal intensities for samples processed within the same 
batch (blue line) versus non-normalised data (orange line) (Figure 5.6). As expected, the volcano 




Figure 5.6. Temporal assessment of cytochrome P450 3A4 for patient 14 post-normalisation. The 
samples of patient 14 were assayed in the same and separate batches, although assays performed in 
separate batches result highly variable signal intensity that does not correlate with visual intensity. To 
account for batch-to-batch effects seen pre-normalisation (orange line), sample batches were normalised 
using Equation 5.2. The results indicate that signal intensities post-normalisation (grey line) are now 
likened to signal intensities of samples processed together (blue line). Abbreviations include: RFU = 




























Figure 5.7. Volcano plot for the CT100 antigens for batches post-normalisation. A volcano plot was 
constructed in RStudio (version 1.0.136) to determine significant fold-changes (fold-Δ) in signal intensities 
between sample batches. Blue dots indicate a significant difference (adjusted p-value ≤ 0.05, fold-Δ ≥ 0.25) 
in signal intensity between batches, whereas the red dots indicate a non-significant (adjusted p-value > 







5.3.  Assessing the autoantibody response between healthy controls and melanoma 
patients 
The blood plasma and/sera of 52 patients across multiple TPs, amounting to 304 samples, were 
assayed on the CT100plus microarray with the methods described in Chapter 7. For each patient, 
blood samples were collected before (TP = 0) and after (TP = 1, 2, 3, …n) immunotherapy 
treatment; in most cases, multiple plasma and/or sera samples were collected post-treatment. 
In this section, the statistical results of the analysis between HCs (HC1 to HC14) and melanoma 
patients (1A to 52A) before immunotherapy are described. The CT100plus microarray images 
were used to extrapolate raw data files using the ArrayPro software, after which data filtering 
was performed using the CT100plus software with the following settings: whole array CV ≤ 25%; 
probe replicate CV ≤ 20%; noise-threshold ≥ 2 SD above background; maximum threshold = 65355 
nm; whole array filtering control = 15 ng/µl Cyanine 5 (Cy5)-biotin-BSA; 57 patient data files 
passed the filtering and normalisation quality control procedure. The median signal intensity for 
each antigen was obtained, and used for subsequent statistical analyses.  
A ROC analysis was performed, which reports the sensitivity and specificity for a tested 
parameter, and in this study, refers to CT100plus antigens. An a priori ROC sample size was 
performed using MedCalc software (version 17.2), with a hypothesised AUC-value of 0.80, a null 
hypothesis value of 0.5, and a sample ratio of 0.17. The results produced a α-value (significance) 
of 0.01 and β-value (1-Power) of 0.10 for the 52 CRC patients and 14 HCs, indicating that our 
sample size was sufficient for the ROC analysis. 
The ROC analysis was performed in R Studio (1.0.136) using the ROCR package (Sing et al., 2005). 
A top10-list was generated from proteins with the highest AUC-values. The top 10 protein list 
included CEACAM 1 isoform 1, DPPA2, FGFR2, ITGB1, MAGEA10, NANOG, PIM1, SPANXB1, THEG 
and XAGE1B, which were selected for further ROC analysis to produce a sensitivity and specificity 
report, displayed in Table 5.1. Combinatory ROC analysis was also performed for the top 10 
antigens using CombiROC (Mazzara et al., 2017), indicating that a combination of CEACAM1 and 
FGFR2 was the best biomarker combination, producing a sensitivity-, specificity-, and AUC-value 
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of 0.93, 0.89, and 0.92, respectively, indicating that this combination outperforms individual 
proteins. The ROC curve in Figure 5.8 represents a combination for CEACAM1 and FGFR2. 
 
Table 5.1. Sensitivity-, specificity-, AUC-, and cut-off-values for top 10 antigens for melanoma patients 
on the CT100plus microarray. Abbreviations include: AUC = area under the receiver operator 
characteristic curve. 
Antigen Sensitivity Specificity AUC Cut-off 
CEACAM 1 (iso1) 0.81 0.71 0.87 587 
DPPA2 1.00 0.71 0.85 444 
FGFR2 0.94 0.79 0.83 336 
ITGB1 0.96 0.71 0.87 307 
MAGEA10 0.77 0.71 0.80 760 
NANOG 0.90 0.64 0.82 326 
PIM1 0.94 0.79 0.79 353 
SPANXB1 0.90 0.71 0.83 307 
THEG 0.96 0.71 0.81 406 





Figure 5.8. ROC curve for melanoma patients and HCs. The ROC curve was constructed using CombiROC. 
A combination of the CEACAM1 and FRGR2 produce the highest AUC is displayed, with the resulting 
sensitivity-, specificity- and AUC-values of 0.93, 0.96 and 0.94, respectively. The yellow star indicates the 
optimal cut-off point. Abbreviations include: ROC = receiver operating characteristic; AUC = area under 
the ROC curve. 
 
It is evident that the signal intensity for each of the top 10 antigens was higher in melanoma 
patients when compared to healthy individuals (Figure 5.9). Further statistical tests were 
performed in R Studio (1.0.136): The Shapiro-Wilk (Shapiro and Wilk, 1965) results indicate a non-
normal data distribution (p-value ≤ 0.05), as such, the Mann-Whitney U (Mann and Whitney, 
1947) and Benjamini-Hochberg (Benjamini and Hochberg, 1995) tests were performed, indicating 
a significant increase (p-value ≤ 0.05; adjusted p-value < 0.05) in signal intensity for melanoma 





Figure 5.9. Pre-immunotherapy-treated melanoma patient and HC raw data files were batch processed 
using the CT100plus software, and a ROC test performed to identify the top 10 upregulated antigens in 
cancer patients. The graph displays the median RFU-values for the top 10 potential antigen biomarkers 
on the CT100plus microarray, and the error bars represents the MAD. Abbreviations include: HC = healthy 
control; ROC = receiver operator characteristic; RFU = relative fluorescence units; MAD = median absolute 
deviation. 
 
Table 5.2. Shapiro-Wilk, Mann-Whitney U and Benjamini-Hochberg test values for the top 10 antigens 








CEACAM 1 (iso1) 2.14 × 10-4 5.43 × 10-5 3.34 × 10-3 
DPPA2 3.30 × 10-3 1.96 × 10-4 5.19 × 10-3 
FGFR2 3.91 × 10-4 2.02 × 10-5 2.47 × 10-3 
ITGB1 4.26 × 10-3 6.40 × 10-4 8.75 × 10-3 
MAGEA10 3.12 × 10-8 2.53 × 10-4 5.19 × 10-3 
NANOG 2.20 × 10-6 7.66 × 10-4 9.42 × 10-3 
PIM1 1.24 × 10-4 1.50 × 10-4 5.19 × 10-3 
SPANXB1 2.67 × 10-4 4.09 × 10-4 7.19 × 10-3 
THEG 5.59 × 10-5 2.18 × 10-4 5.19 × 10-3 
























To further assess the biomarker potential of the top 10 proteins, unsupervised tests including 
PCA multivariate testing and unsupervised hierarchical clustering were performed in Perseus 
(version 1.5.4.1):  
Unsupervised hierarchical clustering analysis produced two major segregating clusters of 
melanoma patients and HCs. Most of the HCs clustered together, except for HCs HC10 and HC12 
who cluster separate from the major HC cluster. Furthermore, HC1 and HC9 are separate from 
other HCs, clustering with patients 17A and 19A (Figure 5.10).   
In agreement with the hierarchical clustering analysis, the 1D and 2D PCA plots display two major 
segregating clusters, each representing CRC patients (red) or HCs (blue), although HC10 cluster 





Figure 5.10. Unsupervised clustering of pre-immunotherapy melanoma patients and HCs. Pre-immunotherapy melanoma patient (N = 52) and 
HC (N = 14) plasma and/or sera were processed on the CT100plus microarray, and the 10 most significantly upregulated antigens in melanoma 
patients were log2-transformed and selected for unsupervised hierarchical clustering using the Perseus software (version 1.5.4.1). Here, the HC 
and melanoma patients form two major clusters. Most of the HCs clustered together, except for HCs HC10 and HC12 who cluster separate from 
the major HC cluster. Furthermore, HC1 and HC9 are separate from other HCs, clustering with patients 17A and 19A. Abbreviations include: HCs = 






Figure 5.11. PCA between pre-immunotherapy treated melanoma patients and HCs. Pre-immunotherapy treated melanoma patient (N = 52) and 
HC (N = 14) plasma and/or sera samples were processed on the CT100plus microarray, and the 10 proteins with the highest AUC-values were log2-
transformed and selected for 1D and 2D PCA multivariate testing using the Perseus (version 1.5.4.1). The 1D and 2D PCA plots display melanoma 
patient (red) and HC (blue) clusters, with overlap between melanoma patient 42A and HC10. Abbreviations include: PCA = principle component 




5.4. Autoimmune responses toward checkpoint inhibitor treatment 
The serum and/or plasma of 52 advanced-stage melanoma patients treated with checkpoint 
inhibitors, including ipilimumab, pembrolizumab, nivolumab, or combinations thereof, was 
assayed on the CT100plus microarray. Microarray images were captured and the numerical data 
extrapolated using the ArrayPro software. The microarray images were re-assayed if images 
showed evidence of spot running, missing spots (due to pin sticking), washing artefacts, dust 
particles and/or faded arrays. The numerical data was filtered and normalised using the 
CT100plus software bioinformatic pipeline for pre-processing and quality control. The data 
filtering and normalisation criteria was as follows: whole array CV ≤ 25%; probe replicate CV ≤ 
20%; noise-threshold ≥ 2 SD above background; maximum threshold = 65355 nm; whole array 
filtering control = 15 ng/µl Cy5-biotin-BSA. Batch-to-batch normalization was performed as 
described in Section 5.2. Re-assaying was repeated only twice after failing visual and computation 
filtering criteria. Here, 99% (N = 300/304) of the samples passed the computation quality control 
procedure; thus, samples 2B, 4B, 13D and 13E were excluded from all further analysis. 
The patient therapy targets the immunomodulatory checkpoint inhibitors: PD-1 and CTLA-4. A 
subgroup of the patients received BRAF inhibitor treatment prior to immunotherapy, although 
the patient identities are unknown. Also, the treatment regimen varied, depending on patient 
response. Thus, the cohort consists of those patients who received one treatment-type only (e.g. 
Ipilimumab only), those that received differing consecutive treatments (e.g. Ipilimumab then 
Pembrolizumab), and those that received co-treatments (e.g. Ipilimumab and Pembrolizumab). 
For each patient, a serum and/plasma sample was collected before receiving immunotherapy, 
with single or multiple sera and/or plasma samples collected after treatment, amounting to 304 
samples. 
Due to the on-going nature of the study and the time of writing this thesis, clinical patient 
information was limited to immunotherapy undergone, which was used for subsequent data 
analysis. The treatment regimen of patients 26 and 33 were not disclosed, and these patients 
were consequently excluded from treatment-type analysis. Patients and their corresponding 
treatment-day and -type are summarised in Table 5.3 to Table 5.10.  
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Table 5.3. Summary of melanoma patients 1 to 7 before and after treatment with checkpoint inhibitors 
at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days trial initiation Immunotherapy treatment 
1 
a – 0 Ipilimumab 
b – 21 Ipilimumab 
c – 46 Ipilimumab 
d – 67 Ipilimumab 
2 
a – 0  Ipilimumab 
b – 20 Ipilimumab 
c – 42 Ipilimumab 
d – 63 Ipilimumab 
3 
a – 0  Ipilimumab 
b – 23 Ipilimumab 
c – 63 Ipilimumab 
d – 189 No treatment 
e – 252  No treatment 
4 
a – 0  Ipilimumab and Pembrolizumab 
b – 42 Ipilimumab and Pembrolizumab 
c – 86 Pembrolizumab 
d – 126 Pembrolizumab 
5 
a – 0  Ipilimumab 
b – 20 Ipilimumab 
c – 49 Ipilimumab 
6 
a – 3 days after BCG Ipilimumab 
b – 21 Ipilimumab 
c – 75 Ipilimumab 
7 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 64 Ipilimumab 
d – 134 No treatment 
e – 188 No treatment 
f – 286 No treatment 
g – 496 No treatment 
h – 509 No treatment 
i – No data Ipilimumab 
j – No data Ipilimumab 








Table 5.4. Summary of melanoma patients 8 to 11 before and after treatment with checkpoint inhibitors 
at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
8 
a – 0  Ipilimumab 
b – 42 Ipilimumab 
c – 63 Ipilimumab 
d – 0 Nivolumab 
e – 32 Nivolumab 
f – 74 Nivolumab 
g – No data Nivolumab 
9 
a – 0  Nivolumab 
b – 28 Nivolumab 
c – 56 Nivolumab 
d – 84 Nivolumab 
e – 112 Nivolumab 
f – 140 Nivolumab 
g – 182 Nivolumab 
h – 210 Nivolumab 
i – 413 Nivolumab 
10 
a – 0  Ipilimumab 
b – 43 Ipilimumab 
c – 64 Ipilimumab 
d – no data No treatment 
e – 253 No treatment 
f – 0 Pembrolizumab 
g – 22 Pembrolizumab 
h – 43 Pembrolizumab 
i – 64 Pembrolizumab 
j – 858 Pembrolizumab 
k – 148 Pembrolizumab 
l – 169 Pembrolizumab 
m – 190 Pembrolizumab 
n – 232 Pembrolizumab 
o – 253 Pembrolizumab 
p – 462  No treatment 
q - 491 No treatment 
11 
a – 0  Ipilimumab 
b – 43 Ipilimumab 
c – 0 Nivolumab 
d – 29 Nivolumab 






Table 5.5. Summary of melanoma patients 12 to 16 before and after treatment with checkpoint 
inhibitors at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
12 
a – 0  Pembrolizumab 
b – 22 Pembrolizumab 
c – 43 Pembrolizumab 
d – 64 Pembrolizumab 
e – 85 Pembrolizumab 
f – 169 Pembrolizumab 
g – 253 Pembrolizumab 
h – 337 Pembrolizumab 
i – 421 Pembrolizumab 
j – 505 Pembrolizumab 
k – 589 Pembrolizumab 
l – 673 Pembrolizumab 
13 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 43 Ipilimumab 
d – 64 Ipilimumab 
e – 85 Ipilimumab 
f – 169 No treatment 
g – 253 No treatment 
14 
a – 0  Ipilimumab 
b – 8 Ipilimumab 
c – 21 Ipilimumab 
d – 78 Ipilimumab 
e – No data Nivolumab 
f – No data Nivolumab 
g – No data Nivolumab 
h – No data Nivolumab 
i – No data Nivolumab 
15 
a – 0  Pembrolizumab 
b – 21 Pembrolizumab 
c – 42 Pembrolizumab 
d – 63 Pembrolizumab 
e – 84 Pembrolizumab 
f – 168 Pembrolizumab 
16 
a – 0  Pembrolizumab 
b – 29 Pembrolizumab 
c – 56 Pembrolizumab 
d – 85 Pembrolizumab 
e – 169 Pembrolizumab 
f – 0 Ipilimumab 
g – 20 Ipilimumab 




Table 5.6. Summary of melanoma patients 17 to 24 before and after treatment with checkpoint 
inhibitors at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
17 
a – 0 BCG 
b – 56 Ipilimumab 
c – 82 No treatment 
d – 120 No treatment 
18 
a – 0  Ipilimumab 
b – 43 Ipilimumab 
c – 64 Ipilimumab 
d – 0 Nivolumab 
e – 72 Nivolumab 
19 
a – 0  Pembrolizumab 
b – 28 Pembrolizumab 
c – 56 Pembrolizumab 
d – 84 Pembrolizumab 
e – 168 Pembrolizumab 
20 
a – 0  Ipilimumab 
b – 29 Ipilimumab 
c – 71 Ipilimumab 
d – 106 No treatment 
e –190 No treatment 
f – 358 No treatment 
g – 442 No treatment 
h – 533 No treatment 
i – 617 No treatment 
j – 701 No treatment 
k – No data No treatment 
21 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 64 Ipilimumab 
22 
a – 0  Pembrolizumab 
b – 21 Pembrolizumab 
23 
a – 0  Ipilimumab 
b – 21 Pembrolizumab 
24 
a – 0  Pembrolizumab 
b – 21 Pembrolizumab 
c – 42 Pembrolizumab 
d – 62 Pembrolizumab 
e –191 No treatment 
f – 225 No treatment 
g – 253 No treatment 
h – 281 No treatment 





Table 5.7. Summary of melanoma patients 25 to 36 before and after treatment with checkpoint 
inhibitors at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
25 
a – 0  Ipilimumab 
b – 44 Ipilimumab 
27 
a - 0 Ipilimumab 
b – 29 (1 week after second treatment) Ipilimumab 
c – 43 Ipilimumab 
28 
a – 0  Pembrolizumab 
b – 28 Pembrolizumab 
c – 56 Pembrolizumab 
d – 153 Pembrolizumab 
e –237 Pembrolizumab 
29 
a – 0  Pembrolizumab 
b – 29 Pembrolizumab 
c – 55 Pembrolizumab 
d – 83 Pembrolizumab 
30 
a – 0  Ipilimumab 
b – 64 Ipilimumab 
c – 85 No treatment 
d – 175 No treatment 
31 
a – 22 days before day 0 No treatment 
b – 24 Ipilimumab 
c – 41 Ipilimumab 
d – 62 Ipilimumab 
32 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 43 Ipilimumab 
d – 0 Nivolumab 
e –29 Nivolumab 
f - 71 Nivolumab 
34 
a – 0  Nivolumab 
b – 28 Nivolumab 
c – No data Nivolumab 
35 
a – 0  Pembrolizumab 
b – 64 Pembrolizumab 
c – 85 Pembrolizumab 
d – 169 Pembrolizumab 
36 
a – 0  Ipilimumab and Nivolumab 
b – 44 Ipilimumab and Nivolumab 
c – 78 No treatment 
d – 218 No treatment 





Table 5.8. Summary of melanoma patients 37 to 45 before and after treatment with checkpoint 
inhibitors at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
37 
a – 0  Nivolumab 
b – 28 Nivolumab 
c – 70 Nivolumab 
d – 154 Nivolumab 
e –No data Nivolumab 
38 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 43 Ipilimumab 
d – 73 No treatment 
e – 157 No treatment 
39 
a – 0  Ipilimumab 
b – 57 Ipilimumab 
c – 99 (no treatment) No treatment 
d – No data No treatment 
e – No data No treatment 
40 
a – 0  Ipilimumab 
b – 43 Ipilimumab 
c – 64 Ipilimumab 
d – 86 No treatment 
e – 126 No treatment 
f – 0  Nivolumab 
g – 72  Nivolumab 
41 
a – 0  Ipilimumab 
b – 43 Ipilimumab 
42 
a – 0  Ipilimumab 
b – 21 Ipilimumab 
43 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 43 Ipilimumab 
d – 64 Ipilimumab 
e – 85 No treatment 
f – 99  No treatment 
44 
a – 0  Ipilimumab 
b – 20 Ipilimumab 
c – 44 Ipilimumab 
45 
a – 0  Nivolumab 
b – 29 Nivolumab 
c – 71 Nivolumab 






Table 5.9. Summary of melanoma patients 46 to 51 before and after treatment with checkpoint 
inhibitors at various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
46 
a – 0  Pembrolizumab 
b – 57 Pembrolizumab 
c – 85 Pembrolizumab 
d – 169 Pembrolizumab 
e –253 Pembrolizumab 
f – 337 Pembrolizumab 
g – 421 Pembrolizumab 
h – 505 Pembrolizumab 
i – 589 Pembrolizumab 
j – 673  Pembrolizumab 
47 
a – 0  Pembrolizumab 
b – 106 Pembrolizumab 
c – No data No treatment 
48 
a – 0  Ipilimumab and Nivolumab 
b – 22 Ipilimumab and Nivolumab 
c – 59 Ipilimumab and Nivolumab 
d – 135 Nivolumab 
e –149 Nivolumab 
f – 177 No treatment 
49 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 44 Ipilimumab 
d – 64 Ipilimumab 
e – 211 No treatment 
f – 295 No treatment 
g – 407 No treatment 
h – 483 No treatment 
50 
a – 0  Ipilimumab 
b – 21 Ipilimumab 
c – 79 Ipilimumab 
d – 98 Ipilimumab 
51 
a – 0  Pembrolizumab 
b – 42 Pembrolizumab 
c – 63 Pembrolizumab 








Table 5.10. Summary of melanoma patient 52 before and after treatment with checkpoint inhibitors at 
various TPs. Abbreviations include: TP = timepoints. 
Patient Timepoint - days post-treatment Immunotherapy treatment 
52 
a – 0  Ipilimumab 
b – 22 Ipilimumab 
c – 43 Ipilimumab 
d – 71 Ipilimumab 
e – 92 No treatment 
f – 106 No treatment 
g – 190 No treatment 
h – 236 No treatment 
i – 259 No treatment 
j – 315  No treatment 
k – 0  Pembrolizumab 
l – 22 Pembrolizumab 
m – 43 Pembrolizumab 
n – 64 Pembrolizumab 
o – 125 Pembrolizumab 
p – 146 Pembrolizumab 
q – 187 Pembrolizumab 
 
The patients were assessed based on the treatment-type undergone. For the analysis, the 
treatment-induced effects were assessed on the CT100plus microarray by comparing 
plasma/serum autoantibody levels before treatment (TP0) and the first sample collected 
thereafter (TP1). The Shapiro-Wilk normality test was used to assess data distribution (p-value ≤ 
0.05), which indicated a non-normal distribution. Thus, non-parametric tests were performed 
when comparing TP0 and TP1, which included Mann-Whitney U test (Mann and Whitney, 1947) 
and Benjamini-Hochberg (Benjamini and Hochberg, 1995) post hoc correction test. 
Longitudinal assessments of autoantibody titres were used to determine the long-term changes 
in autoantibody in response to immunotherapy. Longitudinal assessments of autoantibody titres 
were performed using the Kruskal-Wallis test (Kruskal and Wallis, 1952) for multiple samples and 
Benjamini-Hochberg post hoc correction test. The Mann-Whitney U, Kruskal-Wallis and 
Benjamini-Hochberg tests were performed in R (version 3.3.0) using the PMCMR package 





The combinatorial immunomodulatory effects of all immunotherapies were assessed by 
comparing TP0 and TP1 for all patients on the CT100plus microarray. The Mann-Whitney U test 
results indicate a significant difference in signal intensity which became non-significant after the 
Benjamini-Hochberg post hoc test for ROPN1 (p-value = 0.03, adjusted p-value = 0.72), AKT1 (p-
value = 0.03, adjusted p-value = 0.72), and DPPA (p-value = 0.05, adjusted p-value = 0.72). This 
finding is supported by ROC analysis between TP0 and TP1, performed in RStudio using the ROCR 
package. The ROC analysis was performed for antigens that produced the lowest p-values, 
including ROPN1, which produced AUC-, sensitivity-, and specificity-values of 0.38, 0.50 and 0.38, 
respectively; AKT1, which produced AUC-, sensitivity-, and specificity-values of 0.38, 0.24 and 
0.73; and DPPA2, which produced AUC-, sensitivity-, and specificity-values of 0.39, 0.34 and 0.62. 
The ROC curves for ROPN1, AKT1 and DPPA2 are shown in Figure 5.12. 
 
 
Figure 5.12. ROC curves for ROPN1, AKT1 and DPPA2. Melanoma patient serum/plasma before (TP0) and 
after (TP0) immunotherapy were assayed on the CT100plus microarray to determine changes of 
autoantibody levels against CT100plus antigens. A non-significant change (adjusted p-value > 0.05, 
Benjamini-Hochberg) in autoantibody levels were detected. This result was supported by ROC analysis for 
the 3 proteins with the lowest p-values, to include ROPN1, AKT1 and DPPA2, which produced AUC-values 





Although a non-significant change in autoantibody titres was detected at various TPs, a subset of 
patients produced high autoantibody signal intensities (> 10 000 RFU) toward autoantigens. Only 
proteins detected in more than one patient are reported: For TP0, seven (N = 7/52; 14%) patients 
produced a high (> 10 000 RFU) signal intensity to at least one antigen, including CTAG2 (N = 6/52, 
12%), NY-ESO-1 (N = 6/52, 12%), and PRKCZ (N = 2/52, 4%). For TP1, eleven (N = 11/50, 22%) 
patients produced a high (> 10 000 RFU) signal intensity to at least one antigen including CTAG2 
(N = 6/50, 12%), NY-ESO-1 (N = 6/50, 12%), MAGEB6 (N = 2/50, 4%), NXF2 (N = 2/50, 4%), NY-CO-
45 (N = 2/50, 4%), ACVR2B (N = 2/50, 4%), and CTAG2/LAGE-1b/LAGE-1L (N = 2/50, 4%).  
Taken together, it is evident that high (> 10 000 RFU) signal was detected for CTAG2 and NY-ESO-
1 regardless of treatment, although PRKCZ was detected in 2 patients before treatment, whereas 
signals for MAGEB6, NXF2, NY-CO-45, ACVR2B and CTAG2/LAGE-1b/LAGE-1L were each detected 
in 2 patients after treatment. 
Treatment with Nivolumab 
Nivolumab is an anti-PD-1 cancer immunotherapeutic. Of the 52 patients assessed, 4 patients 
were treated with nivolumab alone. Six other patients received ipilimumab treatment prior to 
nivolumab treatment, and were thus excluded from the analysis due to the possible immune 
modulating effects of ipilimumab. 
Nivolumab treatment-induced effects were assessed on the CT100plus microarray by comparing 
plasma/serum autoantibody levels before treatment (TP0) and the first sample collected 
thereafter (TP1). Here, we observed non-significant (p-value > 0.05) changes in autoantibody 
levels after nivolumab treatment. Together, these results suggest that anti-PD-1-treatment does 
not affect autoantibody titres toward proteins on the CT100plus microarray. Longitudinal 
assessments of autoantibody titres performed also indicate no significant (p-value > 0.05; 
adjusted p-value > 0.05) difference in autoantibody titres between the different TPs for patients 
treated with nivolumab. 
As expected, most patients produced low signal (200 – 2000 RFU) toward antigens across various 
TPs, although patient 9 produced a high (> 10 000 RFU) signal intensity against DDX53.  
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Treatment with Pembrolizumab 
Pembrolizumab is another anti-PD-1 cancer immunotherapeutic. Of the 52 patients assessed, 12 
patients were treated with pembrolizumab alone. Three other patients received ipilimumab 
treatment prior to pembrolizumab treatment, and were thus excluded from the analysis due to 
the possible immune modulating effects of ipilimumab. The treatment-induced effects were 
assessed on the CT100plus microarray by comparing plasma/sera autoantibody titres before 
treatment (TP0) and the first sample collected thereafter (TP1). Here, we observed non-
significant (p-value > 0.05) changes in autoantibody titres after pembrolizumab treatment. 
Together, these results again suggest that anti-PD1-treatment does not affect autoantibody titres 
toward proteins on the CT100plus microarray. Longitudinal assessments of autoantibody titres 
also indicate no significant (p-value > 0.05; adjusted p-value > 0.05) difference in autoantibody 
titres between the different TPs for patients treated with pembrolizumab. 
As expected, most patients produced low signal toward antigens across various TPs, whereas a 
subset of patients produced high signal (> 10 000 RFU) at various TPs toward specific antigens. 
Six (N = 6/12; 50%) patients produced a high signal intensity to at least one antigen, for at least 
one TP, although the antigens were not associated with pre-treatment or post-treatment, or 
treatment duration. The proteins detected with a high signal included CTAG2 (N = 3/12, 25%), 
NY-ESO-1 (N = 3/12, 25%), SPANXA1 (N = 3/12, 25%), CTAG2/LAGE-1b/LAGE-1L (N = 2/12, 17%), 
DDX53 (N = 1/12, 8%), MAGEA1 (N = 1/12, 8%), MAGEA4v4 (N = 1/12, 8%), MAGEB1 (N = 1/12, 
8%), MAGEB5 (N = 1/12, 8%), MAGEB6 (N = 1/12, 8%).  
Treatment with Ipilimumab 
Ipilimumab is an anti-CTLA-4 cancer immunotherapeutic. Of the 52 patients assessed, 32 patients 
were treated with either ipilimumab alone, or prior to treatment with the anti-PD-1 
immunotherapeutics, nivolumab or pembrolizumab.  
The treatment-induced effects were assessed on the CT100plus microarray by comparing 
plasma/sera autoantibody titres before treatment (TP0) and the first sample collected thereafter 
(TP1). A significant (p-value = 0.03) difference in GRWD1 autoantibody titres after treatment was 
detected, although this was to be a non-significant (adjusted p-value = 0.77) result after the post 
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hoc correction test. A ROC analysis was performed for GRWD1, which produced AUC -value of 
0.38. The ROC curves for GRWD1 is shown in Figure 5.13. Together, these results indicate that 
anti-CTLA-4-treatment does not affect autoantibody titres toward proteins on the CT100plalso 
us microarray. Longitudinal assessments of autoantibody titres for anti-CTLA-4-treated patients 
indicate no significant (p-value > 0.05; adjusted p-value > 0.05) difference in autoantibody titres 
between the different TPs for patients treated with Ipilimumab. 
 
 
Figure 5.13. ROC curves for GRWD1. The serum/plasma of ipilimumab-treated melanoma patients before 
(TP0) and after (TP0) immunotherapy were assayed on the CT100plus microarray to determine changes 
of autoantibody levels against CT100plus antigens. A non-significant change (adjusted p-value > 0.05, 
Benjamini-Hochberg) in autoantibody levels were detected. This result was supported by ROC analysis for 
the proteins with the lowest p-value, i.e. GRWD1, which produced an AUC-value of 0.38. 
 
Although a non-significant change in autoantibody titres was detected for patients at various TPs, 
some patients produced high (> 10 000 RFU) autoantibody signal intensities toward individual 
autoantigens. As expected, most patients produced low signal toward antigens across various 
TPs, whereas a subset of patients produced high signal at various TPs toward specific antigens. 
Eight (N = 8/32; 25%) patients produced a high (> 10 000 RFU) signal intensity to at least one 
antigen, for at least one TP, although the antigens were not associated with pre-treatment or 
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post-treatment, or treatment duration. The top 10 proteins detected with a high signal included 
CTAG2 (N = 4/32, 13%), NY-ESO-1 (N = 4/32, 13%), CTAG2/LAGE-1b/LAGE1L (N = 4/32, 13%), 
MAGEB6 (N = 3/32, 9%), NXF2 (N = 3/32, 9%), NY-CO-45 (N = 3/32, 9%), PRKCZ (N = 3/32, 9%), 
MAGEB1 (N = 2/32, 6%), MAGEB5 (N = 2/32, 6%), SPANXA1 (N = 2/32, 6%).  
Consecutive immunotherapeutic treatment with ipilimumab and then nivolumab 
Six (N = 6/52, 12%) patients, including 8, 11, 14, 18, 32 and 40, received Ipilimumab treatment 
followed by nivolumab treatment. To assess the autoantibody response to changed 
immunotherapeutic treatment, all samples before and after treatment change was compared. 
The Mann-Whitney U test results indicate a significant difference in signal intensity which 
became non-significant after the Benjamini-Hochberg post hoc test for p53 C141Y (p-value = 0.03, 
adjusted p-value = 0.40), MAGEB6 (p-value = 0.04, adjusted p-value = 0.4), DPPA3 (p-value = 0.04, 
adjusted p-value = 0.4), SPAG9 (p-value = 0.04, adjusted p-value = 0.4), and CEP290 (p-value = 
0.04, adjusted p-value = 0.4). 
Although a non-significant change in autoantibody titres was detected at various TPs, a subset of 
patients produced high autoantibody signal intensities (> 10 000 RFU) toward autoantigens. 
When patients were treated with Ipilimumab only, two (N = 2/6, 33%) patients produced a high 
(> 10 000 RFU) signal intensity to at least one antigen. The top 4 proteins detected with a high 
signal included CTAG2 (N = 1/6, 17%), NY-ESO-1 (N = 1/6, 17%), ACVR2B (N = 1/6, 17%), and 
CTAG2/LAGE-1b/LAGE-1L (N = 1/6, 17%).  
After patients received nivolumab treatment, two (N = 2/6, 33%) patients produced a high (> 10 
000 RFU) signal intensity to at least one antigen. The top 10 proteins detected with a high signal 
included CTAG2 (N = 4/6, 67%), NY-ESO-1 (N = 4/6, 67%), NY-CO-45 (N = 4/6, 67%), NXF2 (N = 
3/6, 50%), p53 S15A (N = 2/6, 33%), CTAG2/LAGE-1b/LAGE-1L (N = 2/6, 33%), MAGEB6 (N = 1/6, 
18%), p53 S6A (N = 1/6, 18%), p53 T18A (N = 1/6, 18%), and p53 S392A (N = 1/6, 18%).  
Taken together, it is evident that high (> 10 000 RFU) signal was detected for CTAG2 and NY-ESO-
1 regardless of treatment undergone. Furthermore, PRKCZ was detected in only 2 patients before 
treatment, whereas MAGEB6, NXF2, NY-CO-45, ACVR2B and CTAG2/LAGE-1b/LAGE-1L were each 
detected in 2 patients after treatment. Only 1 patient received pembrolizumab treatment 
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followed by Ipilimumab treatment, whereas 2 patients received Ipilimumab treatment followed 
by pembrolizumab treatment, which were omitted from further analysis due to poor statistical 
power.  
Three patients received co-treatment of ipilimumab with nivolumab or ipilimumab with 






















Discussion and conclusion 
In total 52 melanoma patients, amounting to 304 sera and/or plasma samples, were assessed on 
the CT100plus microarray. Quality control tests were performed to ensure that conditions were 
optimal to produce high quality microarrays. 
Due to the large cohort size, the samples were assayed in two separate batches using two 
separate microplate sources. Furthermore, to improve microarray image and data quality, 
images that failed visual and CT100plus software assessments were re-assayed in two separate 
batches. Thus, the resulting data are derived from four sample batches, each referred to as batch 
B1, B2, B3 or B4. From the volcano plot, it was evident that all proteins were dysregulated 
between batches (Figure 5.5). After batch-to-batch normalisation, the volcano plots indicate no 
significant (adjusted p-value > 0.05, fold-Δ > 0.25) difference between the batches (Figure 5.7). 
After the data was normalised, the remaining statistical tests were performed. 
ROC analysis was employed to analyse CT100plus microarray data from 301 CRC patients and 14 
HCs samples, where further analysis into biomarker potential was performed using 10 proteins 
with the highest AUC-values. It is important to note that the HC samples were neither age- nor 
gender-matched to the CRC patients. Furthermore, although neither of the HCs were previously 
diagnosed with cancer, tests were not performed to confirm that the HCs were CRC-free. 
However, since our intention here is to acquire preliminary results for a potentially larger study, 
we decided to use the plasma samples available to assess autoantibody profiles between CRC 
patient and HCs.  
The top 10 proteins include CEACAM 1, DPPA2, FGFR2, ITGB1, MAGEA10, NANOG, PIM1, 
SPANXB1, THEG and XAGE1B; these proteins produced AUC-, sensitivity- and specificity-values 
ranging from 0.79 – 0.87, 0.77 – 1.00 and 0.64 – 0.79, respectively (Table 5.1). A combinatorial 
ROC analysis of the top 10 proteins produced AUC-, sensitivity- and specificity-values of 0.92, 
0.93 and 0.89, respectively. Melanoma Inhibitory Activity (MIA) serological marker is reportedly 
increased in the serum of patients with metastatic uveal melanoma when compared to 
progression-free patients; levels of MIA were previously assessed in a cohort of 503 uveal 
melanoma patients and analysed by ROC analysis, producing an AUC level of 0.84 (Klingenstein 
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et al., 2011). Together, these results indicate that the top 10 proteins identified with the 
CT100plus microarray produced AUC-, sensitivity- and specificity-values in the same range as the 
best reported biomarker, whereas combinatorial ROC results outperformed individual and 
literature-reported potential biomarkers. Furthermore, Kruskal-Wallis and Benjamini-Hochberg 
tests indicated a significant difference in antigen signals between melanoma patients and HCs, 
producing p-values and adjusted p-values less than 0.05 (Table 5.2). The hierarchical clustering 
and PCA results display two segregating clusters, each representing melanoma patients or HCs, 
although overlap is evident between HC1, HC9 and HC10 and melanoma patients. Together, 
these results indicate that the top 10 proteins may be potential CRC biomarkers, although 
alternate methods e.g. validating with another melanoma cohort or using tumour tissues for 
histological confirmation, is required for biomarker validation. 
The 3 proteins with the highest AUC-values, including CEACAM1, FGFR2 and PIM1, were further 
investigated: 
CEA, also known as CEACAM (http://www.uniprot.org/uniprot/Q13984), is a widely-used tumour 
biomarker in melanoma and CRC. In malignant melanoma, surface expression of CEACAM1 
correlates with tumour progression and poor survival (Markel et al., 2010; Sivan et al., 2012). 
Secreted CEACAM1 later emerged as a potential biomarker of malignant melanoma; an increase 
in serum levels is associated with disease progression and lower serum levels positively correlate 
with treatment outcome (Sivan et al., 2012; Ortenberg et al., 2015). CEACAM is also reportedly 
involved in the melanomas ability to evade immune attacks (Sivan et al., 2012). Although 
autoantibody responses to CEACAM1 are not reported for malignant melanoma, its increased 
expression on the cell surface of melanoma and release into patient blood could induce an 
autoantibody response detectable on the CT100plus microarray. 
Fibroblast growth factor receptor 2, also known as FGFR2 
(http://www.uniprot.org/uniprot/P21802), is a tyrosine-protein kinase that acts as a cell surface 
receptor for fibroblast growth factors, and plays an essential role in the regulation of cell 
proliferation, differentiation, migration, apoptosis, and in the regulation of embryonic 
development. FGFR2 expression with loss-of-function mutations  is reported in melanocytes 
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(Diez de Medina et al., 1997; Zhang et al., 2001; Naimi et al., 2002; Gartside et al., 2009; Amann 
et al., 2010). A study of 47 melanoma cell-lines identified mutations in FGFR2, but not for FGFR1, 
for 12% of the tested cell-lines, and in 12% metastatic melanomas (Gartside et al., 2009). Another 
study concluded that FGFR2 genetic variation was identified in melanoma and non-melanocytic 
skin cancer, although there was no association between the genetic variations and risk of disease 
(Nan et al., 2009). The CT100plus microarray contains a non-mutated form of the FGFR2 protein; 
we would therefore not expect to detect autoantibodies directed at mutated epitopes of the 
protein. Instead, an autoantibody response toward FGFR2 overexpression may be detected. 
Although FGFR2 overexpression is not reported for melanoma, neoantigen-specific CD4+ T cells 
may drive affinity maturation of B-cells that have taken up and processed the mutated FGFR 
antigen, with the resulting autoantibody response being directed toward a wild-type epitope. 
Provirus integration site for moloney murine leukaemia virus, also known as PIM1 
(http://www.uniprot.org/uniprot/P11309), is a proto-oncogene with serine/threonine kinase 
activity involved in cell survival and cell proliferation, thus providing a selective advantage in 
tumourigenesis. PIM1 is expressed in melanoma tumours pre- and post-treatment. In vivo studies 
concluded that PIM contributes to melanoma cell proliferation and tumour growth, where PIM 
inhibition with SGI-1776 reduced melanoma proliferation and survival in preclinical models of 
melanoma, indicating that PIM inhibitors are promising additions to targeted therapies available 
to melanoma patients (Shannan et al., 2016). PIM1 has also been shown to be a direct target of 
miR-542-3p, a microRNA which is a tumour suppressor in various cancers, including melanoma. 
miR-542-3p exogenous expression inhibited cell migration, invasion and epithelial-mesenchymal 
transition (EMT) in vitro and lung metastasis in vivo. Overexpression of PIM1 partially rescued 
miR-542-3p-mediated suppression of cell migration, invasion and EMT (Rang et al., 2016). 
Although PIM1 RNA has been reported in skin, protein expression is not detected, thus the 
presence of PIM1 in melanoma likely results in the autoantibody response that was detected by 
the CT100plus microarray. 
Both PD-1 and CTLA-4 prevent autoimmunity, and their effects are reportedly executed at 
different stages of the immune response. Blockade of CTLA-4 impacts T-cell activation in the 
lymph nodes when CTLA-4 expressing Tregs remove B7 from the surface of APCs, limiting their 
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ability to stimulate tumour-specific T-cells (Qureshi et al., 2011). The anti-CTLA-4 can also take 
effect on exhausted CTLA4-4-expressing T-cells and Tregs accumulated within the tumour 
microenvironment (Curran et al., 2010; Salvi et al., 2012). Blocking with anti-PD-1 is thought to 
mainly take place at the effector stage of the immune response as the anti-PD-1 blocks the 
interaction between PD-1 on T-cell and PD-L1 on cancer cells. Since B-cells, the only cell type that 
produces Igs, also express PD-1, treatment with anti-PD-1 may directly increase Ab production in 
response to TAA. 
The CT100plus microarray was used to determine the immunomodulatory effects of all 
immunotherapy treatment. Here, the autoantibody levels of all patients, regardless of treatment-
type, were compared for TP0 and TP1. The Mann-Whitney U test indicates a non-significant (p-
value > 0.05) change in autoantibody titre post-treatment. For all treatment-types in the 
melanoma cohort, an increased T-cell and B-cell response is expected in response to 
immunotherapy. However, our results indicate that none of the 123 proteins on the CT100plus 
microarray correlates with treatment type when assessing outcomes using the Kruskal-Wallis 
test. A power analysis for the Kruskal-Wallis test was performed in R with the pwr package. For 
the power analysis, an effect size of 0.8, a significance level of 0.05, and a power of 0.95 was 
used. The results indicate that a subset of patient within each treatment-type did not have 
enough timepoints to reach the required statistical power (Table 5.11).  It would therefore be 
important to capture more timepoints for these patients in this on-going trial. 
 
Table 5.11. Power analysis for treatment-types for melanoma patient cohort. A power analysis was 
performed for the melanoma cohort to determine the number of patients required to reach statistical 
power for each treatment group. Here, the effect size was set at 0.8, the significance level was set at 0.05, 
and the power was set at 0.95. Abbreviations include: N = number of patients; TP = timepoints. 
Treatment N Number of TP required Patients with sufficient TP 
Nivolumab 4 7.77 1 
Pembrolizumab 12 4.17 7 
Ipilimumab 32 2.56 27 




Although a non-significant change in autoantibody titres was detected at various TPs, a subset of 
patients produced high autoantibody signal intensities toward autoantigens. Interestingly, seven 
(N = 7/52; 14%) patients had a high (> 10 000 RFU) signal intensity at T0 to at least one antigen, 
including CTAG2 (N = 6/52, 12%), NY-ESO-1 (N = 6/52, 12%), and PRKCZ (N = 2/52, 4%). 
Furthermore, at T1, eleven (N = 11/50, 22%) patients produced a high (> 10 000 RFU) signal 
intensity to CTAG2 (N = 6/50, 12%), NY-ESO-1 (N = 6/50, 12%), MAGEB6 (N = 2/50, 4%), NXF2 (N 
= 2/50, 4%), NY-CO-45 (N = 2/50, 4%), ACVR2B (N = 2/50, 4%), or CTAG2/LAGE-1b/LAGE-1L (N = 
2/50, 4%). These results indicate that a subset of the patient cohort have a change in 
autoantibody signature which may result from an autoantibody response towards TAAs released 
from tumours after immunotherapy. It would therefore be interesting to follow up with these 
patients to determine whether the identification of autoantibody signatures relates to patient 
treatment outcome and recurrence.  
High signals were detected for CTAG2 and NY-ESO-1 before and after treatment, regardless of 
treatment-type. However, due to the low detection frequency, which is supported by statistical 
tests outcomes, it is highly unlikely that these proteins could reproducibly detect melanoma or 
be used for disease prognosis. Although CTAG is not reportedly expressed in melanoma, its 
homologue NY-ESO-1 is reportedly expressed at high levels in metastatic (28 - 32 %) versus 
primary (0 - 16 %) malignant melanoma tissues samples. NY-ESO1 is also found to be associated 
with cancer state, primary tumour thickness, CD3+ T-cell tumour infiltration, although no 
association was found with patient survival, gender, age, tumour site, ulceration or lymph node 
sentinel status (Velazquez et al., 2007; Aung et al., 2014; Giavina-Bianchi et al., 2015). Our cohort 
consists of only metastatic melanoma patients, six (N = 6/52, 12%) of which produced high levels 
of NY-ESO-1. Here, we did not find a correlation between NY-ESO-1 levels and patient treatment 
regimen. However, these results may correlate with other patient clinical features that will be 
obtained in future when the clinical trial un-blinds. NY-ESO1 and CTAG2 are also frequently 
detected together, which is also likely due to a common epitope targeted by melanoma 




Table 5.12. Shared homology between frequently detected melanoma antigens. Melanoma sera and/or 
plasma were assayed in the CT100plus microarray. Frequently detected antigens with high signal intensity 
(> 10 000 RFU) were identified, and the protein that shares high homology is summarised with query 
coverage (%), identity (%), and E-values. Abbreviations include: RFU = relative fluorescence units. 
Protein Protein Query coverage (%) Identity (%) E-value 
NY-ESO-1 CTAG2 78 77 1-38 
 
In conclusion, using the CT100plus microarray, we identified a list of 10 proteins that distinguish 
HCs from metastatic melanoma patients. Furthermore, we observed high and distinct signals for 
a subgroup of patients, although we have not yet found an association with patient treatment 
regimen. For future investigations, we will be looking in to possible correlations between other 
patient clinical features, and looking in to the autoantibody profiles of early stage melanoma 

















Chapter 6  
 
Summary, Conclusions and Future Prospectives 
 
6.1. Summary and conclusions 
Cancer is a heterogenous disease capable of forming and spreading in most tissues of the human 
body. Cancer screening and diagnosis can be performed through medical procedures, which are 
typically highly invasive and require an intensive infrastructure e.g. for CRC; protein biomarkers, 
which have low specificity resulting in a high false positive rate, e.g. prostate-specific antigen 
(PSA) for prostate cancer; and medical imaging, which exposes patients to harmful radiation and 
may not be effective in some cases e.g. mammographies are unsuccessful for women with dense 
breasts. It is therefore important to create cost-effective, non-invasive cancer diagnostic tools 
that also give an indication of disease prognosis. With these concepts in mind, the Blackburn lab 
created the CT100plus microarray, a tool that detects autoantibody signals from the blood of 
cancer patients, detectable in the pg/ml range. The CT100plus microarray is functionalised with 
native TSA and TAA, which include CTA. Thus, the autoantibody signals detected for patients are 
specific to aberrant cancer proteins, and should therefore be detected in cancer patients only 
(Beeton-Kempen et al., 2014). Despite the technological advancements of microarrays, 
autoantibody signals are only identified in a subset of the patients, although the reason for this 
is not entirely clear. 
The data from the CT100plus microarray is filtered and normalised through a robust in-house 
developed pipeline built into the CT100plus software. However, the statistical analysis thereafter 
has been limited to using an arbitrary 1000 RFU cut-off, and only antigenic signal intensities 
above this threshold were considered significant. In our study, we re-analysed the CRC patient-
derived CT100plus data using a newly established statistical pipeline (Figure 2.1), including ROC 
analyses, Mann-Whitney U test, unsupervised hierarchical clustering and PCA analysis. Using this 
pipeline, we identified CEACAM1 and GRWD1 as our top antigens for CRC diagnosis, together 
producing sensitivity-, and specificity-, and AUC-values of 1.00, 0.77 and 0.94, respectively, and 
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distinct clusters of HCs and CRC patients for both unsupervised hierarchical clustering and PCA 
analysis. CEACAM1 is a known serological biomarker for CRC, and its presence in blood could 
induce an autoimmune response. Furthermore, COL6A1, THEG and CEACAM7, a homologue of 
CEACAM1, were also identified by AP-MS (See Chapter 2), providing additional supporting 
evidence for biomarker identification. Unfortunately, we did not observe antigen association 
with clinicopathological features. Taken together, we have generated a statistical pipeline that 
distinguishes CRC patients from HCs, which was applied to subsequent cohorts (Chapter 3 and 
5). 
PAD2 is expressed in CRC, and citrullinated cancer-associated proteins have been identified for 
CRC, which we have also identified by AP-MS (See Chapter 4). The CT100plus microarray content 
was modified to include citrullinated proteins, with the subsequent assessment of CRC patient 
autoantibody response. Significantly (p-value ≤ 0.05; adjusted p-value ≤ 0.05) higher signal 
intensities were detected in CRC patients versus HCs for citrullinated CDK7, MAGEB1, MAGEB5, 
MAGEB6 and SYCP1, whereas no significant (p-value > 0.05) difference in autoantibody signal 
was detected on the non-citrullinated microarray for the same patient cohort. Furthermore, ROC 
analyses of these antigens resulted in AUC-, sensitivity- and specificity-ranges of 0.91, 0.87 and 
0.89, respectively Unsupervised hierarchical clustering analyses did not produce distinct clusters 
of patients and HCs, although the PCA results indicate distinct groups of CRC patient and HC 
clusters. Together, here we show for the first time that cancer patients elicit an autoantibody 
response to citrullinated proteins, resulting in potential novel CRC biomarkers. 
Two CRC plasma samples were also processed on the SENGENICS IMMUNOME™ microarray 
functionalized with 1622 native eukaryotic proteins. The highest autoantibody signals were 
toward proteins not present on the CT100plus microarray. Furthermore, we also developed an 
AP-MS assay to detect autoantibody responses to autologous native tissue proteins. Although 
PEG was detected in the spectra, we also detected the proteins or homologues of proteins 
identified on the CT100plus microarray for the same 5 patients. A high degree of non-specific 
binding is detected, although, we account for this by using negative controls (i.e. Plasma and 
Normal). However, it is important that more patient samples are assessed in future to identify 
CRC proteins associated with disease diagnosis and prognosis. 
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Finally, we assayed the serum and/or plasma samples of melanoma patients, and compared 
autoantibody signals to that of HC samples. CEACAM1 and FGFR2 were identified as the top 
antigens for melanoma diagnosis, together producing sensitivity-, and specificity-, and AUC-
values of 0.96, 0.94 and 0.93, respectively, and distinct clusters of HCs and melanoma patients 
for both unsupervised hierarchical clustering and PCA analysis. CEACAM1 is a known serological 
biomarker for melanoma also, and its presence in blood could induce an autoimmune response. 
Each of the 52 patients received treatment with an immunotherapeutic (nivolimumab, 
ipilimumab or pembrolizumab) alone, consecutive treatments with two immunotherapeutics, or 
simultaneous treatment with two immunotherapeutics. Here, we did not observe a significant 
change in autoantibody levels following immunotherapeutic treatments. Alternatively, response 
to treatment may be assessed on microarrays with more proteins e.g. on the SENGENICS 
IMMUNOME™ microarray, or if the autologous tissue samples are available, AP-MS could be used 
to identify known and novel cancer antigens associated with the response of advanced 
melanoma patients to therapy.  
6.2. Future prospectives 
Using two independent immunoproteomics approaches, we show evidence of autoantibody 
signals against TAAs and TSAs.  For future work, obtaining additional HC serum and/plasma 
samples are required to improve statistical power. In the same regard, it is imperative that a 
larger cohort be tested for the AP-MS experiments.  
It would be useful to establish a user-friendly software application available to analyse CT100plus 
microarray – or any other microarray - derived data, which can be performed using R or Java. The 
CT100plus microarray could be developed further to include additional TAAs or TSAs as the 
microarray layout allows for triplicate printing of 170 proteins.  
Finally, it is evident that out robust, highly reproducible, sensitive and specific microarray has 
potential in a clinical setting. Furthermore, the tool can be used in a research capacity to identify 
novel diagnostic, disease progression, prognostic, treatment resistant and predictive biomarkers, 
which could aid in the detection and management of cancer. Our in-house developed microarray 
platform represents a sensitive, high-throughput and readily customizable means to detect and 
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quantify macromolecule interactions. Thus, the platform can be modified to assess the 
autoantibody response in other autoimmune disease e.g. rheumatoid arthritis or Tuberculosis, 






















Chapter 7  
 
Materials and Methods 
 
7.1. Coating NEXTERION® H slides with streptavidin 
7.1.1. Preparing streptavidin solution 
A vial of 100 mg lyophilised streptavidin (ProSpec) was removed from -20°C storage, equilibrated 
at room temperature (RT) for 1 hour, and reconstituted in 10 ml slide coating buffer (see 
Appendix A for preparation) to a final concentration of 1 milligram per millilitre (mg/ml) 
streptavidin. The solution was stored at -20°C until ready to use. 
7.1.2. Coating NEXTERION® H Slides 
The enclosed NEXTERION® H slide (Schott) package, and the 1 mg/ml streptavidin solution, was 
removed from -20°C storage and equilibrated for 1 hour at RT. A 6-chamber slide processing dish 
was cleaned with triple-distilled Millipore water, and air-dried before adding 5 ml 1 mg/ml 
streptavidin solution to each chamber. Six NEXTERION® H slides were removed from their 
packaging, the barcodes were recorded, and each slide transferred to a chamber containing the 
1 mg/ml streptavidin solution. The chamber slide processing dish was placed on the orbital 
shaker (ORBITAL SHAKER SO3, Stuart Scientific) at 100 rotations per minute (RPM) for 1 hour at 
RT. After coating, the slides were immersed in slide wash buffer (see Appendix A for preparation) 
for 5 minutes whilst shaking at RT - the wash step was repeated twice. The slides were immersed 
in triple-distilled Millipore water (high-performance liquid chromatography (HPLC) grade) for 5 
minutes at RT, and dried by centrifugation (Megafuge 1.0R, Heraeus) at 272 ×g for 2 minutes at 
22°C. Once dry, the slides were re-packaged in a slide holder, sealed in a zip seal bag, and stored 
at -20°C. This processed was repeated until the required number of slides were derivatized. The 
remaining streptavidin solution (NB: this solution can be used to coat up to 100 slides) was 
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combined and transferred to a 50 ml tube (Greiner), sealed with parafilm (Bemis), and stored at 
-20°C. Containers with uncoated slides were labelled, placed in a zip seal bag and stored at -20°C. 
7.1.3. Slide coating quality control 
For quality control purposes, a derivatized slide from each batch of NEXTERION® H slides was 
immersed in Cy5-biotin-BSA to assess the variability in coating across the slide surface. For the 
quality control assessment, the streptavidin coated slides were removed from the -20°C storage, 
and equilibrated at RT for 1 hour. A 12 µl aliquot of 0.5 mg/ml Cy5-biotin-BSA and 10 µl aliquot 
of 1M DTT were removed from -20°C storage, and thawed on ice until ready to use. Fresh quality 
control buffer (See Appendix A for preparation) was prepared, and 5 µl 1M DTT and 10 µl 0.5 
mg/ml Cy5-biotin-BSA were added to the quality control buffer, mixed, and transferred a 
chamber in the 6-chamber slide processing dish. 
The equilibrated slide was immersed in the quality control buffer (See Appendix A for 
preparation), and incubated on a shaker at 100 RPM for 1 hour at RT, protected from light. The 
slide was washed in 1× PBST (1× phosphate buffered saline (PBS) and 0.1% Tween®-20) for 5 
minutes on a shaker at 100 RPM at RT - the wash step was repeated twice. After removing the 
wash solution, the slide was finally rinsed in Millipore water (HPLC) for 5 minutes on a shaker at 
100 RPM at RT. The slide was dried by centrifugation at 272 ×g for 2 minutes at 22°C. 
The entire streptavidin-coated area of the NEXTERION® H slide, as well as the four microarray 
printing areas, were scanned using the GenePix 4000A fluorescence microarray scanner (Axon 
Instruments, USA) using the automatic photon multiplier tube (AUTOPMT) setting a 10 µm 
resolution. The GenePix Pro software (Axon Instruments, USA) was used to obtain the mean and 
the standard deviation (SD) of the net RFU. The resulting CV was calculated, where a CV of ≤ 5% 






7.2. Printing microarrays 
7.2.1. Preparing CT100plus microarray cancer antigen lysates and controls 
Stocks of cancer antigen lysates, BCCP lysate, ICL, human IgG (Rocklands), anti-human IgG 
(SIGMA®), and the 0.5 mg/ml Cy5-biotin BSA stock solution were generated and prepared by Dr. 
Aubrey Shoko at the Centre of Proteomic and Genomic Research (CPGR).  
The working concentrations of the cancer antigen lysates, BCCP lysate, ICL, human IgG and anti-
human IgG were prepared by diluting 1:1 in 40% sucrose (in triple-distilled Millipore water) and 
vortexing (Vortex Genie 2, Scientific Industries). The stock and working solutions were 
subsequently stored at -80°C until it was needed to prepare the 384-well Genetix plates (Genetix, 
Separations). Before preparing the working concentrations of the Cy5-biotin-BSA controls, the 
concentration of the protein as well as the molar ratio of Cy5:BSA was measured, and recorded. 
The working concentrations of the Cy5-biotin-BSA controls were prepared by adding 16, 32 and 
48 µl 0.5 mg/ml Cy5-biotin-BSA to 1.584, 1.568 and 1.552 ml CT100plus control buffer (See 
Appendix A for preparation) to generate 5, 10 and 15 ng/µl Cy5-biotin-BSA, respectively. The Cy5-
biotin-BSA working solutions were stored on ice and protected from light. The “buffer” control 
on the microarray refers to CT100plus control buffer (See Appendix A for preparation). The 0.5 
mg/ml Cy5-biotin-BSA aliquoted stock solutions were stored at -20°C, and the working solutions 
were stored at -80°C. 
7.2.2. Transferring cancer antigens and controls to 384-well Genetix microplates 
After removal from -80°C storage, the cancer antigens and controls were thawed on ice. A 384-
well Genetix microplate was placed on ice, 20 µl of each antigen and control were transferred to 
their respective wells; the contents and layout for plate are indicated in Figure 7.1 and Table 7.1, 






 Table 7.1. The 384-well Genetix microplate 1 containing 60 cancer antigens (labelled with gene name) 
and the Cy5-biotin-BSA, anti-human IgG Ab and human IgG controls, as well as the control buffer. 
Well Component Well Component Well Component 
1A-D & 2A-D/8A-D & 9A-D 5 ng/µl Cy5-biotin-BSA 4E / 11E GAGE1 5K / 12K MAGEB6 
1E-H & 2E-H/8E-H & 9E-H 10 ng/µl Cy5-biotin-BSA 4F / 11F GAGE2A 5L / 12L MART-1/MLANA 
1I-L & 2I-L/8I-L & 9I-L 15 ng/µl Cy5-biotin-BSA 4G / 11G GAGE4 5M / 12A MICA 
3B / 10B BAGE2 4H / 11H GAGE5 5N / 12N NLRP4 
3C / 10C BAGE3 4I / 11I GAGE6 5O / 12O NXF2 
3D / 10D BAGE4 4J / 11J GAGE7 5P / 12P NY-CO-45 
3E / 10E BAGE5 4K / 11K GRWD1 6A / 13A NY-ESO-1 
3F / 10F CCDC33 4L / 11L HORMAD1 6B / 13B OIP5 
3G / 10G CEP290 4M / 11M LDHC 6C / 13C p53 
3H / 10H COL6A1 4N / 11N LEMD1 6D / 13D PBK 
3I / 10I COX6B2 4O / 11O LIPI 6E / 13E RELT 
3J / 10J CSAG2 4P / 11P MAGEA1 6F / 13F ROPN1 
3K / 10K CT47.11 5A / 12A MAGEA10 6G / 13G SGY-1/ 
3L / 10L CT62 5B / 12B MAGEA11 6H / 13H SILV 
3M / 10M CTAG2/NY-ESO-2 5C / 12C MAGEA2 6I / 13I SPAG9 
3N / 10N CXorf48.1 5D / 12D MAGEA3 6J / 13J SPANXA1 
3O / 10O DDX53 5E / 12E MAGEA4 v2 6K / 13K SPANXB1 
3P / 10P MMA1 5F / 12F MAGEA4 v3 6L / 13L SPANXC 
4A / 11A FTHL17 5G / 12G MAGEA4 v4 6M / 13M SPANXD 
4B / 11B Control buffer 5H / 12H MAGEA5 6N / 13N SPO11 
4C / 11C Anti-human IgG antibody 5I / 12I MAGEB1 6O / 13O SSX1 




Figure 7.1. 384-well Genetix microplate 1. The figure depicts the layout and contents of a 384-well 
Genetix microplate 1 compatible with the Qarrayer microarray printer. The microplate was prepared by 
adding cancer antigens labelled 1-60 (Table 7.1), as well as the controls: Cy5-biotin-BSA, human IgG, anti-
human IgG Ab and control buffer to the wells indicated. Grey-shaded wells were empty. Abbreviations 














Table 7.2. The 384-well Genetix microplate 2 containing 63 cancer antigens (labelled with gene name) 
and the BCCP-c-Myc, ICL controls, as well as the control buffer. Abbreviations include: BCCP = Biotin 
carboxyl carrier protein; ICL = insect cell lysate. 
Well Component Well Component Well Component 
1A / 8A SSX4 2G / 9G SRC 3I / 10I ACVR2B 
1B / 8B SYCE1 2H / 9H CALM1 3J / 10J ITGB1 
1C / 8C SYCP1 2I / 9I CDC25A 3K/ 10K MAP9 
1D / 8D THEG 2J / 9J CREB1 3L / 10L PIM1 
1E / 8E TPTE 2K/ 9K CTNNB1 3M / 10M TKTL1 Isoform a 
1F / 8F TSGA10 2L / 9L p53 S6A 3N / 10N SPATS1 isoform 1 
1G / 8G TSSK6 2M / 9M p53 C141Y 3O / 10O DPPA2 
1H / 8H TYR 2N / 9N p53 S15A 3P/ 10P SOX1 
1I / 8I XAGE-2 2O / 9O p53 T18A 4E / 11E ROPN1A 
1J / 8J XAGE3a v1 2P/ 9P p53 Q136X 4F / 11F CEACAM1 isoform 1 
1K / 8K XAGE3a v2 3A / 10A p53 S46A 4G / 11G POU5F1 
1L / 8L ZNF165 3B / 10B p53 K382R 4H / 11H NANOG 
1M / 8M AKT1 3C / 10C p53 S392A 4I / 11I BORIS B0 
1N / 8N CDK2 3D / 10D p53 M133T 4J / 11J DPPA4 
1O / 8O CDK4 4A / 11A p53 L344P 4K / 11K DPPA3 
1P / 8P CDK7 4B / 11B CYP3A4 4L / 11L GDF3 
2A / 9A FES 4C / 11C CYPR 4M / 11M CTAG2/LAGE-1b/LAGE-1L 
2B / 9B FGFR2 4D / 11D EGFR 4N / 11N CAMEL 
2C / 9C MAPK1 3E / 10E 5T4/TPBG 4O / 11O NY-ESO-1 ORF2 
2D / 9D MAPK3 3F/ 10F XAGE1B 4P / 11P BCCP 
2E/ 9E PRKCZ 3G / 10G SOX2 5A / 12A Insect cell lysate 




Figure 7.2. 384-well Genetix microplate 2. The figure depicts the layout and contents of a 384-well 
Genetix microplate compatible with the Qarrayer microarray printer. The microplate was prepared by 
adding cancer antigens labelled 61-123 (Table 7.2), as well as the controls: BCCP-c-Myc and control buffer 
(Buffer) to the wells indicated. Grey-shaded wells were empty. 
 
To prevent photobleaching, the Cy5-biotin-BSA controls were transferred last to the microplate, 
while protected from light. Once the transfer was complete, both 384-well Genetix microplates 
were either immediately used to print the CT100plus microarray or the microplate was covered 
with aluminium-foil sealing films (EXCEL Scientific), protected in tin foil (SAPPHIRE), and stored 
at -80°C. The remaining cancer antigen and control working solutions were stored at -80°C until 
required. It is important to note that the Cy5-biotin-BSA controls were stored in tubes protected 






7.2.3. Printing CT100plus microarrays 
7.2.3.1. Preparing derivatised NEXTERION® H slides and the Genetix 384-well microplates 
Streptavidin-coated NEXTERION® H slides were removed from -20°C storage, and equilibrated for 
1 hour at RT. If streaking and/or particles were seen, the slides were rinsed in triple-distilled 
Millipore water (HPLC grade) for 2 minutes at RT, while shaking at 100 RPM and protected from 
light. Slides ware dried by centrifugation at 272 ×g for 2 minutes at 22°C. The two 384-well 
Genetix microplates containing the cancer antigens and controls were removed from -80°C 
storage, and thawed on ice.  
7.2.3.2. Preparing Qarray2 robotic arrayer 
The Qarray2 robotic arrayer (Genetix, Berkshire, UK), equipped with 8 X 300 µm flat-tipped solid 
pins (Genetix aQU 300 µm), was used to print the CT100plus microarray. The print settings are 
summarised in Table 7.3. 
Before starting the printing procedure, the following settings for the Qarray2 robotic arrayer 
were checked: The humidifier and water wash container were topped with triple-distilled 
Millipore water (HPLC grade), and the ethanol wash container was topped with 80% ethanol (in 
triple-distilled Millipore water). Three water and ethanol washes were activated to confirm that 
the hydraulic systems were functional. The printing pins were sonicated for 5 minutes at RT in 
triple-distilled Millipore water (HPLC grade), sprayed with 80% ethanol (in triple-distilled 











Table 7.3. Qarrayer parameter for environmental conditions, print settings and pin wash settings are 










Print settings  
Inking time 500 ms 
Microarray pattern 8 X 8 spots/grid 
Spacing 562 µm 
Max. stamps per ink 1 
Stamps per spot 1 




Pin wash settings  
Water wash 60 sec. 
Ethanol wash 10 sec. 





Datum pointing was performed to calibrate the position of the printing pins relative to the slide. 
A print depth of 150 µm (Table 7.3) was found to be the optimal depth to ensure homogenized 
printing across the slide bed. After completing the datum pointing check, the remaining pins were 
inserted into the printer head. Pin set one printed the first set of microarrays, and pin set 2 
printed the second set of microarrays on the slide (Figure 7.3). Thereafter, the required number 
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of equilibrated slides were loaded in the arrayer, the vacuum was applied to prevent slides from 
moving during the printing procedure, and the array printing area was purged to remove 
potential interfering particles or contaminants. Thereafter, the humidity was set to ~ 50% and 
the Qarray2 light was switched off. Once the above-mentioned parameters were checked, the 
printing procedure was started. 
Replica CT100plus microarrays were printed in a four-plex format on streptavidin-coated 
NEXTERION® H slides. Each CT100plus microarray is subdivided into 8 subarrays, each containing 
cancer antigens, positive and/or negative controls printed in triplicate. The human 
immunoglobulin G “hIgG” positive control was printed in subarrays 4 and 5, and the “anti-human 
immunoglobulin G (anti-humanIgG)” was printed in triplicate in subarray 6. Subarrays 1-3 and 5-
8 contained the “buffer” negative control printed in triplicate, subarray 4 contained the ICL 
negative control printed in triplicate, and subarray 5 contained the “BCCP” negative control 
printed in triplicate. The layout of the entire slide, CT100plus microarray and subarrays is shown 
in Figure 7.4. 
 
 
Figure 7.3. Pin positioning for CT100plus printing. The Qarray2 robotic arrayer printer head and pin 
positioning use to print CT100plus microarrays in a four-plex format. Pin set 1 prints microarray set 1; pin 
set 2 prints microarray set 2 on a streptavidin-coated NEXTERION® H slide. The 5, 10 and 15 ng/µl Cy5-




Figure 7.4 Layout of the CT100plus microarray. CT100plus microarrays were printed in a 4-plex format 
on streptavidin-coated NEXTERION H slides. Each microarray is subdivided into 8 subarrays, each 
containing 123 cancer antigens, as well as positive (Cy5-biotin-BSA, human IgG, anti-human IgG) and/or 
negative controls (buffer, BCCP-c-Myc, ICL) printed in triplicate. Abbreviations include: Cy5 = cyanine 5; 
BSA = bovine serum albumin; IgG = immunoglobulin G; BCCP = biotin carboxyl carrier protein, ICL = insect 
cell lysate. 
 
After the printing procedure was complete, the humidity and vacuum was switched off. Slides 
were removed from their holders and visually inspected for missing spots, spot merging and/or 
drying and dust particles. The slides were re-packaged in slide holders and stored at 4°C, 
protected from light, until the day of assaying.  
7.3.  CT100plus hybridisation assay  
7.3.1. Preparing PAD4 (only Chapter 3) 
The PAD4 enzyme (SIGMA®) was removed from -80°C storage and, thawed on ice. Each 




7.3.2. Preparing sera /plasma samples and detection antibody 
Patient and HC sera and/or plasma were removed from -80°C storage and thawed on ice. The 
serum and/or plasma was diluted 1:800 in 1× PBST (1× PBS and 0.1% Tween®20), mixed by 
vortexing, and stored on ice until the CT100plus assay began. The Alexa fluor 647-coupled goat 
anti-human IgG (H+L) (Invitrogen) was used as a detection Ab at a dilution of 20 µg/ml (in PBST). 
7.3.3. Preparing CT100plus microarray slides 
NB: The CT100plus microarray slides were prepared at RT on a shaker (100 RPM) and protected 
from light.  
The CT100plus microarray slides were removed from 4°C storage, and immediately immersed in 
blocking buffer (see Appendix A for preparation) for 1 hour. The slides were subsequently washed 
in 1× PBST (1× PBS and 0.1% Tween®-20) for 5 minutes – the wash was repeated twice, and finally 
rinsed in triple-distilled Millipore water (HPLC grade) for 5 minutes. The slides were dried by 
centrifuging at 272 ×g for 2 minutes at 22°C. Blocked slides were temporarily stored at RT and 
protected from light until the Tecan Hybridization station (Tecan, Austria) was ready to perform 
the CT100plus assay. 
7.3.4. Tecan hybridisation station 
7.3.4.1. Rinsing procedure 
Before starting the rinsing routine, the Tecan Hybridization station PC, as well as the extension 
and liquid units were switched on. The nitrogen gas supply was set at 270 kPa, and the valve was 
opened to release the nitrogen pressure.  
A routine rinsing procedure was performed before and after each assay. For the rinsing 
procedure, the Tecan Hybridization wash/rinse bottle 6 was topped with fresh 2.25 L triple-
distilled Millipore water (HPLC grade), and the washing/rinsing tubes were placed in bottle 6 of 
the hybridization station. Sterilized slide holders were placed in each slide holder.  The 
hybridization chambers were placed in their allocated modules, module lid carefully closed, and 
each injected port plug tightened. The rinsing procedure was activated, with a final drying step.  
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Once the rinsing procedure was completed, the module lids were opened and the slide and slide 
holders were inspected for water leaks. Once the rinsing procedure was completed, the 
CT100plus assay could start. 
7.3.4.2. Tecan Hybridisation: CT100plus assay 
Before starting the assay, the CT100plus assay hybridization settings (Table 7.4) were loaded in 
the HS Pro Control Manager (Version 4.00).  
 
Table 7.4. Tecan Hybridization protocol settings for the citrullinated CT100plus microarray. 
Abbreviations include: PAD4 = protein arginine deiminase isoform 4; PBST = phosphate buffered saline 
supplemented with tween-20; tH2O = triple-distilled water; min. = minutes. 
Parameter Setting 
  
Incubation: PAD4 2 hours (37°C) 
Wash time (PBST) / Soak time 3 × 1 min. / 3 × 0.5 min. 
Wash time (tH2O) / Soak time 2 × 1 min. / 2 × 0.5 min. 
  
Incubation: Plasma 1 hour (23°C) 
Wash time (PBST) / Soak time 3 × 1 min. / 3 × 0.5 min. 
Wash time (PBST) / Soak time 2 × 1 min. / 2 × 0.5 min. 
  
Incubation: Detection antibody 30 min. (23°C) 
Wash time (PBST) / Soak time 4 × 1 min. / 4 × 0.5 min. 
Wash time (tH2O)  1 × 0.5 min.  
  
Slide drying time/ machine temperature 1.5 min. / 30°C 
  
 
The blocked CT100plus microarray slides were placed in the appropriate module positions, and 
the module lid was closed and covered with a black lid to protect the microarrays from light. The 
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Tecan Hybridization bottles 1 and 2 were topped with 2 L PBST (1× PBS, 0.1% Tween®-20), and 
bottle 1 was topped with 1 L triple-distilled Millipore water (HPLC grade), and tubes 1, 2 and 3 
were placed in their complementary bottles.  
Upon completion of the CT100plus assay, the slides were removed from the modules and 
immediately scanned. The routine Tecan Hybridization station rinse protocol was activated (see 
Section 1.3.3.1.), where after each chamber was manual cleaned by rinsing with 30% ethanol (in 
triple-distilled water) and triple-distilled Millipore water (HPLC grade), and finally dried with lint-
free tissue.  
7.4. CT100plus microarray scanning and visual assessment 
The microarray images were scanned using the parameters summarised in Table 7.5. Unique 
alpha-numeric description was ascribed to each microarray, and the images were subsequently 
used for data extrapolation using the ArrayPro data extraction and analysis software (Media 
Cybernetics, Rockville MD). 
 
Table 7.5. GenePix 4000B scanner settings for the CT100plus microarray.  
Parameter Description 
Scanner GenePix 4000B 
Software GenePix Pro 
Gain setting AUTOPMT 
Saturation threshold 0 % 
Resolution 10 µm 
Image type *.TIFF 
  
To ensure that the numerical outputs from the ArrayPro and CT100+ programs represented 
biologically meaningful data, each CT100plus microarray *.TIFF image was visually assessed for 
spot homogeneity, spot merging, spot bleeding, dust particles, speckling, and variation in 
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background. If either of the aforementioned artefacts affected at least 2 of the triplicate spots, a 
sample re-run was performed until a high-quality image was produced.  
7.5.  ArrayPro data extrapolation and CT100+.jar settings 
The ArrayPro software was used to extrapolate numerical information from the CT100plus 
microarray images. The bioinformatic pipeline for CT100plus quality control measures was 
developed in the Blackburn laboratory. The initial prototype was prepared by Mr. Jean-Michel 
Serufuri, and was later upgraded by Dr. Jessica Duarte, and set in a Java script by Dr. Ryan Goosen. 
Altogether, a robust and user-friendly pipeline was developed, and the following quality control 
measures were applied to the data set for this cohort:  
For the CRC cohort, the default noise- (2 SD above background) and saturation- thresholds (65535 
RFU) were applied. The 15 ng/µl Cy5-biotin-BSA control was used to assess variance across 
microarrays, with a CV threshold set at 25%. The median net RFU was obtained, with the CV-
threshold for antigens set at 20%. Table 7.6 provides descriptions for each filtering and 
normalisation step in the CT100plus application. 
 
Table 7.6. Description for filtering and normalisation steps in the CT100plus application. Abbreviations 
include: BG = background; SDs = standard deviations; CV = coefficient of variation; Cy5 = cyanine 5; BSA 
= bovine serum albumin. 
Parameter Description 
1. Neighbourhood background The median-value of the 8 neighbouring BG-values flanking each 
antigen. 
2. Net intensity Raw intensity minus neighbourhood background. 
3. Acceptable noise threshold Antigen net intensity greater than 2 SDs from background. 
4. CV threshold: Antigens User-defined CV-threshold for mean net intensity of antigens. 
5. CV threshold: Cy5-biotin-BSA User-defined CV-threshold for mean net intensity of Cy5-biotin-
BSA. 
6. Pin-pin normalisation Subarrays normalised with Cy5-biotin-BSA controls using Equation 
1. 
7. Array-to-array normalisation Arrays normalised with Cy5-biotin-BSA controls using Equation 1. 
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7.6. SENGENICS IMMUNOME™ microarray assay 
7.6.1. Blocking SENGENICS IMMUNOME™ microarray slides 
NB: The CT100plus microarray slides were prepared at RT on a shaker (100 RPM) and protected 
from light. 
The SENGENICS IMMUNOME™ microarrays were removed from their storage solution, and 
washed thrice with 1× PBST (PBS and 0.1% Tween®-20) for 5 minutes – the wash step was 
repeated twice, and the slides were finally rinsed in triple-distilled Millipore water for 5 minutes. 
The slides were then immediately immersed in blocking solution (see Appendix A for preparation) 
for 1 hour (hr). The slides were washed in 1× PBST (PBS and 0.1% Tween®-20) for 5 minutes – the 
wash step was repeated twice, and the slides were finally rinsed in triple-distilled Millipore water 
for 5 minutes, and dried by centrifuging at 272 ×g for 2 minutes at 22°C.  
7.6.2. Preparing CRC plasma and detection antibody 
Patient plasmas were removed from -80°C storage, and thawed on ice. The serum and/or plasma 
was diluted 1:800 in 1× PBST (PBS and 0.1% Tween®-20), mixed by vortexing, and stored on ice 
until the CT100plus assay began. The Alexa fluor 647-coupled goat anti-human IgG (H+L) 
(Invitrogen) was used as a detection Ab at a dilution of 20 µg/ml (in PBST). 
7.6.3. Assaying CRC plasma 
Blocked SENGENICS IMMUNOME™ microarrays were incubated with CRC038 or CRC050 plasma 
for 1 hr. The slides were subsequently washed in PBST (PBS and 0.1% Tween®-20) for 5 minutes 
– the wash step was repeated twice, and the slides were finally rinsed in triple-distilled Millipore 
water for 5 minutes. Each slide was incubated with 20 µg/ml Alexa fluor 647-coupled goat anti-
human IgG (H+L) (Invitrogen) for 30 minutes. The slides were washed again in PBST (PBS and 0.1% 
Tween®-20) for 5 minutes – the wash step was repeated twice, and the slides were finally rinsed 
in triple-distilled Millipore water for 5 minutes. The slides were dried by centrifuging at 240 ×g 




7.6.4. SENGENICS IMMUNOME™ microarray scanning and visual assessment 
The microarray images were scanned using the parameters summarised in Table 7.7. The images 
were subsequently used for data extrapolation. 






Software GenePix Pro 
Gain setting 900  
Saturation threshold 0 % 





7.7. Optimising the AP-MS assay 
7.7.1. Capturing IgG from CRC patient plasma 
Protein G is a 22 kDa protein from Streptococcus group C and G that has a high affinity toward all 
subclasses of IgG e.g. IgG1, IgG2, IgG3 and IgG4. For our assays, Protein G-coated magnetic beads 
were used to capture IgG molecules from CRC patient plasma, which we verified through protein 
quantitation, SDS-PAGE with AQUASTAIN and Western blot analyses. The protocols that were 
used are described below: 
7.7.2. Equilibrating MagReSyn® Protein G magnetic beads 
Suspended MagReSyn® Protein G magnetic beads (ReSyn Biosciences) were thoroughly mixed, 
and 50 µl was transferred to a 1.5 ml tube. The shipping solution was removed, and the beads 
were washed with 300 µl binding buffer (See Appendix A for preparation) for 5 minutes – the 
wash step was repeated twice. The beads were then ready to capture IgG from CRC patient 
plasma. 
7.7.3. IgG capture from CRC patient plasma 
CRC patient plasma was removed from -80°C storage, and thawed on ice. For each patient, 15 µl 
CRC plasma was re-suspended in 135 µl binding buffer (See Appendix A for preparation), and 
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mixed by aspirating. The diluted plasma sample was added to the washed Protein G magnetic 
beads (see section 7.7.2), and incubated for 1 hr. Thereafter, unbound proteins were removed, 
and stored for further analysis. The beads were washed with 300 µl binding buffer for 5 minutes 
– this wash step was repeated twice. All bound proteins were eluted with 50 µl 2.5% acetic acid 
(SIGMA®) for 5 minutes – the elution step was repeated twice, and the eluents combined. The 
bound protein eluents were neutralized with 7 µl 5 M NaOH, and stored for protein quantitation 
(see Section 7.7.6), SDS-PAGE with AQUASTATION and Western Blot analysis (see Section 7.7.7). 
7.7.4. Crosslinking Protein G and IgG 
Dimethyl pimelimidate (DMP) is a crosslinker that contains an amine reactive imidoester group 
at each end of a 7-atom spacer arm. It is reactive toward primary amines present on arginine and 
N-termini of peptides and proteins, resulting in the formation of an imidine bond. For the AP-MS 
assay, DMP was used to crosslink Protein G-bound plasma proteins to reduce plasma protein 
contamination during further MS analysis. Prior to crosslinking, 50 µl Protein G beads were 
incubated with either 7.5 or 15 µl patient plasma, and then crosslinked with DMP before low pH 
elution. As a negative control, 50 µl Protein G beads were incubated with 15 µl patient plasma 
without crosslinking followed by low pH elution. The protocol used is described below: 
Protein G beads functionalized with plasma IgG (and non-specific proteins) were incubated with 
crosslinking buffer, containing 20 mM DMP in 0.1 M sodium borate (pH 9.2), for 45 minutes at 
RT. The crosslinking buffer was removed, and the beads were washed with 300 µl 1× PBS for 5 
minutes at RT. The crosslinking and wash steps were repeated twice, and the beads were finally 
washed in 500 µl 0.2 M Tris-HCl (pH 8.0) for 5 minutes at RT. Unbound proteins were eluted with 
50 µl 2.5% acetic acid (SIGMA®) for 5 minutes – the elution step was repeated twice, and the 
eluents for each sample-type combined. The eluents were neutralized with 7 µl 5 M NaOH, and 
stored for protein quantitation (see Section 7.7.6) and SDS-PAGE with AQUASTAIN (see Section 
7.7.7). 
7.7.5. Generating native protein lysate 
For the AP-MS assay, native lysate was generated through the use of the non-denaturing lysis 
buffer described before (Alhamdani et al., 2010). The lysis buffer included HEPES (pH 7.4), which 
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is a Good’s buffer characterised by its high compatibility with biological analysis, good solubility 
in water and minor salt effects (Good et al., 1966). Benzonase was added to block interference 
from nucleic acids. To avoid protein degradation, protease inhibitors (Roche) were added. Most 
critical for the isolation of native proteins was the detergents used – the list of tested detergents 
include Triton™ X-100, IGEPAL® CA-630 and CHAPS, or combinations thereof. Since CRC tissue 
was precious and limited, an SHSY-5Y human neuroblastoma cell line was used to optimize lysis 
buffer composition and lysis conditions. The protocol that was used is described below: 
7.7.5.1. Cell culture 
SHSY-5Y neuroblastoma cells were grown to 80% confluency in 12 sterile 10 cm dishes (Greiner). 
The DMEM media (Gibco®), supplemented with 10% fetal calf serum (Gibco®) and 1% pen/strep 
(LONZA), was removed, and the cells were washed with 1× PBS (Gibco®). The cells were lifted 
with trypsin (LONZA), transferred to a 15 ml tube and centrifuged at 4200 ×g for 5 minutes. The 
supernatant was discarded, and the pellet was further processed, as displayed in Figure 7.5. 
 
 
Figure 7.5. SHSY-5Y lysate generation. SHSY-5Y neuroblastoma cells were used to optimise lysis buffer 
detergent composition for CRC tissues in the AP-MS assay. The non-denaturing lysis buffer was 
supplemented with either CHAPS, Triton™ X-100, IGEPAL® CA-630, “mix”, or no detergent. The 
supernatants were collected, and protein quantification was performed using the BCA protein 
quantitation kit (Pierce™). Here the lysis conditions are described for lysis buffer only (generated with 350 
µl lysis buffer on ice for 2 hours, with intermittent vortexing), although the same procedure was used for 
lysis buffer & PE (generated with 350 µl lysis buffer and homogenizing using a Potter-Elvehjem 
homogenizer, and incubation on ice for 2 hours, with intermittent vortexing) and lysis buffer & shaking 
(generated with 350 µl lysis buffer and homogenizing with a Potter-Elvehjem homogenizer, and 
continuous vortexing 4°C). Abbreviations include: CRC = colorectal cancer; AP-MS = affinity purification-
mass spectrometry; BCA = bicinchoninic acid; PE = Potter-Elvehjem; min. = minute. 
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The pelleted SHSY-5Y neuroblastoma cells were lysed in 350 µl non-denaturing lysis buffer (see 
Appendix A for preparation), each containing various specific non-denaturing detergent, 
including either 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
(SIGMA®), 1% Triton™ X-100 (SIGMA®), 1% IGEPAL® CA-630 (SIGMA®), or a mixture detergents 
(0.25% CHAPS, 0.5% IGEPAL® CA 630, and 0.5% Triton™ X-100). As a negative control, the SHSY-
5Y neuroblastoma cell pellet was incubated with lysis buffer without detergent.  
Three lysis conditions were also assessed for protein yield: 1. Lysis buffer only refers to lysates 
generated by incubating with 350 µl lysis buffer on ice for 2 hours, with vortexing every 10 
minutes. 2. lysis buffer & PE refers to lysates generated by incubating cells with 350 µl lysis buffer 
and homogenizing using a Potter-Elvehjem homogenizer, and then incubated on ice for 2 hours, 
with vortexing every 10 minutes. 3. Lysis buffer & shaking refers to lysates generated by 
incubating cells with lysis buffer and homogenizing with a Potter-Elvehjem homogenizer, and 
then continuous vortexing for 2 hrs at 4°C. Thereafter, the lysates were centrifuged at 15 000 ×g 
for 15 min at 4°C. The supernatants were collected, and the protein concentration determined 
using the BCA protein quantitation kit (See Section 7.7.6).  
7.7.6. BCA protein quantitation  
The bicinchoninic acid (BCA) colorimetric assay was used to quantify proteins. The assay is based 
on the reduction of Cu2+ to Cu1+ by proteins in an alkaline medium. The accumulated cuprous 
(Cu1+) cation is quantified colorimetrically with BCA at 562 nm.  For our assays, we employed the 
BCA protein quantitation kit (Pierce™). The protocol that was used is described below: 
For the BCA protein quantitation, 10 µl sample or 10 µl BSA standard (2, 1.5, 1, 0.75, 0.5, 0.25, 
0.125, 0.025 mg/ml) were transferred in triplicate to a 96-well plate (Greiner bio-one). 
Thereafter, 200 µl working reagent, prepared by mixing BCA solution and copper solution at a 
ratio of 1:50, was added to each well containing sample or standard. The plate was incubated for 





7.7.7. Detecting proteins by SDS-PAGE and Western blot analysis 
SDS-PAGE is a method used to separate denatured proteins. Using a molecular weight marker, 
the molecular weight of protein bands can also be estimated. For our studies, SDS-PAGE was used 
to detect denatured and reduced IgG molecules using AQUASTAIN or Western blot analysis. The 
protocols that were used are described below: 
After proteins were eluted from Protein G magnetic beads, and neutralized, 16 µl protein was 
mixed with 4 µl Laemmli buffer (see Appendix A for preparation) to a final volume of 20 µl, and 
heated at 95 °C for 5 minutes. The lysate was centrifuged at 15 000 ×g for 30 s. The samples were 
subsequently loaded onto a polyacrylamide gel with a 4% stacking gel (see Appendix A for 
preparation) and 10% separating gel (see Appendix A for preparation), and protein separation 
performed in 1× running buffer (see Appendix A for preparation). The initial voltage was set to 
100 volts (V) until the dye front reached the separating gel. The voltage was increased to 200 V 
until the dye front was 0.5 cm from the bottom of the gel. The protein bands were detected by 
incubating with AQUASTAIN for 15 minutes, followed by image capture. 
IgG protein bands were also detected using Western blot analysis. After SDS-PAGE was 
completed, proteins were transferred onto a nitrocellulose membrane (BioTrace™ NT, PALL 
Corporation) at 100 V for 1 hr in ice-cold transfer buffer (See Appendix A for preparation). 
Thereafter, the nitrocellulose membrane was blocked in 5% fat-free milk powder diluted in 1× 
TBST (See Appendix A for preparation) at RT for 1 hr. The membrane was incubated with goat 
anti-human IgG peroxidase Ab (SIGMA®) (1:10000) at 4°C with gentle shaking overnight. Once 
labelled with antibody, the membrane was washed with 1× TBST (See Appendix A for 
preparation) for 10 minutes – the wash was repeated twice. The membrane was treated with 
chemiluminescence substrate (Advansta) for 2.5 minutes, and the relative chemiluminescence 
was detected using the G:BOX (Syngene). Relative quantitation for AQUASTAIN and Western blot 





7.8. AP-MS assays with CRC plasma and tissue lysates 
Once the various steps of the AP-MS assay were optimised, the protocol was used to assay the 
blood plasma and tissues of 5 CRC patients: CRC002, CRC004, CRC017, CRC021 and CRC031. The 
protocol for the optimized assay is described below: 
7.8.1. CRC tissue lysis 
Normal colorectal mucosa and CRC tissues were removed from -80°C storage, and thawed on ice. 
A ~3 mm3 tissue section was removed and minced with a sterile blade (HI-CARE INT). The minced 
tissue was immediately re-suspended in non-denaturing lysis buffer with Triton® X-100 (See 
Appendix A for preparation), and homogenized with a Potter-Elvehjem homogenizer with ~30 
strokes. The suspension was transferred to a 1.5 ml tube (Greiner) and vortexed at 4°C for 2 hrs. 
Thereafter, the lysates were centrifuged at 15 000 ×g at 4°C for 15 minutes. Lysate pellets and 
supernatants were stored separately at -80°C. Before the AP-MS assays, the supernatant was 
diluted to 0.4 mg/ml in binding buffer (See Appendix A for preparation). 
7.8.2. Equilibrating MagReSyn® Protein G magnetic beads 
The protocol describes the AP-MS assay conditions for one patient, although this method was 
applied to all patient samples tested. It is important to note that the washing and incubation 
steps were performed at RT whilst vortexing, unless stated otherwise. 
Suspended MagReSyn® Protein G magnetic beads (ReSyn Biosciences) were thoroughly mixed, 
and 150 µl were transferred to a 1.5 ml tube. The shipping solution was removed, and the beads 
were washed with 900 µl binding buffer (See Appendix A for preparation) for 5 minutes – the 
wash step was repeated twice. The beads were then ready to capture IgG from CRC patient 
plasma. 
7.8.3. Capturing IgG from CRC patient plasma 
CRC patient plasma was removed from -80°C storage and thawed on ice. To capture IgG, 45 µl 
CRC plasma was re-suspended in 405 µl binding buffer (See Appendix A for preparation) and 
mixed by aspirating. The diluted plasma sample was added to the washed Protein G magnetic 
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beads (see section 7.7.2) and incubated for 1 hr. Thereafter, unbound proteins were removed, 
and the beads were washed with 900 µl binding buffer for 5 minutes – this wash step was 
repeated twice. The beads were then ready for crosslinking. 
7.8.4. Crosslinking IgG to MagReSyn® Protein G magnetic beads 
Functionalized MagReSyn® Protein G magnetic beads were crosslinked with 100 µl 20 mM DMP 
in 0.1 M sodium borate (pH 9.2) for 45 minutes. The crosslinking buffer was removed, and the 
beads were washed with 900 µl binding buffer (See Appendix A for preparation) for 5 minutes – 
the wash step was repeated twice. This process was repeated twice, with a final wash in 1200 µl 
0.2 M Tris-HCl (pH 8.0) for 5 minutes. The beads were then ready for incubation with native 
colorectal lysates. 
7.8.5. Adding patient lysate tissues to IgG-functionalised MagReSyn® Protein G magnetic 
beads 
Once the beads were crosslinked, they were separated into 3 tubes each containing ⅓ of the 
functionalized beads.  Each tube was incubated with either 500 µl 0.4 mg/ml native CRC tissue 
lysate, 500 µl 0.4 mg/ml native normal colon or rectal tissue lysate, or with 500 µl binding buffer 
only overnight at 4°C. Thereafter, unbound proteins were removed, and the beads were washed 
with 300 µl binding buffer (See Appendix A for preparation) for 5 minutes – the wash step was 
repeated four times. The beads were then washed with 300 µl 1× PBS for 5 minutes – the wash 
step was repeated four times. The beads were then ready for the elution step. 
7.8.6. Eluting proteins from functionalised MagReSyn® Protein G magnetic beads 
After the beads were functionalized, they were incubated with elution buffer 1 (see Appendix A 
for preparation) for 30 minutes. The beads were washed twice with elution buffer 2 (see 
Appendix A for preparation), and the eluents mixed. The protein samples were digested at 27 °C 
for 18 hrs, and then incubated with 5.5 mM IAA (AMRESCO®) for 30 minutes protected from light. 





7.8.7. Detergent removal 
The HiPPR™ Detergent Removal Resin Column Kit (Thermo Scientific) was used to remove Triton 
X-100 according to the manufacturers protocol: 
Empty spin columns were placed in an empty 2 ml collection tube (Greiner). Thereafter, 200 µl 
evenly suspended resin was placed in the spin column and centrifuged at 1500 ×g for 1 minute 
to remove the storage buffer.  The slurry was equilibrated with 200 µl PBS (pH 7.5), then 
centrifuged at 1500 ×g for 1 minute to remove the equilibration buffer – this step was repeated 
twice. After inserting the bottom plug, peptides were applied directly to the compact resin bed, 
and incubated for 10 minutes at RT. Lastly, the cap was slightly loosened, and the bottom plug 
removed, then centrifuged at 1500 ×g for 1 minute to elute detergent-free peptides.  
7.8.8. Desalting AP-MS peptides 
Digested peptides were desalted using reverse phase extraction, which separates molecules 
based on their hydrophobicity. C-18 was used as the hydrophobic stationary phase to remove 
salts and impurities with an aqueous phase, and hydrophobic molecules eluted for further 
analysis. While solid phase extraction kits are commercially available, we made use of in-house 
prepared stage tips. The protocol is described below: 
As described before (Rappsilber et al., 2007), stage tips were prepared by inserting two C-18 
(Empore™) discs into an irradiated 200 µl tip up to the hilt, which was subsequently inserted into 
the pierced lid of an irradiated 2 ml tube. The C-18 was equilibrated with 100 µl solvent B (see 
Appendix A for preparation), then centrifuged for 2 minutes at 7000 ×g – this equilibration step 
was repeated twice. The C-18 was washed with 100 µl solvent A (see Appendix A for preparation), 
then centrifuged for 2 minutes at 7000 ×g – this wash step was repeated once. The washed C-18 
stage tip was incubated with 10 µg digested peptide, then washed with 50 µl solvent A (see 
Appendix A for preparation) and centrifuged for 2 minutes at 7000 ×g – this wash step was 
repeated twice. The desalted peptides were subsequently eluted in to a glass vial (MACHEREY-
NAGEL) with 50 µl solvent C (see Appendix A for preparation), then centrifuged for 2 minutes at 
7000 ×g – this elution step was repeated twice. The desalted peptides were lyophilized in a 
SpeedVac (Thermo Fisher Scientific, USA) at 35 °C for 45 minutes. The peptides were re-
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suspended in 30 µl solvent A (see Appendix A for preparation) and stored at -20 °C before 
analysing on the mass spectrometer. 
7.8.9. Mass spectrometer-based sample processing 
7.8.9.1. High-performance liquid chromatography (HPLC) 
High-performance liquid chromatography (HPLC) is an analytical chemistry technique used to 
simplify, identify and quantify components within a mixture. During the process, fine 
chromatographic materials are compacted to form the stationary phase to improve mobile phase 
(i.e. the solvent) and stationary phase surface interaction, allowing the use of smaller quantities 
of analyte. Each analyte in the sample interacts slightly differently with the stationary phase, 
resulting in component-specific elution rates. In HPLC, analytes can be separated by ion 
exchange, size exclusion, reverse-phase chromatography. For proteomics-based mass 
spectrometry, peptides, which typically have varying degrees of hydrophobicity, are separated 
using a reverse-phase column, which in our study consisted of a compacted C18 resin. To 
effectively simplify the peptide mixture prior to mass spectrometric analysis, an elution gradient 
of increasing acetonitrile concentration is used to separate peptides based on their 
hydrophobicity. Molecule separation is visualized by a detector, where the time taken for 
compound to elute from the column to the detector is known as the retention time. The protocol 
is described below: 
The vials of 30 µl re-suspended peptides were placed in labelled autosampler glass vials 
(MACHEREY-NAGEL), and loaded in the autosampler tray of the Dionex UltiMate® RSnano LC 
system (Thermo Fisher, San Jose, CA, USA). The nanoflow ultra-high-performance liquid 
chromatography (UHPLC) was performed using a C-18 reverse phase precolumn trap with Luna 
beads (100 µm × 2 cm; 5 µM, 100Å) (Separations, South Africa) connected to an analytical column 
(75 µm × 40 cm; 5 µM, 100Å) (Separations, South Africa) packed with C18 Aeris beads (5 µm 
diameter, 100 Å pore size; Phenomenex 04A-5452) connected to an Ultimate 3500 RS nano UPLC 
system (Dionex). The gradient chromatography was performed at 40 °C with a flow rate of 400 
nL/min and eluted with a 5-35% gradient of water-acetonitrile for 70 minutes using a binary 
mobile system with buffer A and buffer B (See Appendix A for preparation). The gradient for 
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peptide elution was 5% of buffer B (See Appendix A for preparation) for 10 minutes, which 
increased to 35% of buffer B at 70 minutes. After each run, the analytical column was briefly 
washed in-line with 80% buffer B before equilibration at 2% buffer B. 
7.8.9.2. Mass spectrometry 
Mass spectrometry is an analytical method used to ionize analytes, which are sorted according 
to their mass-to-charge (m/z) ratios. This analysis is performed by a mass spectrometer, which is 
a highly sensitive and sophisticated weighing device. Analyte ionization forms an integral part of 
the technique, as mass spectrometry involves the acceleration of ionized analytes through a 
magnetic or electrical field, whereby the analytes acceleration is measured in relation to its m/z 
in a vacuum, producing MS1. In mass spectrometry, analytes are ionized in a gaseous phase 
mainly by two methods: matrix assisted laser desorption ionization (MALDI) and electrospray 
ionization (ESI), although higher sensitivity is achieved using nanospray ESI (Jorabchi and Smith, 
2009). Post-ionization, charged analytes are detected by mass analysers, which include the 
Orbitrap, Fourier transform ion cyclotron (FTIC), ion trap or time-of-flight (TOF). Proteomics-
based MS identification relies on matching sequence tags to theoretical databases, de novo 
interpretation of peptide sequences, or assigning correlation scores for experimental-to-
theoretical spectral matching (McHugh and Arthur, 2008; Frank, 2009; Wang and Wilson, 2013).  
Tandem MS, also known as MS2 or MS/MS, involves the detection of analytes and its fragment 
products by two mass analysers in tandem. Firstly, MS1 are produced as mentioned before, and 
ions of a particular m/z are selected to produce fragment ions. The fragment ions can be 
unimolecular or bimolecular (Cooks and Mueller, 2013). Unimolecular fragmentation, also known 
as post source decay (PSC), occurs when single metastable ions fragment suddenly, producing in 
y/b ions. Bimolecular fragmentation, also known as collision-induced diffraction (CID), occurs 
when precursor ions are bombarded with inert noble gas in a collision cell, also resulting in y/b 
ions. Electron capture dissociation (ECD) and electron transfer dissociation are other form of 
bimolecular fragmentation, although they typically generate z/c fragments (Boersema et al., 
2009b). Tandem MS determines protein identity based on peptides and their fragment ions (i.e. 
bottom-up) (Washburn et al., 2001; Wolters et al., 2001), although intact protein analysis (i.e. 
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top-town) are reported too (Kelleher, 2004; Zhou et al., 2012). In proteomics, absolute 
quantitation is achieved using stable isotope labelling by amino acids in cell culture (SILAC) for in 
vivo labelling (Ong et al., 2002; Ong and Mann, 2006), while isobaric tag for relative and absolute 
quantitation (iTRAQ) (Ross et al., 2004), dimethyl labelling (Boersema et al., 2009a), and tandem 
mass tags (TMT) (Thompson et al., 2003) are in vitro labelling approaches. Label-free 
identification involves peak intensity measurements and MS1 spectral peak integration using the 
“top three” approach and iBAQ. The protocol we used is described below: 
The QExactive™ Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher, San Jose, CA, 
USA) was used in-line with the UltiMate® 3500 RSnano LC system. Mass spectra were collected 
in a data-dependent manner with automatic switching between MS and MS/MS scans using a 
top 10 method. The peptides were ionised by electron spray ionisation, and mass spectra were 
acquired with a resolution of 70 000 at a target-value of 3 × 106, or a maximum integration time 
of 250 milliseconds (ms). The scan range was restricted between 300 and 1750 m/z. Peptide 
fragmentation was performed by high-energy collision dissociation (HCD) and normalised 
collision energy was set at 25. Intensity threshold for ion selection was fixed at 1.7 × 104 with a 
charge exclusion of z = 1 and z > 5. MS2 spectra were acquired at a resolution of 17 500, at a 
target-value of 2 × 105 ions or a maximum integration time of 120 ms and the isolation window 
set at 4.0 m/z.  
7.9. Data analysis 
7.9.1. CT100plus analysis program 
The CT100plus program was developed to provide a customised normalisation and qualitative 
sample clustering using the parameters described in the following sections: 
7.9.1.1. Spot homogeneity 
Homogeneous signals are expected for all pixels within a spot. Deviations from this may be due 
to the “doughnut effect”, caused by inadequate pin height; dust particles, from poor storage 
conditions; high humidity (> 50%), resulting in condensation and uneven intensity. Temperature 
fluctuations and low humidity (< 35%) can also result in spot evaporation. The CV, which is a ratio 
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of median intensity and SD of all pixel intensities with in a spot, is used to evaluate variations 
between replicates – the CV should not exceed 25%. 
7.9.1.2. Spot-to-spot variation 
In principle, it is expected that signals from triplicate spots should be similar, and that spots 
across the microarray should be uniform. Deviations from this may be due to “spot bleeding”, 
whereby a spot spread into the background area; “spot merging”, whereby spots positioned 
closely run into each other. “Spot bleeding” and “spot merging” may result from inadequate 
spotting buffer composition or high humidity (> 50%). Inadequate washing steps may also result 
in the formation of washing artefacts or speckles, resulting in negative spots or additional smaller 
spots, resulting in spot-to-spot variation. 
7.9.1.3. Signal-to-noise ratio 
The net spot intensity, which results from foreground intensity minus background intensity, is 
expected to be higher than the neighbourhood or local background. However, washing artefacts, 
speckles and dust particles may result in a background higher than the foreground. The 
CT100plus program used a signal-to-noise ratio of ≥ 2 as acceptable, where “signal” refers to 
foreground intensity and the “noise” refers to 2 SD above the background intensity. 
7.9.1.4. Pixel saturation 
Accurate relative quantitation relies on signal intensity detection in the linear range of the 
fluorescence scanner. The GenePix scanner has limit of detection of 65535 RFU. If saturated spots 
are detected, the slides should be rescanned at a lower photomultiplier tube (PMT) gain setting 
until saturation is no longer detectible across the microarray. 
7.9.1.5. Background subtraction and correction  
The net intensity is derived by subtracting background from foreground intensity. Inaccurate 
local background values arise from speckling, dust particles, et alia. Alternatively, the 
neighbourhood background is derived from the background values of neighbouring spots, and 
accounts for artefact-effects that may arise from using local background. Thus, the CT100plus 
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software calculates net intensities by subtracting neighbourhood background from the median 
local foreground pixel intensity. 
7.9.1.6. Data normalisation 
Normalisation is an efficient and robust method of correcting technical and systematic bias in 
array-to-array and pin-to-pin discrepancies. For the CT100plus microarray employs total intensity 
based module described by Quackenbush, 2001 (Quackenbush, 2001), which assumes that all 
spots have similar intensities, meaning that intensity sum for all positive controls is constant. The 
scaling method factors in flagged spots – if a positive control spot is flagged, the corresponding 
spot is flagged across all arrays to minimise discrepancies in the number of positive control spots 
used across the microarray. 
7.9.2. MaxQuant analysis 
Proteomics experiments produce large amounts of complex data. Thus, computational analyses, 
algorithms and workflows are required for systems-level identification of biologically significant 
differences. The MaxQuant software uses a C++ based algorithm for the analysis of high 
throughput mass spectrometry proteomic data. MaxQuant allows the proteome-wide 
identification and quantification of proteins from spectra-based peptide masses generated from 
precursor scans (Cox and Mann, 2008). MaxQuant is integrated with the Andromeda search 
engine which does a score-based identification of fragment ions, peptides and protein groups. 
Proteins that share peptides are grouped together and called protein groups. The Andromeda 
scoring system is based on the binomial distribution probability (Cox et al., 2011). A binomial 
experiment requires repeated independent trials which can result in just two possible outcomes 
(i.e. success or failure), and the probability of success is the same for every trial. Peptide scoring 
functions are assigned in a binomial distribution based probabilistic algorithm by comparing 
spectral peak characteristics in experimental to theoretical target databases.  
MaxQuant version 1.5.3.12 was used for the analysis. Raw Xcalibur files generated from the mass 
spectrometer were loaded onto MaxQuant, and an experimental template was generated. The 
minor modifications (Table 7.8) were used with default experimental parameters (Table 7.9). The 
number of threads were set to the number of Xcalibur files plus 1.  
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 Table 7.8. Minor modifications to MaxQuant settings. 
Parameter Settings 
Threads Raw files plus 1 
iBAQ Ticked 
Upload FASTA file Yes 
Variable modifications  Deimination (R) 
Table 7.9. Default MaxQuant settings. 
Parameter Setting 
Variable modifications Oxidation (M) and Acetyl (Protein N-term) 
Multiplicity 2 
Enzyme Trypsin (P) 
First search PPM 20 
Main Search PPM 6 
Separate variable modifications for first search Unticked 
Maximum number of modifications per peptide 5 
Maximum labelled AAs 3 
Maximum missed cleavage 2 
Maximum charge 7 
Individual peptide mass tolerance Ticked 
Type Standard 
MS/MS tolerance for FTMS 20 
MS/MS tolerance for ITMS 0.5 
MS/MS tolerance for TOF 0.1 
Unknown 0.5 
Fixed modifications Carbamidomethyl 
Peptide FDR 0.01 
Site FDR 0.01 
Maximum peptide PEP 1 
Minimum peptides 1 
Minimum razor + unique peptide 1 
Minimum unique peptide 0 
Protein FDR 0.01 
Applied site FRD separately Ticked 
Minimum peptide length 6 
Minimum score 0 
Filter labelled amino acid Ticked 
Second peptide Ticked 
Discard unmodified counterpart peptides Ticked 
Minimum ratio count 2 
Site quantification mode Use least modified peptide 
Use of occupancies Normalised ratio 
Protein quantification use only unmodified peptides Ticked 
Requantify Ticked 
Keep low scoring version of identified peptides No 
Match between runs Unticked 
iBAQ Unticked 






R is a free, open source, C++ based programming language that is useful for large-scale statistical 
and graphical computing of high throughput omics data. RStudio (www.rstudio.com/) is an R 
interface available as a desktop application. Various codes and scripts are deposited as packages 
in the Comprehensive R Archive Network (CRAN) repository (https://cran.r-project.org/). The 
RStudio software (version 1.0.136) was used to analyse and visualise our data. 
For the analyses, required packages were downloaded from CRAN and installed. The working 
directory was set to the location of the experimental dataset, which was subsequently loaded on 
to RStudio. Pre-set scripts were loaded, and the datasets were processed to produce the required 
statistical outputs or graphs.  
7.9.4. Perseus 
Perseus is a user-friendly based software for downstream computational analysis of proteomics 
data. Various statistical tools are integrated into Perseus, including data normalisation, data 
imputation, t-test, analysis of variance (ANOVA), clustering, correlation, enrichment, volcano 
plots, motif identification and scatter plots. 
Perseus (version 1.5.4.1) was used for our analysis. The raw data was loaded in to Perseus, log2 
transformed, the categorical row annotated, missing values replaced by zero, and the relevant 
statistical tests performed. 
7.9.5. Data pre-processing and normalisation 
Raw data requires pre-processing before downstream analyses, as noisy data and missing values 
biases statistical inference and may mask the actual biological meaning of the data. Thus, the 
filtering steps are applied to make the data more amenable to statistical analysis. The filtering 
criteria for microarray or mass spectrometry data are defined in the results section of Chapters 
2, 3, 4 and 5. 
It is also important determine whether the data follows a normal Gaussian distribution to 
determine whether parametric or non-parametric statistical tests should be applied. Data 
distribution can be tested using Shapiro-Wilk (Shapiro and Wilk, 1965), Anderson-Darling 
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(Anderson and Darling, 1952) or Kolmogorov-Smirnov (Feller, 1948) tests. In this study, we used 
Shapiro-Wilk to test data distribution. 
7.9.6. Mann-Whitney U, Kruskal-Wallis test and Benjamini-Hochberg correction 
The Mann-Whitney U test, also known Wilcoxon rank-sum test, is a non-parametric test of the 
null hypothesis that it is equally likely that a random selected value from one sample is less than 
or greater than a randomly selected value from a second sample (Mann and Whitney, 1947). 
Unlike the t-test, the Mann-Whitney U test does not require the assumption of a normal 
distribution. The test was used to identify statistical significant differences between HCs and 
cancer patients, to identify CT100plus antigens associated with clinicopathological features, and 
to construct volcano plots. 
The Kruskal-Wallis test (Kruskal and Wallis, 1952) is like the Mann-Whitney U test, although it is 
used to assess statistical significant differences between multiple groups i.e. more than two 
groups. The test was used to identify CT100plus antigens associated with clinicopathological 
features. 
Type I errors, which are false-positive results, can be reduced by applying multiple testing 
correction.  Multiple correction can be applied adjusting the false discovery rate (FDR) as in the 
Benjamini-Hochberg test (Benjamini and Hochberg, 1995) or by Bonferroni’s correction which 
maintains family wise error rate (FWER). 
7.9.7. Hierarchical clustering 
Hierarchical clustering analysis is an analysis method that seeks to build a hierarchy of clusters. 
Two general clustering strategies are known i.e. agglomerative, which is a bottom up approach 
where each observation starts as its own cluster and pairs of clusters merge as one moves up the 
hierarchy, and divisive, which is a top down approach where all observations start in one cluster, 
and splits are performed recursively as one moves down the hierarchy.  
Hierarchical clustering is used to identify group differences, by using a training set (supervised) 
or by identifying random clustering patters without a training set (unsupervised). In this study, 
hierarchical clustering was performed in Perseus using log2 transformed microarray data using 
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Euclidian distance, average linkage and pre-processing with K-means for the column and row 
trees. 
7.9.8. Principle Component Analysis (PCA) 
PCA is multivariate test that searches for correlations between variables that are orthogonally 
transformed to linear uncorrelated sets of variables known as principle components. The first 
principle component has the largest variance, and subsequent principle components follow with 
decreasing variance. The analysis typically produces 1D, 2D or 3D plots for clusters identification. 
I this study, PCA was performed using Perseus on log2 transformed microarray data. 
7.9.9. Venn diagram 
A Venn diagram, also known as a primary diagram, shows all possible logical relations between a 
finite collection of datasets. The tool is particularly useful for identifying unique and shared 
between study groups. A free online software was used to produce Venn diagrams in this study, 
which can be used at http://bioinformatics.psb.ugent.be/webtools/Venn/. 
7.9.10. Sample size calculation: area under the ROC curve 
The sample size calculator is used to compare the area under the ROC curve with a null hypothesis 
value. The sample size calculator considers the required significance level and power of the test. 
The inputs required include (1) type I error, which is the probability of making a Type I error (α-
level, two sided), i.e. the probability of rejecting the null hypothesis when it is in fact true; (2) 
type II error, which is the probability of making a Type II error (β-level), i.e. the probability of 
accepting the null hypothesis when it is in fact false; (3) area under the ROC curve, which is the 
hypothesised area under the ROC curve; (4) a null hypothesis, which is a null-hypothesis AUC-
value that is 0.5, indicating that the null hypothesis states no difference between the two groups 
tested; and (5) ratio of sample sizes in negative and positive groups, which is the desired ratio of 
negative and positive cases. The outputs show the required sample size for different Type I and 
Type II Error levels.  
In this study, the ROC sample size was performed using MedCalc software (version 17.2), with a 
hypothesised area under the ROC curve of 0.80, a null hypothesis value of 0.5. The remaining 
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cohort-specific parameters (e.g. sample size ratio, α-value and β-value) are described within the 
relevant Chapters. 
7.9.11. ROC analysis  
The ROC analysis was used in this study, which is a sensitivity and specificity report of a tested 
parameter, which in this study refers to antigens.  
In a binary classification, the outcomes are labelled as either positive or negative, resulting in 
four possible outcomes from a binary classifier. If the outcome from a prediction and the actual 
value are both positive, then it is called a true positive; however, if the actual value is negative, 
then it is said to be a false-positive. Conversely, a true negative occurs when both the prediction 
outcome and the actual value are negative, and a false negative is when the prediction outcome 
is negative while the actual value is positive. 
To draw a ROC curve, only the true positive rate and the false positive rate are needed. The true 
positive rate (also known as the sensitivity) defines how many correct positive results occur 
amounts all of the positive samples in the tests. The false positive rate (equal to 1 - specificity) 
defines how many incorrect positive results occur among all negative samples in the test. The 
ROC space is defined by FPR and TPR as x- and y-axes, depicting the relative trade-offs between 
true-positives and false-positive. Thus, each prediction result of the matrix represents one point 
in the ROC space. 
In our study, the ROC analysis produces an AUC-value, a measure of the discriminating efficacy 
of antigen for patients from HCs; a sensitivity-value, indicating the fraction of patients with high 
cancer antigen intensity; and a specificity-value, indicating the fraction of HCs with no or 
significantly lower signal intensity for antigens (Metz, 1978; Vining and Gladish, 1992; Zweig and 
Campbell, 1993). The higher the AUC-, sensitivity- and specificity- values, the better an antigen 
distinguishes patients from HCs.  The ROC curve is widely accepted for selecting an optimal cut-
off point. The cut-off point is used to determine the presence or absence of a disease, where 
values above the cut-off are disease-positive, and values below the cut-off are considered 
disease-negative (Akobeng, 2007). 
218 
 
In this study, we performed the ROC analysis in RStudio using the ROCR package and CombiROC 
(http://www.combiroc.eu/). 
7.10. Databases  
7.10.1. NCBI protein BLAST 
Basic local alignment search tool (BLAST) is an algorithm used to compare primary biological 
sequences of information, like proteins or nucleotides. The BLAST search allows the comparison 
between a query sequence with a database of sequences. In the study, the National Centre for 
Biotechnology Information (NCBI) BLAST tool (https://blast.ncbi.nlm.nih.gov/) was used which 
produces a query cover-value, E-value, identify-value which provides scores for the comparison 
between the query sequence and the database sequence.   
7.10.2. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 
STRING (http://string-db.org) is a web-based and biological database source used to interrogate 
protein-protein interactions (Szklarczyk et al., 2011, 2015).  The data sources in STRING are 
derived from curated literature, computational predictions and experimental data, with a 
resulting physical interaction network assigned weighted confidence scores. The majority of 
STRING associations are from genome-based prediction algorithms or by pre-computed interlog 
transfer. The probabilistic confidence score is derived from separately benchmarked associated 
groups against the manually curated functional scheme of the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database. For the analysis, gene or protein lists are entered, and the organism 
species is specified. The output is a network which includes the prediction of co-expression, 
neighbourhood evidence, occurrence in similar biological pathway and gene fusion events 
(Szklarczyk et al., 2011). 
7.10.3. AAgAtalas v1.0 
The human autoantigen database (AAgAtlast database 1.0) provides a user-friendly interface to 
browse, retrieve and download human autoantigens as well as their associated diseases that is 
freely accessible at http://biokb.ncpsb.org/aagatlas/. To develop the, AAgAtlast database 1.0, the 
authors extracted 45830 autoantigen-related abstracts and 94313 sentences from PubMed using 
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“autoantigen” or “autoantibody” or their lexical variants as keywords. These abstracts were 
reduced to 25520 abstract and 3984 autoantigen candidates using bio-entity recogniser based 
on protein ontology. In total, 1126 genes were identified as autoantigens related to 1071 diseases 
which was used to construct the AAgAtlast database 1.0. The database is a valuable resource for 





















Appendix A: Preparation of stock and working solutions and buffers 
A.1. Slide coating buffer (150 mM NaPO4, pH 8.5) 
150 mM NaH2PO4, pH 4.0 (solution 1) 
- Dissolve 9 g NaH2PO4 in 500 ml triple-distilled Millipore water 
150 mM Na2HPO4, pH 9.0. (solution 2) 
- Dissolve 26.7 g Na2HPO4 in 800 ml triple-distilled Millipore water. 
150 mM NaPO4, pH 8.5, 0.001% Tween®-20 
- Titrate 150 mM Na2HPO4 (solution 1) with 150 mM NaH2PO4 (solution 2) until a pH 8.5 is reached. 
- Add 100 µl Tween®-20 to 100 ml 150 mM NaPO4, pH 8.5. 
 
A.2. Slide washing buffer (50 mM KPO4, pH 8.0) 
1 M KPO4 
- Dissolve 13.94 g K2HPO4 and 2.72 g KH2PO4 to a final volume of 100 ml triple-distilled Millipore water. 
- Adjust pH with KOH or H3PO4 if needed. 
50 mM KPO4, pH 8.0 
- Dilute 50 ml of 1 M KPO4 in 800 ml triple-distilled Millipore water. 
- Adjust to pH 80. With KOH. 
- Add triple-distilled Millipore water to a final volume of 1000 ml.  
 
A.3. Quality control buffer (150 mM NaPO4, pH 8.5) 
150 mM NaH2PO4, pH 4.0 (solution 1) 
- Dissolve 9 g NaH2PO4 in 500 ml triple-distilled Millipore water 
150 mM Na2HPO4, pH 9.0. (solution 2) 
- Dissolve 26.7 g Na2HPO4 in 800 ml triple-distilled Millipore water. 
150 mM NaPO4, pH 8.5, 0.001% Tween®-20 
- Titrate 150 mM Na2HPO4 (solution 1) with 150 mM NaH2PO4 (solution 2) until a pH 8.5 is reached. 
- Add 100 µl Tween®-20 to 100 ml 150 mM NaPO4, pH 8.5. 
 
A.4. CT100plus control Buffer 
- Mix the reagents to the specified final concentration (Table A1), and add triple-distilled Millipore water. 
 
Table A1. Table of basic reagents in CT100plus control buffer. 
Reagent Stock solution Final concentration Manufacturer 
2.5 M HEPES, pH 7.5 2.5 M 12.5 mM SIGMA® 
KCl 1 M 25 mM EMSURE 
Glycerol 100% 10 % univAR 
Triton X-100 10 % 0.05 % SIGMA®  
DTT 1 M 1 mM SIGMA® 










A.5. Blocking buffer 
- Mix the reagents to the specified final concentration (Table A2), and add triple-distilled Millipore water. 
 
Table A2. Table of basic reagents in CT100plus blocking buffer. 
Reagent Stock solution Final concentration Manufacturer 
2.5 M HEPES, pH 7.5 2.5 M 25 mM SIGMA® 
KCl 1 M 50 mM EMSURE 
Glycerol 100% 20 % univAR 
Triton X-100 10 % 0.1 % SIGMA®  
Biotin 50 mM 50 µ SIGMA® 
DTT 1 M 1 mM SIGMA® 
 
- Add DTT just before use. 
 
A.6. PAD4 buffer (prepare fresh before use) 
- Mix the reagents to the specified final concentration (Table A3), and add triple-distilled Millipore water. 
 
Table A3. Table of basic reagents in PAD4 buffer. 
Reagent Stock solution Final concentration Manufacturer 
2.5 M HEPES, pH 7.5 2.5 M 50mM SIGMA® 
CaCl2 500 mM 5 mM SIGMA® 
NaCl 1000 mM 150 mM Merck 
Tween®-20 100 % 0.2 % SIGMA®  
  
 
A.7. 1× PBST  
- 5 PBS tablets (SIGMA®) in triple distilled Millipore water up to 1 L. 
- All 1 ml 100 % Tween® 20 (uniLAB). 
Store at RT. 
 
A.8. Binding buffer 
Prepare fresh before use: 
- 1× PBS tablet (SIGMA®) in triple distilled Millipore water up to 200 ml. 
- All 50 µl 100 % Triton™ X-100 (SIGMA®). 
Store at RT. 
 
A.9. Non-denaturing lysis buffer (Prepare fresh before use) 







Table A4. Table of basic reagents in non-denaturing lysis buffer. 
Reagent Stock solution Final concentration Manufacturer 
2.5 M HEPES, pH 7.5 2.5 M 12.5 mM SIGMA® 
KCl 1 M 25 mM EMSURE, MERCK 
Protease inhibitor 10 × 1 × ROCHE 
Benzonase 250 U 1U/µl SIGMA® 
 
- Add detergents to a final concentration of 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) (SIGMA®), 1% Triton™ X-100 (SIGMA®), 1% IGEPAL® CA-630 (SIGMA®), a 
mixture detergents (0.25% CHAPS, 0.5% IGEPAL® CA 630, and 0.5% Triton™ X-100), or no detergent. 
A.10. 5× Laemmli buffer 
- Dissolve 1.75 g Tris (SIGMA®), 30 ml glycerol (KIMIX) and 5 g SDS (SIGMA®) to a final volume of 50 ml 
triple-distilled Millipore water, pH 6.0. 
- Just before use, add 5 µl 25% bromophenol blue and 150 mM DTT 
- Dilute to 1× laemmli buffer in triple-distilled Millipore water. 
 
A.11. 4% Stacking gel 
Prepare immediately before use: 
- 0.625 ml 1 M Tris (SIGMA®) at pH 6.8. 
- 0.65 ml 40% acrylamide/bisacrylamide (SIGMA®) 
- 50 µl 10 % SDS (SIGMA®) 
- 3.6 ml triple-distilled Millipore water. 
- 25 µl 20 % ammonium persulfate (APS) (SIGMA®) 
- 5 µl 100 % N,N,N’,N’-Tertramethylethylenediamine (TEMED) (SIGMA®) 
 
A.12. 10% Separating gel 
Prepare immediately before use: 
- 3.75 ml 1 M Tris (SIGMA®) at pH 8.8. 
- 2.5 ml 40% acrylamide/bisacrylamide (SIGMA®). 
- 100 µl 10 % SDS (SIGMA®). 
- 3.615 ml triple-distilled Millipore water. 
- 25 µl 20 % APS (SIGMA®) 
- 10 µl 100 % (TEMED) (SIGMA®) 
 
A.13. 10× Running buffer 
- 3.03 g Tris (SIGMA®) 
- 14.5 g glycine (SIGMA®) 
- 35 mM SDS (SIGMA®) 
- Dissolve in 1 litre (L) triple-distilled Millipore water. 
Store at RT. 
 
A.14. 10× Transfer buffer 
- 3.03 g Tris (SIGMA®) 
- 14.5 g glycine (SIGMA®) 
- Dissolve in 1 litre (L) triple-distilled Millipore water. 




A.15. 1× TBST 
- 50 ml 1 M tris (SIGMA®) 
- 20 ml 5 M NaCl (Merck) 
- 250 µl 100% Tween® 20 
- Dissolve in 100 ml triple-distilled Millipore water. 
Store at RT. 
 
A.16. Elution buffer 1 
Prepare immediately before use 
- 2M urea (SIGMA®) 
- 50 mM Tris-HCl (pH 7.5) 
- 5 µg/µl trypsin (Promega) 
 
A.17. Elution buffer 2 
Prepare immediately before use 
- 2M urea (SIGMA®) 
- 50 mM Tris-HCl (pH 7.5) 
- 1 mM DTT (SIGMA®) 
 
A.18. Solvent A 
- 2% acetonitrile (ACN) (SIGMA®) and 0.1% formic acid (FA) (SIGMA®) in triple-distilled Millipore water. 
 
A.19. Solvent B 
- 80% ACN (SIGMA®) and 0.1% FA (SIGMA®) in triple-distilled Millipore water. 
 
A.20. Solvent C 
- 60% ACN (SIGMA®) and 0.1% FA (SIGMA®) in triple-distilled Millipore water. 
 
A.21. Buffer A 
- 0.1% ACN (SIGMA®) and 0.1% FA (SIGMA®) in HPLC grade water.  
 
A.22. Buffer B 










Appendix B: Supplementary Figures and Tables 
 
Figure B1. Signal intensity for antigens on anti-c-Myc-treated CT100plus microarray. The CT100plus 
microarray antigens each have a c-Myc tag which is used as a quality control measure to confirm the 
presence of the CT100plus antigens. For the assay, the CT100plus microarray is treated with Cy3-labelled 






























Table B1. Potential CRC biomarkers identified by CT100plus microarray and AP-MS. CRC patients and HC autoantibody signals against CT100plus 
antigens were assayed and the top 10 antigens with the highest AUC-values were identified. These proteins were searched against proteins 
identified by AP-MS (See Chapter 4), and COL6A1 and THEG were identified. Cancer refers to the AP-MS experiment with patient CRC patient 
plasma and tissue; Normal refers to the AP-MS experiment with patient CRC patient plasma and normal colon tissue; and Plasma refers to the AP-
MS experiment with CRC patient plasma only. Abbreviations include: CRC = colorectal cancer; HC = healthy control; AUC = area under the receiver 
operator characteristic curve; AP-MS = affinity purification-mass spectrometry. 
Patient CRC002 CRC004 CRC017 CRC021 CRC031  
Sample Cancer Normal Plasma Cancer Normal Plasma Cancer Normal Plasma Cancer Normal Plasma Cancer Normal Plasma  
COL6A1 Yes Yes No No Yes No Yes Yes No Yes Yes Yes Yes No No  














RT: 0.00 - 140.00










































70.1122.56 32.92 63.8657.9646.84 53.3124.52 40.90 77.4968.2121.32 83.53 85.59 122.4893.75 106.15102.13 117.4218.98 126.204.27 12.20 131.88
NL:
3.08E9























































































17.75 86.0612.82 100.8227.50 120.27115.43110.5276.3737.32 134.7995.8671.4942.1832.4422.61 105.6890.9366.63 125.1381.3051.9847.04 56.88 129.9461.69
120.4253.55 55.71 59.3249.76 62.7345.35 65.3141.6540.06 125.8268.5736.7833.52 72.1729.87 108.0926.5722.92 75.52 114.1820.04 78.99 129.04 132.23 136.4614.0711.866.08
103.6693.69
NL: 2.98E2








RT: 0.00 - 140.00









































60.2653.4531.54 77.9328.00 46.7232.88 68.21
20.67 82.6752.4243.7139.82 122.1884.78 93.88 95.38 120.90106.10 123.5819.3612.421.46 9.83 133.22
NL:
3.19E9



























































































13.64 40.36 93.0344.4822.72 52.82 97.1235.9331.2826.47 88.1375.0449.2817.65 137.2957.42 110.6471.2962.28 84.2179.63 115.45106.3166.43 128.10123.84102.01 119.83 133.05
120.5358.7451.78 55.09 60.41 64.9049.0641.92 46.2239.0936.91 68.27 125.5432.71 70.6929.4426.99 108.2273.9023.6120.15 114.1777.18 128.6981.20 132.73 137.8614.1511.874.260.62
103.1493.20
NL: 2.46E2








RT: 0.00 - 140.00









































71.1366.7252.85 93.6680.58 90.0257.0739.31 48.13 95.63









42.5426.02 64.0962.7424.52 29.40 48.75 49.25 80.8760.8921.36 93.4454.89 84.12 95.13 99.18 122.40107.14 117.1710.37 126.416.22
NL:
3.13E9










170725_MS_2S #2453 RT: 16.19 AV: 1 NL: 9.98E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]

























































































RT: 0.00 - 140.00

































46.5237.30 63.3125.31 78.4726.55 49.95
90.9782.46
126.0427.72







77.2752.1341.80 67.86 79.4633.28 65.4655.46
23.31 59.20 106.9747.3532.88 79.97 122.7621.14 82.66 88.10 125.09120.28107.9692.77 106.46 130.0010.047.13
NL:
2.26E9

































































































78.8115.47 137.13112.86103.2393.5020.34 127.43117.7574.0764.3254.5010.61 39.9025.20 83.79 108.0749.6335.03 132.2959.3830.11 122.6444.82 98.4088.5469.16












D:\Data\...\MSMITH_PROTG_NONCANCER 8/20/20 5 03:37:27
RT: 0.00 - 140.00































75.0855.0126.48 65.93 90.9652.20 82.42
67.7833.23 47.4042.03 79.66 83.0461.39
39.5931.39 126.0184.76 104.3294.98





70.91 75.3738.59 55.61 79.8552.2842.21 60.93 106.8588.02 125.8222.74 122.8682.73 88.55 109.1993.1121.29 99.84 127.1116.034.44 139.96
NL:
4.86E9



























































































33.81 38.5824.30 29.0219.4914.62 43.43 53.08 72.37 86.7782.0048.17 91.46 101.10 134.80120.4477.20 115.65105.9362.79 96.4367.6257.80 110.85 129.91125.06












D:\Data\2015\August\MSMITH_PROTG_SERA 8/20/20 5 00:07:26
RT: 0.00 - 140.00
































9 .9761.88 76.82 82.7046.63 68.7240.0325.71 27.15
47.41 61.1753.34 104.0393.9284.9333.67 105.68 126.37122.25





37.87 63.71 72.1625.91 56.11
80.08 108.1453.2133.76 48.54 66.9025.76 43.52
107.13 123.0831.64 89.5622.87 126.1922.28 90.08 106.62 108.65 122.2094.76 133.723.61 7.01 13.02
NL:
3.36E9

































































































30.2415.6810.76 54.7440.1120.57 132.4644.93 49.87 79.00 88.82 127.72 137.31103.3598.48 113.0993.6583.8664.36 69.3035.11 74.16 108.3025.35 59.61 117.85 122.87





















RT: 0.00 - 140.00


























































60.07 95.8492.3249.7237.78 41.32 107.0934.18 122.0328.61 125.07111.6024.09
NL:
2.80E9














170725_MS_17C_170727170035 #2020 RT: 16.19 AV: 1 NL: 2.69E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]













































































RT: 0.00 - 140.01

























































98.23 122.71104.88 109.04 119.97
NL:
3.91E9










170725_MS_17N #2029 RT: 16.19 AV: 1 NL: 1.22E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]



















































































RT: 0.00 - 140.00









































74.5466.9664.37 80.12 89.9548.4441.97 57.3338.92
53.18
36.8435.35 43.34 81.73












86.32 96.48 122.74106.00 108.68 118.87 126.15
NL:
5.07E9










170725_MS_17S #2365 RT: 16.19 AV: 1 NL: 7.60E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]


















































































RT: 0.00 - 140.00

























































55.0654.5449.85 92.31 95.9242.1438.01 107.0828.75 122.7826.19 118.31 125.5221.44
NL:
3.89E9














170725_MS_21C_170727192839 #2020 RT: 16.19 AV: 1 NL: 1.39E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]
















































































RT: 0.00 - 140.00









































72.9171.16 89.9679.9866.7447.27 84.0760.9042.27 52.90











95.9591.99 122.70106.15 108.8620.03 119.52 126.39
NL:
3.40E9










170725_MS_21N #1930 RT: 16.19 AV: 1 NL: 9.22E5
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]


















































































RT: 0.00 - 140.00
























































86.27 94.9045.70 46.2136.46 40.00 98.53 122.6325.23 35.95 102.26 126.17119.68
NL:
5.41E9










170725_MS_21S #2189 RT: 16.19 AV: 1 NL: 2.88E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]



















































































RT: 0.00 - 140.01
























































95.4386.8938.44 52.7040.8737.26 107.3997.7831.01 121.8125.92 124.66110.5121.25
NL:
8.03E9










170725_MS_31C #1948 RT: 16.19 AV: 1 NL: 1.14E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]

















































































RT: 0.00 - 140.01




















































94.7584.6770.8063.1836.29 96.0392.2250.7438.7935.28 53.3647.14 122.71100.3331.0724.53 107.02 126.37119.01
NL:
5.39E9














170725_MS_21N_170728085202 #2030 RT: 16.19 AV: 1 NL: 1.24E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]






















































































RT: 0.00 - 140.01


















































95.8653.48 84.2537.97 98.59 122.6040.9236.5827.20 120.33106.79 124.49
NL:
3.2 E9










170725_MS_31S #2083 RT: 16.19 AV: 1 NL: 1.80E6
T: FTMS + p NSI Full lock ms [300.0000-1750.0000]

















































































 Protein Gene Symbol Peptide (modification) 
 A0A075B6N8 SSAVR(1)LR(0.999)SSVPGVR 
 A0A087WUK2 SCDTPPPCPR(1) 
 A0A087WVV2 GSQQYR(1)ALTVPELTQQMFDAK 











 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 CAP1 LQIWDTAGQER(1)FR(0.999)TITSSYYR(0.001) 
 CHD7 R(1)SR(1)NTDEMVELR 
 COG5 LEAVSHTSDMHR(1)GYADSPSK 
 EF1A3 DGNASGTTLLEALDCILPPTR(0.024)PTDKPLR(0.976)LPLQDVYK 
 EFTU FAVR(1)DMR(1)QTVAVGVIK 
 EHD4 RGPAEESSSWR(0.986)DSSR(0.014) 
 EIF3C YEEIDNAPEER(0.972)AR(0.028) 
 EPIPL SYR(1)TDISMSDFENSR 
 FIBA SR(1)TSVQTEDDQLIAGQSAR 






 GFPT1 SSSHSR(1)AGQSAAGAAPGGGVDTR 
 H0YFA4 LWR(1)DGR(1)GALQNIIPASTGAAK 
 HNRPK AGFAGDDAPR(1)AVFPSIVGR(1)PR(1)HQGVMVGMGQK 
 HNRPU SR(1)ANEEYGLR 
 IF4A3 GPSR(1)ASSVTTFTGEPNTCPR 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 IQGA1 SLQER(1)NQEQEKVER 
 J3QR09 LTR(1)GEADR(0.991)DTYR(0.009) 
 K2C8 LLEGEESR(1)LESGMQNMSIHTK 
 LAMB4 HVPR(1)AVFVDLEPTVIDEVR 
 NDRG1 AQALR(1)DNSTMGYMMAK 
 PDCD4 AQALR(1)DNSTMGYMAAK 









 RS14 AVFPSIVGR(0.828)PR(0.172) 






 TBB3 EVVTSEDGSDCPEAMDLGTLSGIGTLDGFR(0.77)HR(0.23) 
 TBB4A GSCNLSR(1)VDSTTCLFPVEEK 
 TBB4B ADNEKLDNQR(1)LK 








 ZO2 FAVR(1)DMR(1)QTVAVGVIK 
232 
 
Table B3. Citrullination sites for Normal sample of CRC002. 
 




 Protein Gene Symbol Peptide (modification) 
 A0A075B6N8 SSAVR(1)LR(0.999)SSVPGVR(0.001) 
 A0A087WVV2 GSQQYR(1)ALTVPELTQQMFDAK 











 CAP1 LQIWDTAGQER(1)FR(0.999)TITSSYYR(0.001) 
 CHD7 R(1)SR(1)NTDEMVELR 
 COG5 LEAVSHTSDMHR(1)GYADSPSK 
 CTNA2 DLYANTVLSGGTTMYPGIADR(1)MQK 
 EF1A3 ATTATMATSGSAR(1)K 
 EFTU FAVR(1)DMR(1)QTVAVGVIK 
 EIF3C YEEIDNAPEER(0.972)AR(0.028) 
 EPIPL SYR(1)TDISMSDFENSR 
 FLNA ADIQTER(1)AYQK 
 G3P TASGSSVTSLDGTR(0.964)SR(0.036) 
 GFPT1 SSSHSR(1)AGQSAAGAAPGGGVDTR 
 HNRPK AGFAGDDAPR(1)AVFPSIVGR(1)PR(1)HQGVMVGMGQK 
 HNRPU SR(1)ANEEYGLR 
 HS90B LHFFMPGFAPLTSR(1)GSQQYR(1)ALTVPELTQQVFDAK 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 IQGA1 SLQER(1)NQEQEKVER 
 J3QR09 LTR(1)GEADR(0.991)DTYR(0.009) 
 K1C20 ISNSR(1)HTVNYGSDLTGGGDLFVGNEK 
 K2C8 LLEGEESR(1)LESGMQNMSIHTK 
 NDRG1 AQALR(1)DNSTMGYMMAK 
 PDCD4 AQALR(1)DNSTMGYMAAK 









 RS14 AVFPSIVGR(0.828)PR(0.172) 















 ZO2 FAVR(1)DMR(1)QTVAVGVIK 
 Protein Peptide (modification) 
 ACTA LDINTLTGEER(1)VPVVNK 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 H0YAW0 ETDTASESSYQLSR(1)HK 
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 Protein Peptide (modification) 
 A0A075B6N8 SSAVR(1)LR(0.999)SSVPGVR(0.001) 
 A0A087WUK2 SCDTPPPCPR(1) 






 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 CTNA2 DLYANTVLSGGTTMYPGIADR(1)MQK 
 EFTU FAVR(1)DMR(1)QTVAVGVIK 
 EIF3C YEEIDNAPEER(0.972)AR(0.028) 
 FLNA ADIQTER(1)AYQK 





 HNRPU SR(1)ANEEYGLR 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 IQGA1 SLQER(1)NQEQEKVER 
 J3QR09 LTR(1)GEADR(0.991)DTYR(0.009) 
 K1C19 MELER(1)PGGNEITR 
 K1C20 ISNSR(1)HTVNYGSDLTGGGDLFVGNEK 
 M0QZC5 SYELPDGQVITIGNER(0.965)FR(0.035) 
 NDRG1 AQALR(1)DNSTMGYMMAK 





 POTEE AGFAGDDAPR(1)AVFPSIVGR(1)PR(1)HQGVMVGMGQK 
 Q5JP53 TSYSYR(1)QSSATSSFGGLGGGSVR 
 RS14 AVFPSIVGR(0.828)PR(0.172) 
 S4R435 MQR(1)ADSEQPSKRPR 





 TBB3 EVVTSEDGSDCPEAMDLGTLSGIGTLDGFR(0.77)HR(0.23) 
 TBB4A GSCNLSR(1)VDSTTCLFPVEEK 






 ZO2 FAVR(1)DMR(1)QTVAVGVIK 
234 
 
Table B6. Citrullination sites for Normal sample of CRC004. 
 
 











 Protein Peptide (modification) 
 A0A075B6N8 SSAVR(1)LR(0.999)SSVPGVR(0.001) 





 EF1A3 DGNASGTTLLEALDCILPPTR(0.024)PTDKPLR(0.976)LPLQDVYK 
 EFTU FAVR(1)DMR(1)QTVAVGVIK 
 FLNA ADIQTER(1)AYQK 
 HNRPK AGFAGDDAPR(1)AVFPSIVGR(1)PR(1)HQGVMVGMGQK 
 HNRPU SR(1)ANEEYGLR 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 IQGA1 SLQER(1)NQEQEKVER 
 K1C20 ISNSR(1)HTVNYGSDLTGGGDLFVGNEK 





 PSMD2 DGNASGTTLLEALDCILPPTR(0.5)PTDKPLR(0.5)LPLQDVYK 
 Q5JP53 TSYSYR(1)QSSATSSFGGLGGGSVR 






 Protein Peptide (modification) 
 A0A075B6N8 SSAVR(1)LR(0.999)SSVPGVR(0.001) 
 ACTA LDINTLTGEER(1)VPVVNK 
 EHD4 RGPAEESSSWR(0.986)DSSR(0.014) 
 HNRPU SR(1)ANEEYGLR 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 K1C20 ISNSR(1)HTVNYGSDLTGGGDLFVGNEK 








Table B8. Citrullination sites for Cancer sample of CRC017. 
 
Table B9. Citrullination sites for Normal sample of CRC017. 
 
 

















 Protein Peptide (modification) 
 A0A075B6N8 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA IQDLNLSR(0.825)QAKADQLR(0.175) 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 H0YAW0 ETDTASESSYQLSR(1)HK 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 K2C8 LLEGEESR(1)LESGMQNMSIHTK 
 PDCD4 AQALR(1)DNSTMGYMAAK 
 VIME TVETR(1)DGQVINETSQHHDDLE 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
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Table B11. Citrullination sites for Cancer sample of CRC021. 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 H0YAW0 ETDTASESSYQLSR(1)HK 
 S4R435 MRYLQQKVTR(1) 
 
 
Table B12. Citrullination sites for Normal sample of CRC021. 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 ACTB NTR(1)TNEKVELQELNDR 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 EHD4 RGPAEESSSWR(0.986)DSSR(0.014) 
 H0YAW0 ETDTASESSYQLSR(1)HK 
 K2C8 LLEGEESR(1)LESGMQNMSIHTK 
 S4R435 MRYLQQKVTR(1) 
 VIME TVETR(1)DGQVINETSQHHDDLE 
 
 
Table B13. Citrullination sites for Plasma sample of CRC021: 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 H0YAW0 ETDTASESSYQLSR(1)HK 















Table B14. Citrullination sites for Cancer sample of CRC031 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTA LDINTLTGEER(1)VPVVNK 
 EF1A3 SR(1)WQQGNIFSCSVMHEALHNR 
 H0YAW0 ETDTASESSYQLSR(1)HK 
 IMA3 IREEYPDR(1)IMNTFSVVPSPK 
 
 
Table B15. Citrullination sites for Normal sample of CRC031 
 Protein Peptide (modification) 
 A0A0U1RQH7 QVLESR(0.995)LQR(0.005)PLPEDLAR 
 ACTBL IQDLNLSR(0.825)QAKADQLR(0.175) 
 EF1A3 SR(1)WQQGNIFSCSVMHEALHNR 
 H0YAW0 ETDTASESSYQLSR(1)HK 
 
 
Table B16. Citrullination sites for Plasma sample of CRC031 
 Protein Peptide (modification) 
 ACTA LDINTLTGEER(1)VPVVNK 
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